WO2004039958A2 - Lutzomyia longipalpis polypeptides and methods of use - Google Patents

Lutzomyia longipalpis polypeptides and methods of use Download PDF

Info

Publication number
WO2004039958A2
WO2004039958A2 PCT/US2003/034453 US0334453W WO2004039958A2 WO 2004039958 A2 WO2004039958 A2 WO 2004039958A2 US 0334453 W US0334453 W US 0334453W WO 2004039958 A2 WO2004039958 A2 WO 2004039958A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
acid sequence
polypeptide
amino acid
set forth
Prior art date
Application number
PCT/US2003/034453
Other languages
French (fr)
Other versions
WO2004039958A3 (en
Inventor
Jesus G. Valenzuela
Jose M.C. Ribeiro
Aldina Barral
Manoel Netto
Claudia Brodskyn
Regis Gomes
Original Assignee
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
Centro De Pesquisa Goncalo Moniz, Lip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA05004714A priority Critical patent/MXPA05004714A/en
Priority to US10/533,811 priority patent/US7485306B2/en
Priority to BRPI0315872-1A priority patent/BR0315872A/en
Priority to EP03781500A priority patent/EP1572968B1/en
Application filed by The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centro De Pesquisa Goncalo Moniz, Lip filed Critical The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services
Priority to DE60327366T priority patent/DE60327366D1/en
Priority to AT03781500T priority patent/ATE429487T1/en
Priority to AU2003287267A priority patent/AU2003287267A1/en
Priority to JP2004548595A priority patent/JP2006516187A/en
Publication of WO2004039958A2 publication Critical patent/WO2004039958A2/en
Publication of WO2004039958A3 publication Critical patent/WO2004039958A3/en
Priority to US12/350,179 priority patent/US8628780B2/en
Priority to US14/097,991 priority patent/US9120867B2/en
Priority to US14/802,168 priority patent/US9382302B2/en
Priority to US15/175,329 priority patent/US9884100B2/en
Priority to US15/866,050 priority patent/US10314900B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the disclosure relates to proteins substantially purified from Lutzomyia longipalpis (Lu. longipalpis) sand fly salivary glands, or recombinant vectors expressing these proteins, and to an immune response produced to these proteins. This disclosure also relates to the production of an immune response that affects survival of Leishmania.
  • Leishmaniasis is a group of diseases caused by protozoa of the genus Leishmania and affect many millions of people worldwide.
  • infection with the parasite manifests either as a cutaneous disease caused mainly by L. major, L. tropica, and L. mexicana; as a mucocutaneous disease caused mainly by L. brasiliensis; or as a visceral disease caused mainly by L. donovani and L. chagasi.
  • Leishmania infections manifest as a visceral disease that can result in high death rates.
  • Maxadilan additionally has immunosuppressive activities of its own (Qureshi et al, Am. J. Trop. Med. Hyg. 6:665, 1996), as do many persistent vasodilators such as prostaglandin E 2 (Makoul et al, J. Immunol. 134:2645, 1985; Santoli and Zurier, J. Immunol 143:1303, 1989; Stockman and
  • the present disclosure relates to salivary proteins from sand fly vectors of Lutzomyia longipalpis (Lu. longipalpis ) and the nucleic acids that encode these proteins. Methods of producing an immune response in a subject are also disclosed.
  • Substantially purified salivary Lu. longipalpis polypeptides are disclosed herein. Also disclosed are polynucleotides encoding the Lu. longipalpis polypeptides.
  • Methods are disclosed for inducing an immune response using a therapeutically effective amount of a substantially purified salivary Lu. longipalpis polypeptide as disclosed herein, or the polynucleotide encoding a Lu. longipalpis polypeptides disclosed herein.
  • methods for inhibiting the symptoms of a Leishmania infection or for preventing a Leishmania infection in a subject.
  • the methods include administering to the subject a therapeutically effective amount of a Lu. longipalpis polypeptide, or a polynucleotide encoding a Lu. longipalpis polypeptide.
  • more than one Lu. longipalpis polypeptide can be administered, or at least one Lu. longipalpis polypeptide in conjunction with a P. ariasi or P. pemiciosus polypeptide.
  • methods of diagnosing Leishmania infection in a subject include contacting a solid substrate comprising at least three, six, or ten Lu.
  • longipalpis polypeptides or an immunogenic fragment thereof, contacting the solid substrate with a sample obtained from the subject and detecting binding of a component of the sample to at least one polypeptide on the solid substrate. Detection of binding of the component to the substrate indicates that the subject is infected with Leishmania.
  • compositions including a pharmaceutically acceptable carrier and a Lu. longipalpis polypeptide.
  • FIG. 1 is a set of bar graphs showing the levels of antibodies against Lutzomyia longipalpis (Lu. longipalpis) saliva in sera of individuals.
  • Human sera were obtained at time 0 (negative anti- Leishmania serology (S ⁇ ) or negative DTH (DTH-)) and 6 months later (positive anti-Leishmania serology (S 4 ) or positive anti-Leishmania DTH (DTH 1 )).
  • ELISA was performed with these sera using salivary gland sonicate of the sand fly Lu. longipalpis.
  • FIG. 1A is a bar graph of anti-saliva IgG levels in individuals who converted from S " -> S + and those who converted from DTH " to DTH 1" .
  • FIG. IB is a bar graph of ⁇ nti-saliva IgE levels in the individuals described in FIG. 1A.
  • FIG. 1C is a bar graph of anti-saliva IgGl levels in the individuals described in FIG. 1A.
  • FIG. ID is a bar graph of anti-saliva IgG4 levels in the individuals described in FIG. 1A.
  • the non-parametric paired Wilcoxon test was used to compare levels of anti-Lu. longipalpis saliva antibodies at time 0 and after 6 months. P value ⁇ 0.05 was established as the significance level.
  • FIG. 2 is a set of two digital images and a bar graph showing salivary proteins recognized by Western blot analysis.
  • FIGS. 2A and 2B are digital images of a Western blot of Lu. longipalpis salivary proteins reacted to human sera of individuals who converted from S ⁇ — > S to Leishmania (lanes 1-6) or from DTH " ⁇ DTH + to Leishmania (lanes 7—14). Symbols: — , time 0; +, 6 months.
  • FIG. 2C is a bar graph of the frequency of salivary proteins recognized by sera of 13 individuals who converted from DTBT ⁇ DTH + to Leishmania. The x-axis shows the different Lu. longipalpis salivary proteins (labeled by the approximate molecular weight) recognized by Western blot analysis, while the y-axis indicates the number of human sera recognizing a particular salivary protein.
  • nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
  • SEQ ID NO 1 is the amino acid sequence of LJL34.
  • SEQ ID NO: 2 is the nucleic acid sequence of LJL34.
  • SEQ ID NO 3 is the amino acid sequence of LJL18.
  • SEQ ID NO 4 is the nucleic acid sequence of LJL18.
  • SEQ ID NO 5 is the amino acid sequence of LJS193.
  • SEQ ID NO 6 is the nucleic acid sequence of LJS193.
  • SEQ ID NO 7 is the amino acid sequence of LJS201.
  • SEQ ID NO 8 is the nucleic acid sequence of LJS201.
  • SEQ ID NO 9 is the amino acid sequence of LJL13.
  • SEQ ID NO 10 is the nucleic acid sequence of LJL13.
  • SEQ ID NO 11 is the amino acid sequence of LJL23.
  • SEQ ⁇ D NO 12 is the nucleic acid sequence of LJL23.
  • SEQ ID NO 13 is the amino acid sequence of LJM10.
  • SEQ ID NO 14 is the nucleic acid sequence of LJM10.
  • SEQ ID NO 15 is the amino acid sequence of LJL143.
  • SEQ ID NO 16 is the nucleic acid sequence of LJL143.
  • SEQ ID NO 17 is the amino acid sequence of LJS142.
  • SEQ ID NO 18 is the nucleic acid sequence of LJS142.
  • SEQ ID NO: 19 is the amino acid sequence of LJL17.
  • SEQ ID NO: 20 is the nucleic acid sequence of LJL17.
  • SEQ ID NO: 21 is the atriino acid sequence of LJM06.
  • SEQ ID NO: 22 is the nucleic acid sequence of LJM06.
  • SEQ ID NO: 23 is the amino acid sequence of LJMl 7.
  • SEQ ID NO: 24 is the nucleic acid sequence of LJM17.
  • SEQ ID NO: 25 is the amino acid sequence of LJL04.
  • SEQ ID NO: 26 is the nucleic acid sequence of LJL04.
  • SEQ ID NO: 27 is the amino acid sequence of LJMl 14.
  • SEQ ID NO: 28 is the nucleic acid sequence of LJMl 14.
  • SEQ ID NO: 29 is the amino acid sequence of LJMl 11.
  • SEQ ID NO: 30 is the nucleic acid sequence of LJMl 11.
  • SEQ ID NO: 31 is the amino acid sequence of LJM78.
  • SEQ ID NO: 32 is the nucleic acid sequence of LJM78.
  • SEQ ID NO: 33 is the amino acid sequence of LJS238.
  • SEQ ID NO: 34 is the nucleic acid sequence of LJS238.
  • SEQ ID NO: 35 is the amino acid sequence of LJS169.
  • SEQ ID NO: 36 is the nucleic acid sequence of LJS169.
  • SEQ ID NO: 37 is the amino acid sequence of LJL11.
  • SEQ ID NO: 38 is the nucleic acid sequence of LJL11.
  • SEQ ID NO: 39 is the amino acid sequence of LJL08.
  • SEQ ID NO: 40 is the nucleic acid sequence of LJL08.
  • SEQ ID NO: 41 is the amino acid sequence of LJS105.
  • SEQ ID NO: 42 is the nucleic acid sequence of LJS105.
  • SEQ ID NO: 43 is the amino acid sequence of LJL09.
  • SEQ ID NO: 44 is the nucleic acid sequence of LJL09.
  • SEQ ID NO: 45 is the arnino acid sequence of LJL38.
  • SEQ ID NO: 46 is the nucleic acid sequence of LJL38.
  • SEQ ID NO: 47 is the arnino acid sequence of LJM04.
  • SEQ ID NO: 48 is the nucleic acid sequence of LJM04.
  • SEQ ID NO: 49 is the amino acid sequence of LJM26.
  • SEQ ID NO: 50 is the nucleic acid sequence of LJM26.
  • SEQ ID NO: 51 is the arnino acid sequence of LJS03.
  • SEQ ID NO: 52 is the nucleic acid sequence of LJS03.
  • SEQ ID NO: 53 is the amino acid sequence of LJS192.
  • SEQ ID NO: 54 is the nucleic acid sequence of LJS192.
  • SEQ ID NO: 55 is the amino acid sequence of LJMl 9.
  • SEQ ID NO: 56 is the nucleic acid sequence of LJM19.
  • SEQ ID NO: 57 is the amino acid sequence of LJL138.
  • SEQ ID NO: 58 is the nucleic acid sequence of LJL138.
  • SEQ ID NO: 59 is the amino acid sequence of LJL15.
  • SEQ ID NO: 60 is the nucleic acid sequence of LJL15.
  • SEQ ID NO: 61 is the ainino acid sequence of LJL91.
  • SEQ ID NO: 62 is the nucleic acid sequence of LJL91.
  • SEQ ID NO: 63 is the amino acid sequence of LJMl 1.
  • SEQ ID NO: 64 is the nucleic acid sequence of LJMl 1.
  • SEQ ID NO: 65 is the amino acid sequence of LJS138.
  • SEQ ID NO: 66 is the nucleic acid sequence of LJS138.
  • SEQ ID NO: 67 is the amino acid sequence of LJL124.
  • SEQ JD NO: 68 is the nucleic acid sequence of LJL124.
  • SEQ ID NO: 69 is the amino acid sequence of LJL35.
  • SEQ ID NO: 70 is the nucleic acid sequence of LJL35.
  • SEQ ED NO: 71 is an oligonucleotide primer.
  • SEQ ID NO: 72 is an oligonucleotide primer.
  • SEQ ID NO: 73 is an oligonucleotide primer.
  • CAV canine adenovirus
  • CHV canine herpes virus
  • Amplification of a nucleic acid molecule (for example, a DNA or RNA molecule): A technique that increases the number of copies of a nucleic acid molecule in a specimen.
  • An example of amplification is the polymerase chain reaction, in which a biological sample collected from a subject is contacted with a pair of oligonucleotide primers, under conditions that allow for the hybridization of the primers to a nucleic acid template in the sample.
  • the primers are extended under suitable conditions, dissociated from the template, and then re-annealed, extended, and dissociated to amplify the number of copies of the nucleic acid.
  • the product of amplification may be characterized by electrophoresis, restriction endonuclease cleavage patterns, oligonucleotide hybridization or ligation, and/or nucleic acid sequencing using standard techniques.
  • Other examples of amplification include strand displacement amplification, as disclosed in U.S. Patent No. 5,744,311; transcription- free isothermal amplification, as disclosed in U.S. Patent No. 6,033,881 ; repair chain reaction amplification, as disclosed in WO 90/01069; ligase chain reaction amplification, as disclosed in EP 0320308; gap filling ligase chain reaction amplification, as disclosed in U.S. Patent No. 5,427,930; and NASBATM RNA transcription-free amplification, as disclosed in U.S. Patent No. 6,025,134.
  • Antibody immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, for instance, molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen.
  • a naturally occurring antibody for example, IgG, IgM, IgD
  • IgG, IgM, IgD includes four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
  • H heavy
  • L light
  • binding fragments encompassed within the term antibody include (i) an Fab fragment consisting of the V L , V H; CL, and CHI domains; (ii) an Fd fragment consisting of the V H and CHI domains; (iii) an Fv fragment consisting of the V L and V H domains of a single arm of an antibody, (iv) a dAb fragment (Ward et al, Nature 341:544-546, 1989) which consists of a V H domain; (v) an isolated complimentarity determining region (CDR); and (vi) an F(ab') 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region.
  • Immunoglobulins and certain variants thereof are known and many have been prepared in recombinant cell culture (for example, see U.S. Patent No. 4,745,055; U.S. Patent No. 4,444,487; WO 88/03565; EP 0256654; EP 0120694; EP 0125023; Faoulkner et al, Nature 298:286, 1982; Morrison, /. Immunol. 123:793, 1979; Morrison et al, Ann Rev. Immunol 2:239, 1984).
  • Animal Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds.
  • the term mammal includes both human and non-human mammals.
  • the term "subject" includes both human and veterinary subjects, such as dogs.
  • Conservative amino acid substitutions are those substitutions that do not substantially affect or decrease an activity or antigenicity of the Lu. longipalpis polypeptide. Specific, non-limiting examples of a conservative substitution include the following examples: Original Residue Conservative Substitutions
  • non-conservative substitutions are those that reduce an activity or antigenicity.
  • cDNA complementary DNA: A piece of DNA lacking internal, non-coding segments (introns) and expression control sequences. cDNA is synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells.
  • Degenerate variant A polynucleotide encoding a Lu. longipalpis polypeptide that includes a sequence that is degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the disclosure as long as the arnino acid sequence of the Lu. longipalpis polypeptide encoded by the nucleotide sequence is unchanged.
  • Delayed-type hypersensitivity An immune reaction in which T cell-dependent macrophage activation and inflammation cause tissue injury.
  • a DTH reaction to the subcutaneous injection of antigen is often used as an assay for cell-mediated immunity.
  • Epitope An antigenic determinant. These are particular chemical groups or peptide sequences on a molecule that are antigenic, for instance, that elicit a specific immune response.
  • An antibody specifically binds a particular antigenic epitope on a polypeptide.
  • Specific, non-limiting examples of an epitope include a terra- to penta-peptide sequence in a polypeptide, a tri- to penta- glycoside sequence in a polysaccharide.
  • Expression Control Sequences Nucleic acid sequences that control and regulate the expression of a nucleic acid sequence, such as a heterologous nucleic acid sequence, to which it is operably linked. Expression control sequences are operably linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence.
  • expression control sequences can include appropriate promoters, enhancers, transcription terrninators, polyA signals, a start codon (for instance, ATG) in front of a protein-encoding polynucleotide sequence, splicing signal for introns, maintenance of the correct reading frame of that gene to permit proper translation of mRNA, and stop codons.
  • control sequences is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.
  • Expression control sequences can include a promoter.
  • a promoter is a minimal sequence sufficient to direct transcription of a nucleic acid. Promoters maybe cell-type specific or tissue specific. A promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase H type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements which can be located as much as several thousand base pairs from the start site of transcription. Both constitutive and inducible promoters are included (see for example, Bitter et al, Methods in Enzymology 153:516-544, 1987).
  • inducible promoters such as pL of bacteriophage lambda, plac, ptrp, ptac (ptrp-lac-hybrid promoter) and the like may be used.
  • promoters derived from the genome of mammalian cells for example, metallothionein promoter
  • mammalian viruses for example, the retrovirus long te ⁇ riinal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter
  • Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences.
  • a polynucleotide can be inserted into an expression vector that contains a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host.
  • the expression vector typically contains an origin of replication, a promoter, as well as specific nucleic acid sequences that allow phenotypic selection of the transformed cells.
  • the promoter is a cytomegaloviras promoter.
  • Host cells Cells in which a vector can be propagated and its DNA expressed.
  • the cell may be prokaryoric or eukaryotic.
  • the term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell” is used. Also includes the cells of the subject.
  • Immune response A response of a cell of the immune system, such as a B cell, T cell, or monocyte, to a stimulus.
  • the response is specific for a particular antigen (an "antigen-specific response").
  • the response can also be a non-specific response (not targeted specifically to salivary polypeptides) such as production of lymphokines.
  • an immune response is a T cell response, such as a CD4+ response or a CD8+ response.
  • the response is a Thl (a subset of helper T cells) response.
  • the response is a B cell response, and results in the production of specific antibodies.
  • Immunogenic polypeptide A polypeptide which comprises an allele-specific motif, an epitope or other sequence such that the polypeptide will bind an MHC molecule and induce a cytotoxic T lymphocyte ("CTL”) response, and/or a B cell response (for example, antibody production), and/or T-helper lymphocyte response, and/or a delayed type hypersensitivity (DTH) response against the antigen from which the immunogenic polypeptide is derived.
  • CTL cytotoxic T lymphocyte
  • B cell response for example, antibody production
  • T-helper lymphocyte response for example, antibody production
  • DTH delayed type hypersensitivity
  • immunogenic polypeptides are identified using sequence motifs or other methods known in the art.
  • algorithms are used to determine the "binding threshold" of polypeptides to select those with scores that give them a high probability of binding at a certain affinity and will be immunogenic.
  • the algorithms are based either on the effects on MHC binding of a particular amino acid at a particular position, the effects on antibody binding of a particular amino acid at a particular position, or the effects on binding of a particular substitution in a motif- containing polypeptide.
  • a "conserved residue” is one which appears in a significantly higher frequency than would be expected by random distribution at a particular position in a polypeptide.
  • a conserved residue is one where the MHC structure may provide a contact point with the immunogenic polypeptide.
  • Immunogenic composition A composition that, when a ⁇ niinistered to a subject induces an immune response to a Lu. longipalpis salivary polypeptide. In one embodiment, in particular a positive DTH response.
  • Isolated An "isolated" biological component (such as a nucleic acid or protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, for instance, other chromosomal and extra-chromosomal DNA and RNA, proteins, and organelles.
  • Nucleic acids and proteins that have been "isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant technology as well as chemical synthesis.
  • Label A detectable compound or composition that is conjugated directly or indirectly to another molecule to facilitate detection of that molecule.
  • Specific, non-limiting examples of labels include fluorescent tags, enzymatic linkages, and radioactive isotopes.
  • Leishmaniasis A parasitic disease spread by the bite of infected sand flies.
  • the trypanosomatid parasite of the genus Leishmania is the etiological agent of a variety of disease manifestations, which are collectively known as leishmaniasis.
  • Leishmaniasis is prevalent through out the tropical and sub-tropical regions of Africa, Asia, the Mediterranean, Southern Europe (old world), and South and Central America (new world). The old world species are transmitted by the sand fly vector Phlebotomus sp. Humans, wild animals and domestic animals (such as dogs) are known to be targets of these sand flies and to act as reservoir hosts or to develop leishmaniasis.
  • Cutaneous leishmaniasis starts as single or multiple nodules that develop into ulcers in the skin at the site of the bite.
  • the chiclero ulcer typically appears as a notch-like loss of tissue on the ear lobe.
  • the incubation period ranges from days to months, even a year in some cases. The sores usually last months to a few years, with most cases healing on their own.
  • the mucocutaneous type can develop into erosive lesions in the nose, mouth, or throat and can lead to severe disfigurement.
  • Visceral leishmaniasis often has fever occurring in a typical daily pattern, abdominal enlargement with pain, weakness, widespread swelling of lymph nodes, and weight loss, as well as superimposed infections because of a weakened immune system.
  • Visceral leishmaniasis can result in high death rates. The onset of symptoms can be sudden, but more often tends to be insidious.
  • Lutzomyia longipalpis (Lu. longipalpis): A species of sand fly endogenous to the New
  • Lymphocytes A type of white blood cell that is involved in the immune defenses of the body. There are two main types of lymphocytes: B cells and T cells.
  • Mammal This term includes both human and non-human mammals. Similarly, the term “subject” includes both human and veterinary subjects.
  • Oligonucleotide A linear polynucleotide sequence of up to about 100 nucleotide bases in length.
  • Open reading frame (ORF) A nucleic acid sequence having a series of nucleotide triplets
  • a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
  • a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
  • operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.
  • polypeptide Modifications Lu. longipalpis polypeptides include synthetic embodiments of polypeptides described herein. In addition, analogues (non-peptide organic molecules), derivatives (chemically functionalized peptide molecules obtained starting with the disclosed polypeptide sequences) and variants (homologs) of these proteins can be utilized in the methods described herein.
  • Each polypeptide of the disclosure is comprised of a sequence of amino acids, which may be either L- and/or D- amino acids, naturally occurring and otherwise. Polypeptides may be modified by a variety of chemical techniques to produce derivatives having essentially the same activity as the unmodified polypeptides, and optionally having other desirable properties.
  • carboxylic acid groups of the protein may be provided in the form of a salt of a pharmaceutically-acceptable cation or esterified to form a C C 16 ester, or converted to an amide of formula NR ⁇ R 2 wherein Ri and R 2 are each independently H or C r C ⁇ 6 alkyl, or combined to form a heterocychc ring, such as a 5- or 6- membered ring.
  • Amino groups of the peptide may be in the form of a pharmaceutically-acceptable acid addition salt, such as the HC1, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric, and other organic salts, or may be modified to C r C ⁇ 6 alkyl or dialkyl arnino or further converted to an amide.
  • a pharmaceutically-acceptable acid addition salt such as the HC1, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric, and other organic salts
  • Hydroxyl groups of the peptide side chains may be converted to C r C ⁇ 6 alkoxy or to a C r C ⁇ 6 ester using well-recognized techniques.
  • Phenyl and phenolic rings of the peptide side chains may be substituted with one or more halogen atoms, such as fluorine, chlorine, bromine, or iodine, or with C ⁇ -C 16 alkyl, C ⁇ -C )6 alkoxy, carboxylic acids and esters thereof, or amides of such carboxylic acids.
  • Methylene groups of the peptide side chains can be extended to homologous -C 4 alkylenes.
  • Thiols can be protected with any one of a number of well-recognized protecting groups, such as acetamide groups.
  • protecting groups such as acetamide groups.
  • Those skilled in the art will also recognize methods for introducing cyclic structures into the peptides of this disclosure to select and provide conformational constraints to the structure that result in enhanced stability.
  • Peptidomimetic and organomimetic embodiments are envisioned, whereby the three- dimensional arrangement of the chemical constituents of such peptido- and organomimetics mimic the three-dimensional arrangement of the peptide backbone and component amino acid side chains, resulting in such peptido- and organomimetics of a L. longipalpis polypeptide having measurable or enhanced ability to generate an immune response.
  • a pharmacophore is an idealized, three-dimensional definition of the structural requirements for biological activity.
  • Peptido- and organomimetics can be designed to fit each pharmacophore with current computer modeling software (using computer assisted drug design or CADD). See Walters, "Computer-Assisted Modeling of Drugs,” Klegerman & Groves (eds.), 1993, Pharmaceutical Biotechnology, Interpharm Press: Buffalo Grove, IL, pp. 165-174 and Principles of Pharmacology Munson (ed.) 1995, Ch. 102, for descriptions of techniques used in CADD. Also included are mimetics prepared using such techniques.
  • parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like
  • solid compositions for example, freeze-dried pastille, powder, pill, tablet, or capsule forms
  • conventional non-toxic solid vehicles or excipients can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate.
  • immunogenic compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • non-toxic auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • Phlebotomus ariasi A species of Phlebotomus (sand flies) genus endogenous to the Old World, in particular to southern Europe and Mediterranean countries, more particularly to Spain and France. This sand fly is a proven vector of visceral leishmaniasis. P. ariasi is a member of the subgenera of Phlebotomus Larroussius.
  • Phlebotomus pechasus A species of Phlebotomus (sand flies) genus endogenous to the Old World, in particular to southern Europe, and Mediterranean countries, more particularly to France, Italy, Greece, Sydney, and Spain. This sand fly is a proven vector of the visceral leishmaniasis. P. perniciosus is a member of the subgenera of Phlebotomus Larroussius.
  • Polynucleotide The term polynucleotide or nucleic acid sequence refers to a polymeric form of nucleotide at least 10 bases in length, thus including oligonucleotides and genes.
  • a recombinant polynucleotide includes a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived.
  • the term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (for example, a cDNA) independent of other sequences.
  • the polynucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide.
  • the term includes single -and double -stranded forms of DNA.
  • Polypeptide Any chain of amino acids, regardless of length (thus encompassing oligopeptides, peptides, and proteins) or post-translational modification (for example, glycosylation, phosphorylation, or acylation).
  • a polypeptide encompasses also the precursor, as well as the mature protein.
  • the polypeptide is a polypeptide isolated fcomLu. longipalpis, or encoded by a nucleic acid isolated from Lu. longipalpis, such as the Lu. longipalpis polypeptides disclosed herein.
  • a probe comprises an isolated polynucleotide attached to a detectable label or reporter molecule.
  • Primers are short polynucleotides. In one embodiment, polynucleotides are 15 nucleotides or more in length. Primers may be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, for example, by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods known in the art.
  • PCR polymerase chain reaction
  • probes and primers may be selected that comprise at least 15, 20, 25, 30, 35, 40, 50 or more consecutive nucleotides.
  • Protein Purification The Lu. longipalpis polypeptides disclosed herein can be purified by any of the means known in the art. See, for example, Guide to Protein Purification, Deutscher (ed.), Meth.
  • a substantially purified protein is at least 60%, 70%, 80%, 90%, 95%, or 98% pure.
  • a substantially purified protein is 90% free of other proteins or cellular components.
  • a purified polypeptide preparation is one in which the polypeptide is more enriched than the polypeptide is in its natural environment.
  • a polypeptide preparation is substantially purified such that the polypeptide represents several embodiments at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98%, of the total polypeptide content of the preparation.
  • the polypeptides disclosed herein can be purified by any of the means known in the art (see, for example, Guide to Protein Purification, Inc.), Meth. Enzymol. 185, Academic Press, San Diego, 1990; and Scopes, Protein Purification: Principles and Practice, Springer Verlag, New York, 1982).
  • a recombinant polynucleotide is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, for example, by genetic engineering techniques.
  • a recombinant polynucleotide encodes a fusion protein.
  • nucleic acid hybridization reactions the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (for example, GC v. AT content), and nucleic acid type (for example, RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.
  • a specific, non-limiting example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2 x SSC/0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C (high stringency conditions).
  • Hybridization conditions 2 x SSC/0.1% SDS at about room temperature
  • low stringency conditions low stringency conditions
  • 0.2 x SSC/0.1% SDS at about 42°C moderate stringency conditions
  • 0.1 x SSC at about 68°C high stringency conditions
  • NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al, J. Mol. Biol. 215:403, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn, and tblastx. A description of how to determine sequence identity using this program is available on the NCBI website on the internet.
  • Homologs and variants of a Lu. longipalpis polypeptide are typically characterized by possession of at least 75%, for example at least 80%, sequence identity counted over the full length alignment with the amino acid sequence of the Lu. longipalpis polypeptide using the NCBI Blast 2.0, gapped blastp set to default parameters. The comparison between the sequences is made over the full length alignment with the amino acid sequence given in this present disclosure, employing the Blast 2 sequences function using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1).
  • the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity. When less than the entire sequence is being compared for sequence identity, homologues and, variants will typically possess at least 80% sequence identity over short windows of 10-20 amino acids, and may possess sequence identities of at least 85% or at least 90% or 95% depending on their similarity to the reference sequence.
  • sequence identity An agent that binds substantially only to a defined target.
  • a Lu. longipalpis specific binding agent is an agent that binds substantially to a Lu. longipalpis polypeptide.
  • the specific binding agent is a monoclonal or polyclonal antibody that specifically binds the Lu. longipalpis polypeptide.
  • Subject Living multi-cellular vertebrate organisms, a category that includes both human veterinary subjects, including human and non-human mammals.
  • the subject is a member of the canine family, such as a dog.
  • the subject is a human.
  • T Cell A white blood cell critical to the immune response.
  • T cells include, but are not limited to, CD4 + T cells and CD8 + T cells.
  • a CD4 + T lymphocyte is an immune cell that carries a marker on its surface known as "cluster of differentiation 4" (CD4). These cells, also known as helper T cells, help orchestrate the immune response, including antibody responses as well as killer T cell responses.
  • CD8 + T cells carry the "cluster of differentiation 8" (CD8) marker.
  • a CD8 T cells is a cytotoxic T lymphocytes.
  • a CD8 cell is a suppressor T cell.
  • Therapeutically active polypeptide An agent, such as a Lu. longipalpis polypeptide, that causes induction of an immune response, as measured by clinical response (for example, increase in a population of immune cells, production of antibody that specifically binds the Lu. longipalpis polypeptide, a measurable reduction in symptoms resulting from exposure to Leishmania, or protection from infection with Leishmania).
  • Therapeutically active molecules can also be made from nucleic acids. Examples of a nucleic acid based therapeutically active molecule is a nucleic acid sequence that encodes a Lu. longipalpis polypeptide, wherein the nucleic acid sequence is operably linked to a control element such as a promoter.
  • Therapeutically active agents can also include organic or other chemical compounds that mimic the effects ofthe - w. longipalpis polypeptide.
  • terapéuticaally effective fragment of a Lu. longipalpis polypeptide includes any fragment of the Lu. longipalpis polypeptide, or variant of the Lu. longipalpis polypeptide, or fusion protein including a Lu. longipalpis polypeptide, that retains a function of the Lu. longipalpis polypeptide (such as immunogenicity), or retains the ability to reduce the symptoms from exposure to Leishmania, or to protect from infection with Leishmania.
  • a therapeutically effective amount of a fragment of Lu. longipalpis polypeptide is an amount used to generate an immune response to the polypeptide.
  • a therapeutically effective amount of a fragment of a Lu. longipalpis polypeptide is an amount of use to prevent or treat a Leishmania infection in a subject. Treatment refers to a therapeutic intervention that confers resistance to infection with Leishamania, or a reduction in the symptoms associated with exposure to Leishamania.
  • Specific, non-limiting examples of a polypeptide fragment are the N-terminal half or the C-terminal half of one of the P. Lu. longipalpis polypeptide disclosed herein.
  • fusion proteins are included, such as a fusion with six histidine residues, a c-myc tag, or any other polypeptide tag. Such fusions are known to one of skill in the art, and are often used in protein purification.
  • transduced A transduced cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques.
  • transduction encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.
  • a nucleic acid molecule as introduced into a host cell, thereby producing a transduced host cell.
  • a vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication.
  • a vector may also include one or more selectable marker genes and other genetic elements known in the art.
  • Vaccine Composition that when administered to a subject, induces a decrease of the severity of the symptoms of a disorder or disease. In one embodiment, a vaccine decreases the severity of the symptoms of leishmaniasis and/or decreases the parasitic load.
  • Salivary polypeptides from sand fly species Lu. longipalpis are disclosed herein.
  • LJL138 (SEQ ID NO: 57) MHLQLNLCAILLSVLNGIQGAPKSINSKSCAISFPENVTAKKEPVYLKPSNDGSLSTPLQPSGP
  • LJL15 (SEQ ID NO: 59) MNLHLAIILFVSYFTLITATDLIEl ⁇ LSDCK-KIFISKAELTWFQALDFCTEQNLTLLSIKSAR-EN DEVTl V] EVHLPDT ⁇ SHIWLGGIRYDQD] ⁇ DFRWISDGTTVTKTVYlNWYQGEPNGGR YQI ⁇ FCMELYFKTPAGQWIWDICTAKHHFICQEKK
  • LJL91 (SEQ ID NO: 61) MNLPLAIILFVSYFTLITAADLTEKELSDGKIOFISKAELSWFDALDACTEKDLTLLTIKSAREN EEVTK-AVRAEVHLPDT1 ⁇ SHIWLGGIRYDQD1 ⁇ FRWISDGTTVTKT ⁇ INWYQGEPNGGRY QKEFCMELYFKTPAGQWNDDICTAKHHFICQEKK
  • LJS138 (SEQ ID NO: 65) MQSKILSFVLFTLSLGYVLGETCSNAKVKGATSYSTTDATFVSQIAFVTEFSLECSNPGSEKISL FAEVDGOTPVAMIGDTTYQVSWNEEVNKARSGDYSVKLYDEEGYGAVRKAQRSGEENKV - ⁇ LATVVVRHPGTYTGPWFNSEILAAGLIAVVAYFAFSTRSKILS
  • LJL124 (SEQ ID NO: 67) MVSILLISLILNLLVFYAl ⁇ RPLEDISSDLSPDYYITEGYDGVK ⁇ KREIELWVTFGIFNIHTTPA PRITFEW
  • a polypeptide including SEQ ID NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ ID NO: 9, SEQ ID NO: 15, SEQ ED NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ED NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ED NO: 61, SEQ ED NO: 63, SEQ ED NO: 65, or SEQ ED NO: 67 is disclosed herein.
  • Homologous polypeptides having an amino acid sequence at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence as set forth as SEQ ID NO: 3, SEQ ED NO: 5, SEQ ID NO: 7, SEQ ED NO: 9, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ED NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ED NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67 are disclosed herein.
  • Fusion proteins including SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ED NO: 9, SEQ ED NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ID NO: 21, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ED NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67 are also disclosed herein.
  • a fragment of a Lu. longipalpis polypeptide includes at least 8, 10, 15, or 20 consecutive amino acids of a Lu. longipalpis polypeptide.
  • a fragment of a Lu. longipalpis polypeptide includes a specific antigenic epitope found on a full-length Lu. longipalpis polypeptide.
  • a fragment is at least 19 amino acids, at least 23 amino acids, at least 25 amino acids, or at least 30 amino acids in length from any polypeptide (including polypeptides as given in SEQ ED NO: 3, SEQ ED NO: 5, SEQ ID NO: 7, SEQ ED NO: 9, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ D NO: 31, SEQ ED NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ED NO: 61, SEQ ED NO: 63, SEQ ED NO: 65, or SEQ ED NO: 67 conservative variants thereof, and homo
  • a fusjon protein includes an amino acid sequence set forth as SEQ ED NO: 3, SEQ ED NO: 5, SEQ ED NO: 1, SEQ ED NO: 9, SEQ ID NO: 15, SEQ JD NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ED NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ID NO: 61, SEQ ED NO: 63, SEQ ID NO: 65, or SEQ ED NO: 67, or a conservative variants thereof, and a
  • Marker polypeptides include, but are not limited to, polypeptide tags, such as a polypeptide to aid in protein purification (for example, six histidine residues or c-myc polypeptide), or an enzymatic marker (for example, alkaline phosphatase), or a fluorescent maker (for example, green fluorescent protein).
  • polypeptide tags such as a polypeptide to aid in protein purification (for example, six histidine residues or c-myc polypeptide), or an enzymatic marker (for example, alkaline phosphatase), or a fluorescent maker (for example, green fluorescent protein).
  • Lu. longipalpis polypeptide can purify using standard techniques for protein purification.
  • the substantially pure polypeptide will yield a single major band on a non-reducing polyacrylamide gel.
  • the purity of the Lu. longipalpis polypeptide can also be determined by amino-terminal amino acid sequence analysis.
  • Lu. longipalpis polypeptide primary amino acid sequences may result in peptides which have substantially equivalent activity as compared to the unmodified counterpart polypeptide described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein.
  • Polynucleotides encoding salivary polypeptides from Lu. longipalpis sand fly are disclosed herein, such as polynucleotides encoding SEQ ID NO: 3, SEQ ID NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ED NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ED NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67.
  • Lu. longipalpis nucleic acid sequences include SEQ TD NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ JD NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:26, SEQ ED NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ED NO:42, SEQ ID NO:44, SEQ ID NO:46, or SEQ ID NO:48, SEQ ED NO:50, SEQ ED NO:52, SEQ JD NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ JD NO:68, and degenerate variants thereof.
  • polynucleotides include DNA, cDNA, and RNA sequences that encode a Lu. longipalpis polypeptide. It is understood that all polynucleotides encoding a Lu. longipalpis polypeptide are also included herein, as long as they encode a polypeptide with the recognized activity, such as the binding to an antibody that recognizes the polypeptide, the induction of an immune response to the polypeptide, or an effect on survival of Leishmania when administered to a subject having leishmaniasis or who undergoes a decrease in a sign or a symptom of Leishmania infection.
  • the polynucleotides of the disclosure include sequences that are degenerate as a result of the genetic code. There are 20 natural arnino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the disclosure as long as the amino acid sequence of the Lu. longipalpis polypeptide encoded by the nucleotide sequence is functionally unchanged.
  • LJL34 (SEQ ID NO:2) AGTTGTGGAGCTTTTGGTCATTT ⁇ ACGTGATGTTGCAAATTAAACATCTTCTGATTTTTGT GGGATTGCTCGTGGTTGTTAATGCACAGAGCAATTACTGCAAACAGGAATCGTGCTCAT
  • fragments of the above-described nucleic acid sequences that are at least
  • the LJL34 unprocessed protein is encoded by nucleic acids 30-842 of SEQ ID NO: 1
  • the mature protein is encoded by the nucleic acid sequence 87-842 of SEQ ID NO:l.
  • the LJL18 unprocessed protein is encoded by nucleic acids 56-532 of SEQ ID NO:3, and the mature protein is encoded by the nucleic acid sequence 113-532 of SEQ ID NO:3.
  • the LJS193 unprocessed protein is encoded by nucleic acids 216-502 of SEQ JD NO:5, and the mature protein is encoded by the nucleic acid sequence 276-502 of SEQ ID NO:5.
  • the LJS201 unprocessed protein is encoded by nucleic acids 48-353 of SEQ ID NO:7, and the mature protein is encoded by the nucleic acid sequence 117-352 of SEQ ED NO:7.
  • the LJL1 unprocessed protein is encoded by nucleic acids 26-766 of SEQ TD NO:9, and the mature protein is encoded by the nucleic acid sequence 83-766 of SEQ ID NO:9.
  • the LJL23 unprocessed protein is encoded by nucleic acids 18-992 of SEQ TD NO:ll, and the mature protein is encoded by the nucleic acid sequence 81-992 of SEQ TD NO: 11.
  • the LJM10 unprocessed protein is encoded by nucleic acids 92-571 of SEQ D NO:13, and the mature protein is encoded by the nucleic acid sequence 149-571 of SEQ TD NO:13.
  • the LJL143 unprocessed protein is encoded by nucleic acids 46-948 of SEQ JD NO:15, and the mature protein is encoded by the nucleic acid sequence 115-948 of SEQ TD NO: 15.
  • the LJS142 unprocessed protein is encoded by nucleic acids 25-507 of SEQ ED NO:17, and the mature protein is encoded by the nucleic acid sequence 85-507 of SEQ ED NO: 17.
  • the LJL17 unprocessed protein is encoded by nucleic acids 28-342 of SEQ ID NO: 19, and the mature protein is encoded by the nucleic acid sequence 88-342 of SEQ TD NO:19.
  • the LJM06 unprocessed protein is encoded by nucleic acids 50-523 of SEQ ED NO:21 , and the mature protein is encoded by the nucleic acid sequence 107-523 of SEQ ID NO:21.
  • the LJM17 unprocessed protein is encoded by nucleic acids 24-1264 of SEQ ID NO:23, and the mature protein is encoded by the nucleic acid sequence 83-1264 of SEQ ID NO:23.
  • the LJL04 unprocessed protein is encoded by nucleic acids 30-914 of SEQ ID NO:25, and the mature protein is encoded by the nucleic acid sequence 81-914 of SEQ ID NO:25.
  • the LJMl 14 unprocessed protein is encoded by nucleic acids 29-475 of SEQ ID NO:27, and the mature protein is encoded by the nucleic acid sequence 101-475 of NO:27.
  • the LJMl 11 unprocessed protein is encoded by nucleic acids 24-1214 of SEQ ID NO:29, and the mature protein is encoded by the nucleic acid sequence 78-1214 of SEQ ID NO:29.
  • the LJM78mature unprocessed protein is encoded by nucleic acids 42-1091 of SEQ ID NO:
  • the mature protein is encoded by the nucleic acid sequence 102-11091 of SEQ ID NO:31.
  • the LJS238 unprocessed protein is encoded by nucleic acids 27-206 of SEQ ID NO:33, and the mature protein is encoded by the nucleic acid sequence 87-206 of SEQ ID NO:33.
  • the LJS169 unprocessed protein is encoded by nucleic acids 11-370 of SEQ ED NO:35, and the mature protein is encoded by the nucleic acid sequence 77-370 of SEQ ED NO:35.
  • the LJL11 unprocessed protein is encoded by nucleic acids 30-1745 of SEQ TD NO:37, and the mature protein is encoded by the nucleic acid sequence 105-1745 of SEQ ID NO:37.
  • the LJL08 unprocessed protein is encoded by nucleic acids 26-238 of SEQ JD NO:39, and the mature protein is encoded by the nucleic acid sequence 95-238 of SEQ ED NO:39.
  • the LJS105 unprocessed protein is encoded by nucleic acids 24-275 of SEQ ED NO:41, and the mature protein is encoded by the nucleic acid sequence 81-275 of SEQ ID NO:41.
  • the LJL09 unprocessed protein is encoded by nucleic acids 74-1954 of SEQ ID NO:43, and the mature protein is encoded by the nucleic acid sequence 128-1954 of SEQ ID NO:43.
  • the LJL38 unprocessed protein is encoded by nucleic acids 40-165 of SEQ ID NO:45, and the mature protein is encoded by the nucleic acid sequence 100-165 of SEQ TD NO:45.
  • the LJM04 unprocessed protein is encoded by nucleic acids 40-456 of SEQ ED NO:47, and the mature protein is encoded by the nucleic acid sequence 100-456 of SEQ ID NO:47.
  • the LJM26 unprocessed protein is encoded by nucleic acids 96-1616 of SEQ ED NO:49, and the mature protein is encoded by the nucleic acid sequence 147-1616 of SEQ TD NO:49.
  • the LJS03 unprocessed protein is encoded by nucleic acids 41-553 of SEQ ID NO:51, and the mature protein is encoded by the nucleic acid sequence 98-553 of SEQ ID NO:51.
  • the LJS192 unprocessed protein is encoded by nucleic acids 18-344 of SEQ ID NO:53, and the mature protein is encoded by the nucleic acid sequence 87-344 of SEQ ID NO:53.
  • the LJM19 unprocessed protein is encoded by nucleic acids 16-360 of SEQ ED NO:55, and the mature protein is encoded by the nucleic acid sequence 82-360 of SEQ ID NO:55.
  • the LJL138 unprocessed protein is encoded by nucleic acids 12-1238 of SEQ ED NO:57 and the mature protein is encoded by the nucleic acid sequence 72-1238 of SEQ ID NO:57.
  • the LJL15 unprocessed protein is encoded by nucleic acids 63-542 of SEQ ID NO:59, and the mature protein is encoded by the nucleic acid sequence 120-542 of SEQ ID NO:59.
  • the LJL91 unprocessed protein is encoded by nucleic acids 63-542 of SEQ ID NO:61, and the mature protein is encoded by the nucleic acid sequence 120-542 of SEQ ID NO:61.
  • the LJMl lunprocessed protein is encoded by nucleic acids 20-1216 of SEQ ID NO:63, and the mature protein is encoded by the nucleic acid sequence 74-1216 of SEQ ID NO:63.
  • the LJS138 unprocessed protein is encoded by nucleic acids 12-1238 of SEQ ED NO:65, and the mature protein is encoded by the nucleic acid sequence 72-138 of SEQ ID NO:65.
  • the LJL124 unprocessed protein is encoded by nucleic acids 23-241 of SEQ ID NO:67, and the mature protein is encoded by the nucleic acid sequence 83-241 of SEQ ID NO:67.
  • the LJL35 unprocessed protein is encoded by nucleic acids 12-1238 of SEQ ED NO:69, and the mature protein is encoded by the nucleic acid sequence 72-1238 of SEQ ID NO:69.
  • polynucleotide encoding a Lu. longipalpis polypeptide is a polynucleotide having at least 75%, 85%, 90%, 95%, or 99% homology to one of the sequences set forth above that encodes a polypeptide having an antigenic epitope or function of a Lu. longipalpis polypeptide.
  • Yet another specific non-limiting example of a polynucleotide encoding a Lu. longipalpis polypeptide is a polynucleotide that encodes a polypeptide that is specifically bound by an antibody that specifically binds the Lu. longipalpis polypeptide. The Lu.
  • longipalpis polynucleotides include a recombinant DNA which is inco ⁇ orated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (for example, a cDNA) independent of other sequences.
  • the nucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide.
  • the term includes single and double forms of either nucleotide.
  • the term includes single and double forms of DNA.
  • Recombinant vectors are also disclosed herein that include a polynucleotide encoding a polypeptide or a fragment thereof according to the disclosure.
  • Recombinant vectors include plasmids and viral vectors and may be used for in vitro or in vivo expression.
  • a plasmid may include a DNA transcription unit, for instance a nucleic acid sequence that permit it to replicate in a host cell, such as an origin of replication (prokaryotic or eukaryotic).
  • a plasmid may also include one or more selectable marker genes and other genetic elements known in the art. Circular and linear forms of plasmids are encompassed in the present disclosure.
  • the promoter is generally of viral or cellular origin.
  • the cytomegalovirus (CMV) early promoter (CMV-IE promoter) is of use.
  • the CMV-IE promoter can be of human or murine origin, or of other origin such as rat or guinea pig (see EP 0260148; EP 0323597; WO 89/01036; Pasleau et al, Gene 38:227-232, 1985; Boshart M. et al, Cell 41:521-530, 1985). Functional fragments of the CMV-IE promoter may also be used (WO 98/00166).
  • the SV40 virus early or late promoter and the Rous Sarcoma virus LTR promoter are also of use.
  • Other promoters include but are not limited to, a promoter of a cytoskeleton gene, such as (but not limited to ⁇ the desmin promoter (Kwissa M. et al, Vaccine 18(22):2337-2344, 2000), or the actin promoter (Miyazaki J. et al, Gene 79(2):269-277, 1989).
  • a promoter of a cytoskeleton gene such as (but not limited to ⁇ the desmin promoter (Kwissa M. et al, Vaccine 18(22):2337-2344, 2000), or the actin promoter (Miyazaki J. et al, Gene 79(2):269-277, 1989).
  • the plasmids may also comprise other transcription regulating elements such as, for example, stabilizing sequences of the intron type.
  • the plasmids include the first intron of CMV-IE (Published PCT Application No. WO 89/01036), the intron II of the rabbit ⁇ - globin gene (van Ooyen et al, Science 206:337-344, 1979), the signal sequence of the protein encoded by the tissue plasminogen activator (tPA; Montgomery et al, Cell. Mol Biol. 43:285-292, 1997), and/or a polyadenylation signal (polyA), in particular the polyA of the bovine growth hormone (bGH) gene (U.S. Patent No.
  • the pVR1020 plasmid (VICAL Inc.; Luke C. et al, Journal of Infectious Diseases 175:91-97, 1997; Hartikka J. et al, Human Gene Therapy 7:1205- 1217, 1996)) can be utilized as a vector for the insertion of such a polynucleotide sequence, generating recombinant plasmids.
  • the plasmids are evaluated in dogs in order to determine their efficacy against a Leishmania infection (Vidor E. et al, P3.14, XXIV World Veterinary Congress, Rio de Janeiro, Brazil, 18-23 August 1991).
  • Various viral vectors are also of use with a polynucleotide encoding a Lu. longipalpis polypeptide.
  • a specific, non-limiting example includes recombinant poxvirus, including avipox viruses, such as the canarypox virus.
  • Another specific, non-limiting example includes recombinant poxvirus, including vaccinia viruses (U.S. Patent No. 4,603,112), such as attenuated vaccinia virus such as NYVAC (see U.S. Patent No. 5,494,807) or Modified Vaccinia virus Ankara (MVA, Stickl H. and Hochstein-Mintzel V., Munch. Med. Wschr. 113:1149-1153, 1971; Sutler G.
  • the insertion sites may be in particular in the ORFs C3, C5 or C6.
  • the heterologous polynucleotide can be inserted under the control of a poxvirus specific promoter, such as the vaccinia virus 7.5kDa promoter (Cochran et al, J. Virology 54:30-35, 1985), the vaccinia virus I3L promoter (Riviere et al, J.
  • Virology 66:3424-3434, 1992 the vaccinia virus HA promoter (Shida, Virology 150:451-457, 1986), the cowpox virus ATI promoter (Funahashi et al, J. Gen. Virol. 69:35-47, 1988), other vaccinia virus H6 promoter (Taylor et al, Vaccine 6:504-508, 1988; Guo et al, J. Virol. 63:4189-4198, 1989; Perkus et al, J. Virol. 63:3829-3836, 1989).
  • herpes virus or adenovirus vectors include a canine herpes virus (CHV) or canine adenovirus (CAV) vector (for example, see U.S. Patent No. 5,529,780; U.S. Patent No. 5,688,920; Published PCT Application No. WO 95/14102).
  • CHV canine herpes virus
  • CAV canine adenovirus
  • the insertion sites may be in particular in the thymidine kinase gene, in the ORF3, or in the UL43 ORF (see U.S. Patent No. 6, 159,477).
  • CAV the insertion sites may be in particular in the E3 region or in the region located between the E4 region and the right ITR region (see U.S.
  • the insert in general under the control of a promoter (as described above for the plasmids), such as CMV-IE promoter.
  • each polynucleotide insert is inserted under the control of different promoters.
  • the insertion can be done tail-to-tail, head-to-head, tail-to-head, or head-to-tail.
  • IRES elements Internal Ribosome Entry Site, see European Patent EP 0803573
  • Bacterial vectors can also be used for in vivo expression. Any polynucleotide according to the disclosure can be expressed in vitro by DNA transfer or expression vectors into a suitable host cell.
  • the host cell may be prokaryotic or eukaryotic.
  • the term "host cell” also includes any progeny of the subject host cell. Methods of stable transfer, meaning that the foreign polynucleotide is continuously maintained in the host cell, are known in the art.
  • Host cells can include bacteria (for example, Escherichia coli), yeast, insect cells, and vertebrate cells. Methods of expressing DNA sequences in eukaryotic cells are well known in the art.
  • Baculovirus vectors for example, Autographa California Nuclear Polyhedrosis Virus (AcNPV)
  • AcNPV Autographa California Nuclear Polyhedrosis Virus
  • polyhedrin promoters can be utilized with insect cells (for example, Spodopterafrugiperda cells, like Sf9 cells available at the ATCC under the Accession number CRL- 1711, or Sf21 cells) (see for example, Smith et al, Mol. Cell Biol. 3:2156-2165, 1983; Pennock e? ⁇ /., Mol. Cell Biol. 4: 399-406, 1994; Vialard et al, J. Virol.
  • BaculoGold TM Starter Package (Cat # 21001K) from Pha ⁇ riingen (Becton Dickinson) can be used.
  • recombinant E. coli can be used with a vector.
  • inducible promoters such as arabinose promoter, pL of bacteriophage lambda, plac, ptrp, ptac (ptrp-lac hybrid promoter), and the like may be used.
  • Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art.
  • the host is prokaryotic, such as E. coli
  • competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl 2 method using procedures well known in the art.
  • CaCl 2 or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell if desired, or by electroporation.
  • Eukaryotic cells can also be cotransformed with Lu. longipalpis polynucleotide sequences, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene.
  • a eukaryotic viral vector such as a herpes virus or adenovirus (for example, canine adenovirus 2)
  • a transfection agent can be utilized, such as dioleoyl-phosphatidyl-emanolamine (DOPE).
  • DOPE dioleoyl-phosphatidyl-emanolamine
  • Isolation and purification of recombinantly expressed polypeptide may be carried out by conventional means including preparative chromatography (for example, size exclusion, ion exchange, affinity), selective precipitation and ultra-filtration.
  • a recombinantly expressed polypeptide is part of the present disclosure.
  • the methods for production of such a polypeptide are also encompassed, in particular the use of a recombinant expression vector comprising a polynucleotide according to the disclosure and of a host cell.
  • Antibodies A Lu. longipalpis polypeptide of the disclosure or a fragment thereof according to the disclosure can be used to produce antibodies.
  • Polyclonal antibodies, antibodies which consist essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibodies are included. Such antibodies are of use as markers for exposure, and as immunodiagnostic tools to follow the development of the immune response to Lu. longipalpis salivary proteins.
  • polyclonal antibodies The preparation of polyclonal antibodies is well-known to those skilled in the art. See, for example, Green et al, "Production of Polyclonal Antisera,” Immunochemical Protocols, pp. 1-5, Manson, ed., Humana Press, 1992; Coligan et al, "Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters," Current Protocols in Immunology, section 2.4.1, 1992. The preparation of monoclonal antibodies likewise is conventional. See, for example,
  • monoclonal antibodies can be obtained by injecting mice with a composition comprising an antigen, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B lymphocytes, fusing the B lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.
  • Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion- exchange chromatography. See, for example, Coligan et al, sections 2.7.1-2.7.12 and sections 2.9.1- 2.9.3; Barnes et al, "Purification of Immunoglobulin G (IgG),” Methods in Molecular Biology, Vol. 10, pp. 79-104, Humana Press, 1992.
  • Multiplication in vitro may be carried out in suitable culture media such as Dulbecco's Modified Eagle Medium or RPMI 1640 medium, optionally supplemented by a mammalian serum such as fetal calf serum or trace elements and growth-sustaining supplements such as normal mouse peritoneal exudate cells, spleen cells, thymocytes, or bone marrow macrophages.
  • suitable culture media such as Dulbecco's Modified Eagle Medium or RPMI 1640 medium
  • a mammalian serum such as fetal calf serum or trace elements
  • growth-sustaining supplements such as normal mouse peritoneal exudate cells, spleen cells, thymocytes, or bone marrow macrophages.
  • Multiplication in vivo may be carried out by injecting cell clones into mammals histocompatible with the parent cells, for example, syngeneic mice, to cause growth of antibody-producing tumors.
  • the animals are primed with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane) prior to injection. After one to three weeks, the desired monoclonal antibody is recovered from the body fluid of the animal.
  • Antibodies can also be derived from subhuman primate antibody. General techniques for raising therapeutically useful antibodies in baboons can be found, for example, in WO 91/11465, 1991, and Losman et ⁇ /., 7»t. J. Cancer 46:310, 1990.
  • an antibody that specifically binds a polypeptide can be derived from a humanized monoclonal antibody.
  • Humanized monoclonal antibodies are produced by transferring mouse complementarity deteiniining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then substituting human residues in the framework regions of the murine counterparts.
  • the use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by Orlandi et al, Proc. Nat'lAcad. Sci. USA 86:3833, 1989.
  • Antibodies can be derived from human antibody fragments isolated from a combinatorial immunoglobulin library. See, for example, Barbas et al, Methods: a Companion to Methods in Enzymology, Vol. 2, p. 119, 1991; Winter et al, Ann. Rev. Immunol. 12:433, 1994.
  • Cloning and expression vectors that are useful for producing a human immunoglobulin phage library can be obtained, for example, from STRATAGENE Cloning Systems (La Jolla, CA).
  • antibodies can be derived from a human monoclonal antibody.
  • Such antibodies are obtained from transgenic mice that have been "engineered” to produce specific human antibodies in response to antigenic challenge.
  • elements of the human heavy and light chain loci are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy and light chain loci.
  • the transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody- secreting hybridomas.
  • Methods for obtaining human antibodies from transgenic mice are described by Green et al, Nature Genet. 7:13, 1994; Lonberg et al, Nature 368:856, 1994; and Taylor et al, Int. Immunol. 6:579, 1994.
  • Antibodies include intact molecules as well as fragments thereof, such as Fab, F(ab') 2 , and Fv which are capable of binding the epitopic dete ⁇ riinant. These antibody fragments retain some ability to selectively bind with their antigen or receptor and are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain (L) and a portion of one heavy chain(H); (2) Fab', the fragment of an antibody molecule that can be obtained by treating a whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule;
  • (Fab') 2 the fragment of the antibody that can be obtained by treating a whole antibody with the enzyme pepsin without subsequent reduction;
  • F(ab') 2 is a dimer of two Fab' fragments held together by two disulfide bonds;
  • Fv defined as a genetically engineered fragment containing the variable region of the light chain (V L ) and the variable region of the heavy chain (V H ) expressed as two chains;
  • Single chain antibody defined as a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.
  • Antibody fragments can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli of DNA encoding the fragment.
  • Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods.
  • antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab') 2 .
  • This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments.
  • a thiol reducing agent optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages
  • an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly (see U.S. Patent No. 4,036,945 and U.S. Patent No. 4,331,647, and references contained therein ⁇ isonhoff et ⁇ t., rc/z. Biochem. Biophys. 89:230, 1960; Porter, Biochem.
  • Fv fragments comprise an association of V H and V L chains. This association may be noncovalent (Inbar et al, Proc. Nat'lAcad. Sci. USA 69:2659, 1972). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. See, for example, Sandhu, supra.
  • the Fv fragments comprise V H and V L chains connected by a peptide linker.
  • sFv single-chain antigen binding proteins
  • the structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli.
  • the recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains.
  • Methods for producing sFvs are known in the art (see Whitlow et al, Methods: a Companion to Methods in Enzymology, Vol. 2, page 97, 1991; Bird et al, Science 242:423, 1988; U.S. Patent No. 4,946,778; Pack et al, Bio/Technology 11:1271, 1993; and Sandhu, supra).
  • CDR peptides (“minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells (Larrick et al, Methods: a Companion to Methods in Enzymology, Vol. 2, page 106, 1991).
  • Antibodies can be prepared using an intact polypeptide or fragments containing small peptides of interest as the i ⁇ imunizing antigen.
  • the polypeptide or a peptide used to immunize an animal can be derived from substantially purified polypeptide produced in host cells, in vitro translated cDNA, or chemical synthesis, which can be conjugated to a carrier protein, if desired.
  • carrier protein if desired.
  • Such commonly used carriers which are chemically coupled to the peptide include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid.
  • KLH keyhole limpet hemocyanin
  • BSA bovine serum albumin
  • the coupled peptide is then used to immunize an animal (for example, a mouse, a rat, or a rabbit).
  • Polyclonal or monoclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound.
  • a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound.
  • Those of skill in the art will know of various techniques common in the immunology arts for purification and or concentration of polyclonal antibodies, as well as monoclonal antibodies (See for example, Coligan et al, Unit 9, Current Protocols in Immunology, Wiley Interscience, 1991).
  • an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region that is the "image" of the epitope bound by the first mono-clonal antibody.
  • label for example, enzymes or fluorescent molecules
  • an antibody that binds a Lu. Longipalpis polypeptide can be used to assess whether a subject has been bitten by a sand fly.
  • a sample is obtained from a subject of interest, such as a human or a dog.
  • the sample can be a body fluid (for example, blood, serum, urine, saliva, etc.) or a tissue biopsy.
  • the sample or a fraction thereof is contacted with the antibody, and the ability of the antibody to form an antigen-antibody complex is assessed.
  • One of skill in the art can readily detect the formation of an antigen-antibody complex. For example, ELISA, Western blot, or radio-immune assays can be utilized.
  • the immunogenic compositions and vaccines include a polypeptide.
  • the immunogenic compositions and vaccines include a recombinant vector, such as a viral vector or a plasmid.
  • a cellular response such as a Thl response, produced against the salivary protein can indirectly kill a Leishmania parasite.
  • a Thl type response can allow macrophages to take up Leishmania antigens and present them to T cells in a Thl context.
  • the induction the Thl response can produce an anti-Leishmania immune response, or can prime the immune system of the mammalian host for anti-Leishmania immunity in response to a later infection.
  • the immunogenic composition or the vaccine includes an effective amount of at least one Lu. longipalpis polypeptide disclosed herein.
  • the immunogenic composition and the vaccine can include a pharmaceutically acceptable excipient and/or an adjuvant.
  • the immunogenic composition or vaccine includes a polypeptide having an amino acid sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ TD NO: 7, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ED NO: 33, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ID NO: 51, SEQ ED NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ED NO: 61, SEQ ED NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67, a polypeptide at least 80%, at least 90%, at least 95%, or at least 99%) homologous to one of these
  • the immunogenic composition or vaccine includes a polypeptide having an amino acid sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ED NO: 17, SEQ ED NO: 19, SEQ JD NO: 21, SEQ JD NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ TD NO: 31, SEQ TD NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ TD NO: 49, SEQ ID NO: 51, SEQ TD NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ED NO: 67.
  • the immunogenic composition includes a polypeptide having a sequence set forth as one of SEQ TD NO: 3, SEQ ID NO: 11, SEQ ID NO: 19, SEQ ED NO: 29, SEQ ED NO: 55, or SEQ ID NO: 59.
  • the immunogenic composition includes more than one Lu. longipalpis polypeptide, such as two, three, four, five, six, ten or more of the polypeptides disclosed herein.
  • the immunogenic composition includes at least one polypeptide having an amino acid sequence as set forth as SEQ ID NO: 3, SEQ TD NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ TD NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ED NO: 33, SEQ ID NO: 35, SEQ ED NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ TD NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ID NO
  • the immunogenic composition includes an amino acid having a sequence as set forth as SEQ ID NO: 1, SEQ ID NO: 23, SEQ ID NO: 39, a polypeptide at least 80%, at least 90%, at least 95%, or at least 99% homologous to one of these polypeptides, a conservative variant of one of these polypeptides, or a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides, or a combination of these polypeptides.
  • the immunogenic composition can include a polypeptide having a sequence as set forth as SEQ ID NO: 1, SEQ ID NO: 23, or SEQ ID NO: 39.
  • compositions include, but are not limited to, an immunogenic composition including a polypeptide having a sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 11, SEQ ED NO: 19, SEQ ED NO: 29, SEQ ED NO: 55, or SEQ ID NO: 59, and a polypeptide having a sequence as set forth as SEQ ID NO: 1, SEQ LD NO: 23, or SEQ ID NO: 39.
  • the immunogenic composition or the vaccine can include a pharmaceutically acceptable excipient and/or an adjuvant.
  • the immunogenic composition or the vaccine includes an effective amount of at least one Lu. longipalpis polypeptide in conjunction with one or more P. perniciosus polypeptide(s) and/or one or more P. ariasi polyeptide(s).
  • Lu. longipalpis polypeptide in conjunction with one or more P. perniciosus polypeptide(s) and/or one or more P. ariasi polyeptide(s).
  • the immunogenic composition or the vaccine comprises an effective amount of a recombinant vector expressing at least one Lu. longipalpis polypeptide disclosed herein and a pharmaceutically acceptable vehicle or excipient.
  • the recombinant vector encodes at least one polypeptide having an amino acid sequence as set forth as SEQ JD NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ TD NO: 15, SEQ ED NO: 17, SEQ ED NO: 19, SEQ ID NO: 21, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59,
  • the vector encodes a polypeptide having a sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 19, SEQ ID NO: 29, SEQ ID NO: 55, or SEQ TD NO: 59, a polypeptide at least 80%), at least 90%, at least 95%, or at least 99% homologous to one of these polypeptides, a conservative variant, a homolog, an immunogenic fragment, or a fusion protein thereof.
  • the vector encodes one or more polypeptides having a sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 19, SEQ ED NO: 29, SEQ ED NO: 55, or SEQ ED NO: 59.
  • the vector can also optionally encode a polypeptide having a sequence as set forth as SEQ TD NO: 1, SEQ ED NO: 23, or SEQ ID NO: 39.
  • the immunogenic composition can include a nucleic acid sequence encoding a P. ariasi polypeptide(s) and/or a P. perniciosus polypeptide(s) (see U.S. Provisional Application No. 60/412,327, which is incorporated by reference herein in its entirety).
  • the Lu in one embodiment, the Lu.
  • Lu. longipalpis polypeptide(s), a P. ariasi polypeptide(s) and/or a P. perniciosus polypeptide(s) are encoded by different recombinant vectors.
  • the Lu. longipalpis polypeptide can be administered by any means known to one of skill in the art (See Banga, A., "Parenteral Controlled Delivery of Therapeutic Peptides and Proteins,"
  • IM intramuscular
  • ID intradermal
  • SC subcutaneous
  • intravenous injection but even oral, nasal, or anal administration is contemplated.
  • administration is by subcutaneous, intradermal, or intramuscular injection using a needleless injector (BiojectorTM, Bioject, Oregon, USA).
  • the peptide or protein can be provided as an implant, an oily injection, or as a particulate system.
  • the particulate system can be a microparticle, a microcapsule, a microsphere, a nanocapsule, or similar particle, (see, for example, Banja, supra).
  • a particulate carrier based on a synthetic polymer has been shown to act as an adjuvant to enhance the immune response, in addition to providing a controlled release.
  • Aluminum salts may also be used as adjuvants to produce a humoral immune response.
  • a Lu. longipalpis polypeptide is aciministered in a manner to induce a humoral response.
  • a Lu. longipalpis polypeptide is administered in a manner to direct the immune response to a cellular response (that is, a CTL response), rather than a humoral (antibody) response.
  • a cellular response that is, a CTL response
  • humoral (antibody) response a cellular response
  • Lipids have been identified as agents capable of assisting in priming CTL in vivo against various antigens. For example, as described in U.S. Patent No.
  • palmitic acid residues can be attached to the alpha and epsilon amino groups of a lysine residue and then linked (for example, via one or more linking residues, such as glycine, glycine-glycine, serine, serine-serine, or the like) to an immunogenic peptide.
  • the lipidated peptide can then be injected directly in a micellar form, incorporated in a liposome, or emulsified in an adjuvant.
  • coli lipoproteins such as tripalrnitoyl-S-glycerylcysteinylseryl-serine can be used to prime tumor specific CTL when covalently attached to an appropriate peptide (see, Deres et al, Nature 342:561, 1989). Further, as the induction of neutralizing antibodies can also be primed with the same molecule conjugated to a peptide which displays an appropriate epitope, the two compositions can be combined to elicit both humoral and cell-mediated responses where that is deemed desirable.
  • an MHC class El-restricted T-helper epitope is added to the polypeptide of the disclosure to induce T-helper cells to secrete cytokines in the microenvironment to activate CTL precursor cells.
  • the technique further involves adding short lipid molecules to retain the construct at the site of the injection for several days to localize the antigen at the site of the injection and enhance its proximity to dendritic cells or other "professional” antigen presenting cells over a period of time (see Chesnut et al, "Design and Testing of Peptide-Based Cytotoxic T-Cell- Mediated Immunotherapeutics to Treat Infectious Diseases and Cancer," Powell, et al, (eds.), Vaccine Design, the Subunit and Adjuvant Approach, Plenum Press, New York, 1995).
  • An immunogemc composition or a vaccine according to the disclosure can be prepared in accordance with standard techniques well known to those skilled in the pharmaceutical or veterinary art. Such compositions can be administered in dosages and by techniques well known to those skilled in the medical or veterinary arts, taking into consideration such factors as the age, sex, weight, species, and condition of the particular subject, and the route of administration.
  • the immunogenic composition or the vaccine can be a ⁇ niinistered alone, or in combination with adjuvant(s) and or with other antigen(s).
  • the other antigen(s) can be a Leishmania antigen.
  • the Leishmania antigen is the A2 antigen, such as the A2 antigen from L. infantum (see Published PCT Patent Application No.
  • the other antigen(s) can be present in the composition as a protein, or as an immunological fragment thereof (for example, an epitope), or as an insert in an expression vector (for example, recombinant viral vector, recombinant plasmid, in particular the pVR1012 (Vical Inc.; Hartikka J. et al, Human Gene Therapy 7:1205-1217, 1996)).
  • an expression vector for example, recombinant viral vector, recombinant plasmid, in particular the pVR1012 (Vical Inc.; Hartikka J. et al, Human Gene Therapy 7:1205-1217, 1996).
  • Any immunogenic composition, vaccine, or therapeutic composition according to the disclosure can be mixed with an adjuvant.
  • Polypeptide-based compositions :
  • the polypeptide-based immunogenic compositions and vaccines according to the disclosure are formulated with (1) vitamin E, saponin (for example, Quil ATM, QS21TM), aluminum hydroxide, aluminum phosphate, aluminum oxide ("Vaccine Design, The subunit and adjuvant approach," Pharmaceutical Biotechnology, vol. 6, Edited by Micheal F. Powell and Mark J. Newman, 1995, Plenum Press New York), (2) an acrylic acid or methacrylic acid polymer, a polymer of maleic anhydride and of alkenyl derivative, (3) an immunostimulating sequence (ISS), in particular an oligodeoxyribonucleotidic sequence bearing one or more non- methylated CpG groups (Klinman D. M. et al, Proc.
  • ISS immunostimulating sequence
  • cytokines cytokines
  • cytokines (5) that can be added to the composition, include, but are not limited to, GM-
  • CSF granulocyte-macrophage colony stimulating factor
  • cytokines inducing Thl for example, IL-12
  • All these cytokines can be added to the composition as a protein or as a vector encoding this cytokine protein.
  • the cytokines are from canine origin, for example, canine GM- CSF, for which a gene sequence has been deposited at the GenBank database (Accession No. S49738). This sequence can be used to create the vector in a manner similar to what was made in the Published PCT Patent Application No. WO 00/77210.
  • the adjuvant contains two or more of an emulsifier, a micelle-forming agent, and an oil.
  • Suitable emulsifiers, micelle-forming agents, and oils are detailed in U.S. Patent Nos. 5, 585,103; 5,709,860; 5,270,202; and 5,695,770, all of which are incorporated by reference.
  • An emulsifier is any molecule that allows the components of the emulsion to remain as a stable emulsion.
  • Such emulsifiers include polysorbate 80 (Sorbitan-mono-9-octadecenoate-poly(oxy- 1,2-ethanediyl); manufactured by ICI Americas, Wilmington, Del), polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 85, dodecyl-N,N-dimethyl-3-ammonio- 1-propanesulfonate, TEEPOL HB7 TM, and SPAN 80 TM SPAN 85 TM, ethoxylated fatty alcohols, ethoxylated fatty acids, ethoxylated castor oil (hydrogenated or not).
  • these emulsifiers are provided in an amount of approximately 0.05 to approximately 0.5%. In another embodiment, these emulsifiers are provided in an amount of approximately 0.2%.
  • a micelle forming agent is an agent which is able to stabilize the emulsion formed with the other components such that a micelle-like structure is formed. Examples of such agents include polymer surfactants described by BASF Wyandotte publications, for example, Schmolka, J. Am. Oil. Chem. Soc. 54:110, 1977, and Hunter et al, J. Immunol. 129:1244, 1981, PLURONICTM L62LF, L101, L121, and L64, PEG1000, and TETRONICTM 1501, 150R1, 701, 901, 1301, and 130R1.
  • the agent is chosen to have a hydrophile-lipophile balance (HLB) of between about 0 and about 2, as defined by Hunter and Bennett, J. Immun. 133:3167, 1984.
  • HLB hydrophile-lipophile balance
  • the agent can be provided in an effective amount, for example between about 0.5 and about 10%.
  • the agent can be provided in an effective amount, for example between about 1.25 and about 5%.
  • the oil included in the composition is chosen to promote the retention of the antigen in oil-in-water emulsion, for instance, to provide a vehicle for the desired antigen.
  • the oil has a melting temperature of less than about 65° C such that emulsion is formed either at room temperature (about 20° C to about 25° C), or once the temperature of the emulsion is brought down to room temperature.
  • the oil-in-water emulsion (4) can be based in particular on light liquid paraffin oil
  • isoprenoid oil such as squalane, squalene, EICOSANE TM or tetratetracontane
  • esters of acids or of alcohols containing a linear alkyl group more particularly plant oils, ethyl oleate, propylene glycol di(caprylate/caprate), glyceryl tri(caprylate/caprate) or propylene glycol dioleate
  • esters of branched fatty acids or alcohols in particular isostearic acid esters.
  • the oil is used in combination with emulsifiers to form the emulsion.
  • the emulsifiers are nonionic surfactants, in particular esters of sorbitan, mannide (for example, arihydrornannitol oleate), glycerol, polyglycerol, propylene glycol, and oleic, isostearic, ricinoleic, or hydroxystearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in particular the Pluronic® products, especially L121.
  • the oil is provided in an amount between about 1 and about 60%. In another specific, non-limiting example, the oil is provided in an amount between about 5 and about 30%.
  • the adjuvant is a mixture of emulsifiers, nacelle-forming agent, and oil available under the name Provax® (EDEC Pharmaceuticals, San Diego, CA).
  • the acrylic acid or methacrylic acid polymers (2) can be cross-linked in particular with polyalkenyl ethers of sugars or of polyalcohols. These compounds are known under the term "carbomer” (Pharmeuropa, Vol. 8, No. 2, June 1996). A person skilled in the art may also refer to U.S. Patent No. 2,909,462 (incorporated by reference) describing such acrylic polymers cross-linked with a polyhydroxylated compound containing at least 3 hydroxyl groups. In one embodiment, a polyhydroxylated compound contains not more than 8 hydroxyl groups.
  • the hydrogen atoms of at least 3 hydroxyls are replaced with unsaturated aliphatic radicals containing at least 2 carbon atoms.
  • radicals contain from about 2 to about 4 carbon atoms, for example, vinyls, allyls, and other ethylenically unsaturated groups.
  • the unsaturated radicals can themselves contain other substituents, such as methyl.
  • Carbopol® Noveon Inc., Ohio, USA
  • Carbopol® are particularly suitable. They are cross-linked with an allyl sucrose or with allylpentaerythritol Among these, mention may be made of the products Carbopol® 974P, 934P, and 971P.
  • copolymers of maleic anhydride and of an alkenyl derivative such as the EMA® products (Monsanto) which are copolymers of maleic anhydride and of ethylene, maybe linear or cross-linked, for example cross-linked with divinyl ether.
  • EMA® products Monsanto
  • the acrylic acid or methacrylic acid polymers and the EMA® products are formed from units based on the following formula:
  • y 1.
  • the dissolution of these polymers in water leads to an acid solution, which is neutralized to physiological pH, in order to give to the subject the adjuvant solution into which the immunogenic composition or the vaccine itself is incorporated.
  • the carboxyl groups of the polymer are then partly in COO " form.
  • a solution of adjuvant, especially of carbomer is prepared in distilled water.
  • a solution of adjuvant, especially of carbomer is prepared in the presence of sodium chloride, the solution obtained being at acidic pH.
  • this stock solution is diluted by adding it to the desired quantity (for obtaining the desired final concentration), or a substantial part thereof, of water charged with NaCl.
  • stock solution is diluted by adding it to the desired quantity of physiological saline (NaCl 9 g/1) all at once in several portions with concomitant or subsequent neutralization (pH 7.3 to 7.4).
  • the stock solution is neutralized with NaOH.
  • This solution at physiological pH is used as it is for mixing with the immunogenic composition or with the vaccine, which may be especially stored in freeze-dried, liquid or frozen form.
  • the polymer concentration in the final vaccine composition is from about 0.01 to about 1.5% W/V. In another embodiment, the final vaccine composition is from about 0.05 to about 1% W/V. In yet another embodiment, the final vaccine composition is from about 0.1 to about 0.4% W/V.
  • Lipids have been identified as agents capable of stimulating the immune response for various antigens. For example, as described in U.S. Patent No. 5,662,907, palmitic acid residues can be attached to the alpha and epsilon amino groups of a lysine residue and then linked (for example, via one or more linking residues, such as glycine, glycine-glycine, serine, serine-serine, or the like) to an immunogenic peptide.
  • the lipidated peptide can then be injected directly in a micellar form, incorporated in a liposome, or emulsified in an adjuvant.
  • E. coli lipoproteins such as tripaln ⁇ oyl-S-glyceiylcyste ylsei ⁇ l-serine, can be used.
  • the peptide or protein can be provided as an implant, an oily injection, or as a particulate system.
  • the particulate system can be a microparticle, a microcapsule, a microsphere, a nanocapsule, or similar particle, (see, for example, Banja, supra).
  • a particulate excipient based on a synthetic polymer has been shown to act as an adjuvant to enhance the immune response, in addition to providing a controlled release.
  • the plasmid-based compositions is formulated with cationic lipids, in particular with cationic lipids containing a quaternary ammonium salt having the following formula:
  • Rl is a saturated or unsaturated linear aliphatic radical from 12 to 18 carbon atoms
  • R2 is another aliphatic radical comprising from 2 to 3 carbon atoms
  • X is an hydroxyl or amine group.
  • DMRIE N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(terradecyloxy)-l- propanammonium; Published PCT Application No. WO 96/34109
  • the cationic lipid is in association with a neutral lipid, for example DOPE (dioleoyl- phosphatidyl-ethanolamine; Behr J.
  • the mixture is made extemporaneously about 10 minutes to about 60 minutes before administration. In another embodiment, the mixture is made extemporaneously about 30 minutes before administration.
  • the molar ratio DMRIE/DOPE is from about 95/5 to about 5/95. In another embodiment, the molar ratio DMRIE/DOPE is about 1/1.
  • the weight ratio plasmid/DMRIE or DMRIE- DOPE adjuvant is from about 50/1 to about 1/10. In another embodiment, the weight ratio plasmid/DMRIE or DMRIE-DOPE adjuvant is from about 10/1 to about 1/5.
  • the weight ratio plasmid DMRIE or DMRIE-DOPE adjuvant is from about 1/1 to about 1/2.
  • a cytokine or non-methylated CpG groups is added to the composition, as described above for polypeptide-based compositions. The addition can be done advantageously by a plasmid encoding the cytokine.
  • Viral vector-based composition is a composition of Viral vector-based composition:
  • the recombinant viral vector-based composition can be supplemented with fMLP (N- formyl-methionyl-leucyl-phenylalanine; U.S. Patent No. 6,017,537) and/or acrylic acid or methacrylic acid polymer adjuvant as described above for polypeptide-based compositions. They can also be formulated with emulsions as described above. In one embodiment, cytokines, non-methylated CpG groups, or emulsions are added to the composition as described above for polypeptide-based compositions. The addition can be done advantageously by a viral vector encoding said cytokine.
  • the immunogenic compositions and vaccines according to the disclosure are conserved and stored either in formulated form at 5°C, or in lyophihzed form.
  • the immunogenic compositions and vaccines according to the disclosure are conserved and stored either in formulated form at 5°C, or in lyophihzed form with a stabilizer. Freeze-dryrng can be done according to well-known standard freeze-drying procedures.
  • the pharmaceutically acceptable stabilizers may be SPGA (sucrose phosphate glutamate albumin) (Bovarnik et al, J.
  • the present disclosure provides methods for inducing an immune response to a Lutzomyia sand fly polypeptide in a subject.
  • the present disclosure provides further methods for inhibiting or preventing leishmaniasis in a subject. These methods include the administration of at least one immunogenic composition or vaccine according to the disclosure.
  • compositions or a vaccine according to the disclosure can be prepared in accordance with standard techniques well known to those skilled in the pharmaceutical or veterinary art. Such compositions can be administered in dosages and by techniques well known to those skilled in the medical or veterinary arts, taking into consideration such factors as the age, sex, weight, species, and condition of the particular subject, and the route of administration.
  • the delay between two sequential administrations is from about 1 week to about 6 months. In another embodiment, the delay is from about 3 weeks to about 6 weeks. In yet another embodiment, the delay is from about 4 weeks. Following vaccination, annual boost administrations may be done.
  • At least one prime-adininistration can be done with a composition containing a plasmid according to the disclosure, following by at least one booster aclminisrration done with a composition containing a recombinant viral vector according to the disclosure, on the condition that a same Lu. longipalpis salivary polypeptide is present twice, coded by the plasmid and by the viral vector.
  • the booster a ⁇ n ⁇ inistration can be done with a composition containing a polypeptide according to the disclosure, on the condition that a same Lu. longipalpis salivary polypeptide is present twice, coded by the prime-administration plasmid and in the booster polypeptide-based composition.
  • the antigen(s) may be in admixture with a suitable vehicle or excipient such as sterile water, physiological saline, glucose, or the like.
  • a suitable vehicle or excipient such as sterile water, physiological saline, glucose, or the like.
  • the compositions can contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, adjuvants, gelling, or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. Standard texts, such as Remington's Pharmaceutical Science, 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.
  • the compositions can also be lyophihzed.
  • Suitable dosages can also be based upon the examples below.
  • the route of administration can be ED, EM, SC, intravenous, oral, nasal, or anal. This a ⁇ -ministration can be made with a syringe and a needle or with a needle-less apparatus like, for example, BiojectorTM (Bioject, Oregon, USA).
  • polypeptide dosages can be from about 1 to 250 ⁇ g/ml, from about 15 to about 150 ⁇ g/dose, or from about 20 to about 100 ⁇ g/dose.
  • the volume of a dose can be between about 0.1 ml and about 0.5 ml.
  • the volume of a dose can be about 0.25 ml.
  • Administration with multiple points of injection is preferred.
  • the volumes are from about 0.1 to about 2 ml.
  • the volumes are from about 0.5 to about 1 ml.
  • the route of administration can be ID, IM, SC, intravenous, oral, nasal, or anal. This administration can be made with a syringe and a needle or with a needle-less apparatus like, for example, BiojectorTM.
  • the dosage is from about 50 ⁇ g to about 500 ⁇ g per plasmid.
  • DMRIE-DOPE is added, about 100 ⁇ g per plasmid is preferred.
  • the plasmid encoding this protein is present at a dosage from about 200 ⁇ g to about 500 ⁇ g. In another embodiment, the plasmid encoding this protein is present at a dosage of about 200 ⁇ g.
  • the volume of a dose can be between about 0.1 ml and about 0.5 ml. In another embodiment, the volume of a dose can be about 0.25 ml. In yet another embodiment, a ⁇ ninistration is performed using multiple points of injection. In one embodiment, for conventional injection with a syringe and a needle, the volumes are from about 0.1 to about 2 ml. In another embodiment, the volumes are from about 0.5 to about 1 ml. The dosage are the same than mentioned above.
  • the route of administration can be ID, EM,
  • the dosage is from about 10 3 pfu to about 10 9 pfu per recombinant poxvirus vector.
  • the dosage is from about 10 5 pfu to about 10 9 pfu.
  • the dosage is from about 10 6 pfu to about 10 s pfii.
  • the volume of needle-less apparatus doses could be between about 0.1 ml and about 0.5 ml.
  • the volume of needle-less apparatus dose is 0.25 ml.
  • administration is performed using multiple points of injection.
  • the volumes are from about 0.1 to about 2 ml.
  • the volumes are from about 0.5 to about 1 ml.
  • the dosages are the same as mentioned above.
  • the injection is IM.
  • the prime-administration is made with a plasmid-based composition and the boost administration is made with a recombinant viral vector-based composition.
  • the boost administration is made with a canarypox vector.
  • Both priming and boosting administrations include vectors encoding at least one identical Lu. longipalpis salivary antigens, and optionally Leishmania A2 antigens.
  • the dosage of plasmids and recombinant viral vectors are the same as above.
  • the boost admimstration can be done with a polypeptide-based composition. In this case, the dosage of polypeptide is from about 1 to about 250 ⁇ g/ml, from about 15 to about 150 ⁇ g/dose, or from about 20 to about 100 ⁇ g/dose.
  • the methods include liposomal delivery of the nucleic acids (or of the synthetic peptides themselves), and immune-stimulating constructs, or ISCOMS TM, negatively charged cage-like structures of 30-40 nm in size formed spontaneously on mixing cholesterol and Quil ATM (saponin).
  • ISCOMS TM immune-stimulating constructs
  • Protective immunity has been generated in a variety of experimental models of infection, including toxoplasmosis and Epstein-Barr virus-induced tumors, using ISCOMS TM as the delivery vehicle for antigens (Mowat and Donachie, Immunol Today 12:383, 1991).
  • Doses of antigen as low as 1 ⁇ g encapsulated in ISCOMS TM have been found to produce class I mediated CTL responses (Takahashi et al, Nature 344:873, 1990).
  • a Lu. longipalpis polypeptide, or an immunogenic fragment thereof can also be expressed by attenuated viral hosts or vectors or bacterial vectors.
  • Recombinant vaccinia virus, adeno-associated virus (AAV), herpes virus, retrovirus, or other viral vectors can be used to express the peptide or protein, thereby eliciting a CTL response.
  • vaccinia vectors and methods useful in immunization protocols are described in U.S. Patent No. 4,722,848.
  • BCG Bacillus Calmette Guerin
  • a nucleic acid encoding a Lu. longipalpis polypeptide, or an immunogenic fragment thereof is introduced directly into cells.
  • the nucleic acid may be loaded onto gold microspheres by standard methods and introduced into the skin by a device such as Bio-Rad's HeliosTM Gene Gun.
  • a needless injector can also be utilized, such as a Bioinjector2000TM.
  • the nucleic acids can be "naked," consisting of plasmids under control of a strong promoter.
  • the DNA is injected into muscle, although it can also be injected directly into other sites.
  • Exemplary dosages for injection are around 0.5 ⁇ g/kg to about 50 mg/kg, and typically are about 0.005 mg/kg to about 5 mg/kg (see, for example, U.S. Patent No. 5,589,466).
  • a prime-boost strategy for immunization is utilized.
  • a nucleic acid encoding a Lu. longipalpis polypeptide is administered to the subject, followed by immunization with an attenuated or inactivated form of Leishmania.
  • compositions and the vaccines disclosed herein can be administered for preventative and therapeutic treatments.
  • compositions are administered to a subject suffering from a disease, such as Leishmaniasis, in a therapeutically effective amount, which is an amount sufficient to cure or at least partially arrest the disease or a sign or symptom of the disease. Amounts effective for this use will depend upon the severity of the disease and the general state of the subject's health. An effective amount of the compound is that which provides either subjective relief of a symptom(s) or an objectively identifiable improvement as noted by the clinician or other qualified observer.
  • the dosage is adniinistered once as a bolus, but in another embodiment can be applied periodically until a therapeutic result is achieved. Generally, the dose is sufficient to treat or ameliorate symptoms or signs of disease without producing unacceptable toxicity to the subject.
  • the dosage of the composition varies depending on the weight, age, sex, and method of administration. The dosage can also be adjusted by the individual physician as called for based on the particular circumstances.
  • the compositions can be administered conventionally as vaccines containing the active composition as a predetermined quantity of active material calculated to produce the desired therapeutic or immunologic effect in association with the required pharmaceutically acceptable carrier or diluent (for instance, carrier or vehicle). For example, about 50 ⁇ g of a DNA construct vaccine of the present disclosure can be injected intradermally three times at two week intervals to produce the desired therapeutic or immunologic effect.
  • a about 1 mg/Kg dosage of a protein vaccine of the present disclosure can be injected intradermally three times at two week intervals to produce the desired therapeutic or immunologic effect.
  • a vaccine is provided herein that includes a Lu. longipalpis polypeptide or polynucleotide.
  • the subject is a human subject.
  • the subject is a canine subject, such as a dog.
  • a method for diagnosing infection with Leishmana by detecting the presence of antibodies that specifically bind one or more polypeptides having an amino acid sequence as set forth as SEQ ID NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ TD NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ TD NO: 29, SEQ LD NO: 31, SEQ JD NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ED
  • the method can utilize a single Lu. Longipalpis polypeptide or a combination of these polypeptides.
  • the method of diagnosis detects antibodies that specifically bind at least 3, 6, or 10 of these polypeptides, or immunogenic fragments thereof.
  • one or more Lu. Longipalpis polypeptide can be bound to a solid substrate.
  • the Lu. Longipalpis polypeptide having an amino acid sequence as set forth as SEQ TD NO: 3, SEQ ED NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ID NO: 21, SEQ TD NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ED NO: 33, SEQ ID NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67 can be bound to the substrate.
  • One of more of these polypeptides can be bound to the substrate, for example at least 3, 6, or 10 of these polypeptides, or an immunogenic fragment thereof.
  • one or more polypeptides having a sequence set forth as one of SEQ ID NO: 3, SEQ ID NO: 11, SEQ D NO: 19, SEQ ID NO: 29, SEQ ED NO: 55, or SEQ ID NO: 59 can be bound to the substrate.
  • one or more Lu Longipalpis a polypeptides having a sequence set forth as one of SEQ ID NO: 1, SEQ ID NO: 23, or SEQ ID NO: 39 can be bound to the substrate.
  • at least six Lu is
  • Longipalpis polypeptides are bound to a solid substrate, wherein each of the polypeptides comprises an amino acid sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 19, SEQ D NO: 29, SEQ ID NO: 55, or SEQ ED NO: 59, or an immunogenic fragment thereof. In another specific, non-limiting example, at least three Lu. Longipalpis polypeptides are bound to a solid substrate, wherein each of the polypeptides comprises an amino acid sequence as set forth as SEQ ED NO: 1, SEQ ID NO: 23, or SEQ ED NO: 39, or an immunogenic fragment thereof.
  • two or more (for example at least 3, 6, or 10) Lu Longipalpis polypeptides (or immunogenic fragments thereof) are applied to a solid substrate, for example as a series of "dots," such as in a "dot blot" assay.
  • two or more Lu Longipalpis polypeptides are applied to a substrate such as in a linear array.
  • Lu Longipalpis polypeptides are applied to a membrane in a two-dimensional array. In this manner, the presence of antibodies to more than one Lu. Longipalpis polypeptide is assessed. ⁇ a ⁇ xLu. Longipalpis polypeptide can be applied directly to the surface of a membrane in a single location or in a combination of locations.
  • the solid substrate can be a polystyrene bead, a membrane, a chip or a plate.
  • a plastic or glass substrate can be utilized.
  • a membrane is utilized that is composed of porous materials such as nylon, nitrocellulose, cellulose acetate, glass fibers, and other porous polymers.
  • the surface of a solid support may be activated by chemical processes that cause covalent linkage of polypeptide to the support.
  • any other suitable method may be used for immobilizing a polypeptide to a solid support including, without limitation, ionic interactions, hydrpphobic interactions, covalent interactions and the like.
  • the substrate can be contacted with a substance, such as protem-containing solution, which non-specifically saturates the binding sites thereon.
  • a substance such as protem-containing solution
  • a protein- containing solution include a solution made from powdered milk or serum albumin, such as bovine serum albumin.
  • a specimen for example, sera, blood, plasma, urine, semen, saliva, sputum, lacrimal fluid, lymph fluid
  • a specimen for example, sera, blood, plasma, urine, semen, saliva, sputum, lacrimal fluid, lymph fluid
  • a labeled secondary antibody is used to detect the antibodies that specifically bind the Lu. Longipalpis polypeptides.
  • the label can be a radiolabel (for example, I25 I), an enzymatic label (for example, alkaline phosphatase or horseradish peroxidase), or a fluorescent label (for example, fluoroscein isothiocyanate). Detection systems for these labels are known to one of skill in the art. Binding of the specimen, or a component of the specimen, to the Lu. Longipalpis polypeptide, as indicated by the presence of the marker, indicates infection with Leishmania.
  • a radiolabel for example, I25 I
  • an enzymatic label for example, alkaline phosphatase or horseradish peroxidase
  • a fluorescent label for example, fluoroscein isothiocyanate
  • the specimen is adsorbed onto a solid substrate containing binding sites for polypeptides, such as antibody molecules.
  • the solid substrate is a polystyrene bead, a chip, a membrane or a plate.
  • the substrate is thereafter contacted with a substance, such as a protein-containing solution that non-specifically saturates the binding sites thereon.
  • the substrate is then washed with a buffer.
  • a solution of one or more Lu. Longipalpis polypeptides is then added to the bound specimens.
  • the Lu. Longipalpis polypeptide is directly labeled. The labeling of the Lu.
  • Longipalpis polypeptide can be brought about by use of any marker, such as by incorporation of a radioactive isotope or group, or by coupling this component to an enzyme, a dyestuff, for example a chromophoric moiety or a fluorescent group.
  • a marker such as by incorporation of a radioactive isotope or group, or by coupling this component to an enzyme, a dyestuff, for example a chromophoric moiety or a fluorescent group.
  • the enzymes of use are those which can be colorimetrically, spectrophotometrically, or fluorimetrically determined.
  • Non-limiting examples of enzymes for use in the present invention include enzymes from the group of oxidoreductases, such as catalase, peroxidase, glucose oxidase, beta-glucuronidase, beta-D-glucosidase, beta-D-galactosidase, urease and galactose oxidase. After the labeled Lu.
  • oxidoreductases such as catalase, peroxidase, glucose oxidase, beta-glucuronidase, beta-D-glucosidase, beta-D-galactosidase, urease and galactose oxidase.
  • Longipalpis polypeptide is incubated with the solid substrate, any unbound labeled Lu. Longipalpis polypeptide is removed by washing. Bound labeled Lu. Longipalpis polypeptide is then detected by an appropriate assay. Binding of the labeled Lu. Longipalpis polypeptide to the specimen, or to a component of the specimen, is indicative of infection with Leishmania.
  • the incubation steps utilized in carrying out the procedures can be performed in a known manner, such as by incubating at temperatures between about 4° C and about 25° C, for about 30 minutes to about 48 hours.
  • Washings can be included with an aqueous solution such as a buffer, wherein the buffer is from about pH 6 to about pH 8, such as by using an isotonic saline solution of a pH of about 7.
  • aqueous solution such as a buffer
  • the buffer is from about pH 6 to about pH 8, such as by using an isotonic saline solution of a pH of about 7.
  • Competitive binding assays are also of use in detecting infection with Leishmania.
  • One of skill in the art, given the Lu. Longipalpis polypeptides disclosed herein, will readily be able to design additional assays, such as competitive binding assays, of use in detecting Leishmania infection.
  • a diagnostic test kit for detecting a Leishmania infection includes a solid substrate having applied thereon one or more Lu. Longipalpis polypeptide disclosed herein.
  • the kit includes written instructions and/or a container including a specified amount of labeled antibodies to immunoglobulins, such as IgG or IgM, or labeled secondary antibodies that bind antibodies from a species of interest.
  • labeled antibodies can be provided that specifically detect dog or human immunoglobulins.
  • the labeled antibodies can be fiuorescently labeled, enzymatically labeled, or radiolabeled. Labeled antibodies used in the above- described test kits can be packaged in either solution form, or in lyophilized forms suitable for reconstitution.
  • test kit includes a specified amount of one or more Lu. Longipalpis polypeptide described herein in a container, and written instructions. In one example, the Lu. Longipalpis polypeptide is directly labeled. In another example, the one or more Lu.
  • Longipalpis polypeptide is unlabeled. If the Lu. Longipalpis polypeptide is unlabeled, a container can also be included with a detection reagent that specifically binds the Lu. Longipalpis polypeptide, such as a labeled monoclonal antibody. The kit can also optionally include a solid substrate for binding the specimen. The above described process and test kit for detection of antibodies to the Lu. Longipalpis polypeptides disclosed herein can be utilized in many applications, including, but not limited to detecting Leishmania infection in a subject using the methods disclosed herein. The tests and kits disclosed herein can be used to detect the efficacy of a therapeutic treatment in a subject.
  • tests and kits disclosed herein can also be used to assess a primary infection with Leishmania or to predict recovery from Leishmania infection by taking a body fluid from an infected subject, for example at various times following infection, and applying the above described detection procedures.
  • PBS sterile phosphate buffered saline
  • the salivary gland of Lu. longipalpis is a sac-like structure consisting of a unicellular epithelium layer surrounding a large lumen (Adler and Theodor, Ann. Trop. Med. Parasitol 20: 109, 1926). After a blood meal, the gland total protein content decreases to half or less from its ⁇ l ⁇ g value (Ribeiro et al, Insect Biochem. 19:409-412, 1989). Accordingly, most of the protein from the fly SGH must be destined for secretion. Indeed, SDS-PAGE of SGH reveals a low complexity composition consisting of ⁇ 12 major bands varying from 10-100 kD (Valenzuela et al, J. Exp. Med.
  • Tris-glycine gels (16%), 1 mm thick, and NUPAGE 12% BIS- tris gels were used (Invitrogen, Carlsbad, CA). Gels were run with either Tris-glycine or MOPS Nupage running buffer according to the manufacturer's instructions. To estimate the molecular weight of the samples, See BlueJ markers from Invitrogen (myosin, BSA, glutamic dehydrogenase, alcohol dehydrogenase, carbonic anhydrase, myoglobin, lysozyme, aprotinin, and insulin, chain B) were used.
  • longipalpis salivary gland mRNA was reverse transcribed to cDNA using Superscript II RNase H- reverse transcriptase (Gibco-BRL, Gaithersburg, MD) and the CDS/3 ' primer (Clontech, Palo Alto, CA) for 1 hour at 42° C.
  • Second strand synthesis was performed using a PCR-based protocol by using the SMART III primer (Clontech, Palo Alto, CA) as the sense primer and the CDS/3' primer as anti-sense primer, these two primers additionally, create at the ends of the nascent cDNA Sfil A and B sites respectively.
  • Double strand cDNA synthesis was done on a Perkin Elmer 9700 Thermal cycler (Perkin Elmer Corp., Foster City, CA) and using the Advantage Klen-Taq DNA polymerase (Clontech, Palo Alto, CA). PCR conditions were the following: 94° C for 2 minutes; 19 cycles of 94°C for 10 seconds and 68° C for 6 minutes. Double-stranded cDNA was immediately treated with proteinase K (0.8 ⁇ g/ ⁇ l) for 20 minutes at 45° C and washed three times with water using Amicon filters with a 100 kDa cut off (Millipore Corp., Bedford MA). The double-stranded cDNA was then digested with Sfi I for 2 hours at 50° C (The Sfi I sites were inserted to the cDNA during the second strand synthesis using the
  • the cDNA was then fractionated using columns provided by the manufacturer (Clontech, Palo Alto, CA). Fractions containing cDNA of more than 400 base pairs (bp) were pooled, concentrated, and washed three times with water using an Amicon filter with a 100 kDa cut-off. The cDNA was concentrated to a volume of 7 ⁇ l The concentrated cDNA was then ligated into a lambda triplex2 vector (Clontech, Palo Alto, CA), and the resulting ligation reaction was packed using the Gigapack gold III from Stratagene/Biocrest (Cedar Creek, TE) following manufacturer's specifications.
  • the obtained library was plated by infecting log phase XLl-blue cells (Clontech, Palo Alto, CA) and the amount of recombinants was determined by PCR using vector primers flaiiking the inserted cDNA and visualized on a 1.1 % agarose gel with ethidium bromide (1.5 ⁇ g/ml)
  • Lu. longipalpis salivary gland cDNA library was plated to approximately 200 plaques per plate (150 mm Petri dish). The plaques were randomly picked and transferred to a 96 well polypropylene plate containing 100 ⁇ l of water per well The plate was covered and placed on a gyrator shaker for 1 hour at room temperature. Four microliters of a phage sample was used as a template for a PCR reaction to amplify random cDNAs.
  • the primers used for this reaction were sequences from the triplex2 vector, the primers were named PT2F1 (5'- AAGTACTCT AGCAAT TGTGAGC- 3') (SEQ ID NO:71) which is positioned upstream of the cDNA of interest (5' end), and PT2R1 (5'- CTCTTCGCTATTACGCCAGCT G- 3') (SEQ ID NO:72) which is positioned downstream of the cDNA of interest (3' end).
  • Platinum Taq polymerase Gibco-BRL, Gaithersburg, MD was used for these reactions.
  • Amplification conditions were the following: 1 hold of 75° C for 3 minutes, 1 hold of 94° C for 3 minutes and 34 cycles of 94° C for 30 seconds, 49° C for 30 seconds and 72° C for 1 minute and 20 seconds. Amplified products were visualized on a 1.1% agarose gel with ethidium bromide. Clean PCR was used as a template for a cycle sequencing reaction using the DTCS labeling kit fromBeckman Coulter Inc. (Fullerton, CA). The primer used for sequencing (PT2F3) (5'- TCTCGGGAAGCGCGCCATTGTGTT - 3') (SEQ ED NO:73) is upstream of the inserted cDNA and downstream of the primer PT2F1.
  • Sequencing reaction was performed on a Perkin Elmer 9700 thermacycler. Conditions were 75° C for 2 minutes, 94° C for 4 minutes, and 30 cycles of 96° C for 20 seconds, 50° C for 20 seconds and 60° C for 4 minutes.
  • a cleaning step was done using the multi-screen 96 well plate cleaning system from Millipore (Bedford, MA).
  • the 96 well multi-screening plate was prepared by adding a fixed amount (according to the manufacturer's specifications) of Sephadex-50 (Amersham Pharmacia Biotech, Piscataway, NJ) and 300 ⁇ l of deionized water. After 1 hour of incubation at room temperature, the water was removed from the multi screen plate by centrifugation at 750 g for 5 minutes.
  • Samples were sequenced immediately on a CEQ 2000 DNA sequencing instrument (Beckman Coulter Inc., Fullerton, CA) or stored at -30° C. The entire cDNA of selected genes was fully sequenced using custom primers using a CEQ 2000 DNA sequencing instrument (Beckman Coulter Inc., Fullerton, CA) as described above.
  • the VR-2001-TOPO (a variant of the VRl 020 plasmid from Vical) plasmid contains a kanamycin resistance gene, the human cytomegalovirus promoter, and the tissue plasminogen activator signal peptide upstream of the TOPO TA cloning site.
  • Plasmids were transformed into the TOP-10 strain of is. coli (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The transformed bacteria were grown in LB medium and the plasmid was subsequently purified using the commercial plasmid purification kit Megaprep (Qiagen, Valencia, CA). Each plasmid was named according to the name of the polypeptide. Thus pLJL34 is a plasmid encoding LJL34, and pLJMl 1 is a plasmid encoding LJMl 1 polypeptide, etc. Study population.
  • Sera used in the study using human subjects were obtained from an epidemiologic survey of visceral leishmaniasis (VL) in children less than 7 years of age in an endemic region of Sao Luiz, Maranhao State, in northeastern Brazil.
  • VL visceral leishmaniasis
  • anti-Leishmania DTH and serology were performed twice a year during 1997 and 1998. Only children who had neither VL, a positive serology, nor DTH on the first survey were included in the study. None of the individuals in the data set had the disease, and all had negative responses to leishmanial antigen during the preceding 6-month period.
  • Anti-sand fly saliva serology Anti-sand fly saliva serology ELISA was performed as previously described (Barral et al, ibid). Sera IgG subclasses were determined using anti-human IgGl, IgG3, or IgG4 alkaline-phosphatase conjugates (Sigma-Aldrich, St. Louis, MO). To determine IgE levels, sera were previously absorbed using Rheumatoid Factor. Anti-human IgE (Sigma-Aldrich, St. Louis, MO) was used in the ELISA.
  • DNA data derived from the mass sequencing project were analyzed by an in-house program written in VisualBASIC (Microsoft). This program removed vector and primer sequences from the raw sequence. Stripped sequences were compared to the NCBI non-redundant protein database using the program BlastX using the BLOSUM-62 matrix (Altschul et al, Nucleic Acids Research 25:3389, 1997). DNA sequences were clustered by blasting the database against itself with a preselected threshold cutoff, usually le "10 (BlasfN program) (Altschul et al, Nucleic Acids Research 25:3389, 1997). Sequences from the same cluster were aligned using ClustalX (Jeanmougin et al, Trends
  • PAGE gels were transferred to PVDF membranes, and the amino terminal sequence of each cut band by Edman degradation were estimated.
  • the number and pattern of Lu. longipalpis salivary proteins recognized by the sera of individuals who converted either from S ⁇ -> S + or from DTH " -> DTH + was evaluated by Western blot. From seven randomly selected sera of individuals who converted their anti-Leishmania serology, two poorly recognized two different salivary proteins of 33 kDa and 200 kDa, respectively (FIG. 2A, lane 4); the remaining sera did not recognize any salivary protein at any time point. Conversely, from 13 randomly selected sera of DTH " — > DTH individuals, 12 recognized a variety of salivary proteins with various intensities. FIGS. 2A and 2B show the diversity of salivary antigens recognized by these sera (lanes 7-14).
  • the sera of the DTH " -> DTH + individuals recognized a total of 16 different salivary proteins; however, the frequency of recognition varies among these individuals (FIG. 2C).
  • a salivary protein of 45 kDa was recognized by 12 sera, followed by proteins of 44 and 43 and 35 kDa recognized by 8 sera (each), a protein of 17 kDa by 6 sera, and a protein of 16 kDa by 5 sera.
  • Other salivary proteins were recognized as well but with less frequency (3 sera or less, FIG. 2C).
  • IgGl has been related to a human Thl response. Elevation of IgE antibodies suggests the development of an immediate hypersensitivity, since IgE is considered a marker of Th2-type responses. Without being bound by theory, it is likely that a mixed Tl ⁇ 2-type (related to immediate hypersensitivity) and Thl-like response (related to DTH) against saliva components coexist in individuals who recently converted their anti-Leishmania DTH. In fact, this type of mixed response was reported in individuals exposed to insect bites, where the host immune response against insect saliva starts with DTH response and evolves to a predominant immediate-type hypersensitivity and finally desensitization (Melanby, Nature. 158, 554-555.13, 1946).
  • mice were purchased from Taconic Farms. Mice were maintained in the NIAED Animal Care Facility under pathogen-free conditions. Mice were inoculated in the right ear with 30 ⁇ g of the plasmid encoding the selected cDNA from Lu. longipalpis suspended in 5 ⁇ l of PBS. Each group is boosted 2 weeks later using the same regimen. Mice were challenged on the opposite ear with salivary gland homogenate of Lu. longipalpis and delayed type hypersensitivity (DTH) response is measured 24 hours after the injection by measuring thickness and redness of ear (++: at least 2 mice with a good DTH response, +++ : at least three mice had a good DTH response).
  • DTH delayed type hypersensitivity
  • DTH delayed type hypersensitivity
  • naive dogs are immunized with the Lu. longipalpis salivary gland protein expressed by a plasmid in order to evaluate the capability to induce a cellular immune response measured by DTH.
  • Twelve dogs approximately three years old with natural immunity against Leishmaniasis are injected via an intradermal route (ID) in the back after shaving, with 100 ⁇ g of each individual plasmid suspended in 100 ⁇ l of PBS. Each plasmid is injected at a different point. The points are separated by at least 3 cm to avoid interference between DTH responses.
  • ID intradermal route
  • the DTH response is assessed 72 hours after injection by measuring the larger diameter of the skin tumefaction area. The results are expressed as the mean value of the tumefaction area for all the dogs and as a percentage of dogs having a positive DTH response.
  • a positive DTH is a tumefaction area diameter greater than or equal to 4 mm at 72 hours after injection.
  • 10 na ' ive dogs 4 to 6 months old are immunized by ID injection in 10 points (100 ⁇ l per point) in the right ear with a pool of the plasmids encoding a Lu. longipalpis polypeptide, 100 ⁇ g for each one suspended in 1000 ⁇ l of PBS.
  • dogs are injected in 10 points (100 ⁇ l per point) in the left ear and in 10 points (100 ⁇ l per point) in the belly with a pool of the plasmids, 100 ⁇ g for each one suspended in 2000 ⁇ l of PBS. All dogs are challenged on day 35 by inoculation by ED route in the back (after shaving), with 100 ⁇ g of each individual plasmid suspended in 100 ⁇ l of PBS. Each plasmid is injected at a different point. The points are separated by at least 3 cm to avoid interference. As a negative control, 100 ⁇ l of buffer is inoculated intradermally. The DTH response is assessed 72 hours after challenge, by measuring the larger diameter of the skin tumefaction area.
  • results are expressed as the mean value of the tumefaction area for all the dogs and as a percentage of dogs having a positive DTH response.
  • a positive DTH is a tumefaction area diameter higher or equal of 4 mm at 72 hours after injection.
  • the results of this study show that plasmids can induce a cellular immunity in dogs after injection, a cellular immunity revealeded by a DTH response.
  • the variation of the DTH response level can be by the variation of the expression of the insert.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Substantially purified salivary lu. longipalpis polypeptides, and polynucleotides encoding these polypepetides are disclosed. Vectors and host cells including the lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing leishmaniasis are disclosed.

Description

LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE
PRIORITY CLAIM This application claims the benefit of U.S. Provisional Application No. 60/422,303, filed
October 29, 2002, which is incorporated herein by reference.
FIELD
The disclosure relates to proteins substantially purified from Lutzomyia longipalpis (Lu. longipalpis) sand fly salivary glands, or recombinant vectors expressing these proteins, and to an immune response produced to these proteins. This disclosure also relates to the production of an immune response that affects survival of Leishmania.
BACKGROUND
Leishmaniasis is a group of diseases caused by protozoa of the genus Leishmania and affect many millions of people worldwide. In humans, infection with the parasite manifests either as a cutaneous disease caused mainly by L. major, L. tropica, and L. mexicana; as a mucocutaneous disease caused mainly by L. brasiliensis; or as a visceral disease caused mainly by L. donovani and L. chagasi. In canids, Leishmania infections manifest as a visceral disease that can result in high death rates.
All leishmanial diseases are transmitted to their vertebrate hosts by pmebotomine sand flies, which acquire the pathogen by feeding on infected hosts and transmit them by regurgitating the parasite at the site of a subsequent blood meal (Killick-Kendrick, Biology of Leishmania in pMebotomine sand flies. In Biology of the Kinetoplastida. W. Lumsden and D. Evans, editors. Academic Press, New York. 395, 1979).
While obtaining a blood meal, sand flies salivate into the host's skin. This saliva contains anticlotting, antiplatelet, and vasodilatory compounds that increase the hemorrhagic pool where sand flies feed (Ribeiro et al, Comp. Biochem. Physiol 4:683, 1986; Charlab et al, Proc. Natl Acad. Sci. USA. 26:15155, 1999). Some of these components are additionally immunomodulatory. For example, the New World sand fly Lutzomyia longipalpis contains the 6.5 kDa peptide, maxadilan, which is the most potent vasodilator known (Lerner et al, J. Biol. Chem. 17:11234, 1991). Maxadilan additionally has immunosuppressive activities of its own (Qureshi et al, Am. J. Trop. Med. Hyg. 6:665, 1996), as do many persistent vasodilators such as prostaglandin E2 (Makoul et al, J. Immunol. 134:2645, 1985; Santoli and Zurier, J. Immunol 143:1303, 1989; Stockman and
Mumford, Exp. Hematol 2:65, 1974) and calcitonin gene-related peptide (Nong et al, J. Immunol. 1 :45, 1989). Old World sand flies do not have maxadilan but instead use AMP and adenosine as vasodilators (Ribeiro et al, J. Exp. Biol 11:1551, 1999). Adenosine is also an immunomodulatory component, promoting the production of IL-10 and suppressing TNF-c. and IL-12 in mice (Hasko et al, J. Immunol. 10:4634, 1996; Webster, Asian Pac. J. Allergy Immunol. 2:311, 1984; Hasko et al, FASEB J. 14:2065, 2000). Despite what is known about the role of sand fly saliva and disease transmission, much remains unknown, and an effective vaccine does not exist. Thus, there is a need for agents that can be used to induce an immune response to the organisms that cause leishmaniasis.
SUMMARY
The present disclosure relates to salivary proteins from sand fly vectors of Lutzomyia longipalpis (Lu. longipalpis ) and the nucleic acids that encode these proteins. Methods of producing an immune response in a subject are also disclosed.
Substantially purified salivary Lu. longipalpis polypeptides are disclosed herein. Also disclosed are polynucleotides encoding the Lu. longipalpis polypeptides.
Methods are disclosed for inducing an immune response using a therapeutically effective amount of a substantially purified salivary Lu. longipalpis polypeptide as disclosed herein, or the polynucleotide encoding a Lu. longipalpis polypeptides disclosed herein.
In another embodiment methods are disclosed herein for inhibiting the symptoms of a Leishmania infection or for preventing a Leishmania infection in a subject. The methods include administering to the subject a therapeutically effective amount of a Lu. longipalpis polypeptide, or a polynucleotide encoding a Lu. longipalpis polypeptide. In two non-limiting examples, more than one Lu. longipalpis polypeptide can be administered, or at least one Lu. longipalpis polypeptide in conjunction with a P. ariasi or P. pemiciosus polypeptide. Also disclosed herein are methods of diagnosing Leishmania infection in a subject. The methods include contacting a solid substrate comprising at least three, six, or ten Lu. longipalpis polypeptides, or an immunogenic fragment thereof, contacting the solid substrate with a sample obtained from the subject and detecting binding of a component of the sample to at least one polypeptide on the solid substrate. Detection of binding of the component to the substrate indicates that the subject is infected with Leishmania.
Pharmaceutical compositions are disclosed including a pharmaceutically acceptable carrier and a Lu. longipalpis polypeptide.
The foregoing and other features and advantages will become more apparent from the following detailed description of several embodiments, which proceeds with reference to the accompanying figures.
BRIEF DESCRIPTION OF THE FIGURES FIG. 1 is a set of bar graphs showing the levels of antibodies against Lutzomyia longipalpis (Lu. longipalpis) saliva in sera of individuals. Human sera were obtained at time 0 (negative anti- Leishmania serology (S~) or negative DTH (DTH-)) and 6 months later (positive anti-Leishmania serology (S4) or positive anti-Leishmania DTH (DTH1)). ELISA was performed with these sera using salivary gland sonicate of the sand fly Lu. longipalpis. FIG. 1A is a bar graph of anti-saliva IgG levels in individuals who converted from S" -> S+ and those who converted from DTH" to DTH1". FIG. IB is a bar graph of αnti-saliva IgE levels in the individuals described in FIG. 1A. FIG. 1C is a bar graph of anti-saliva IgGl levels in the individuals described in FIG. 1A. FIG. ID is a bar graph of anti-saliva IgG4 levels in the individuals described in FIG. 1A. The non-parametric paired Wilcoxon test was used to compare levels of anti-Lu. longipalpis saliva antibodies at time 0 and after 6 months. P value < 0.05 was established as the significance level.
FIG. 2 is a set of two digital images and a bar graph showing salivary proteins recognized by Western blot analysis. FIGS. 2A and 2B are digital images of a Western blot of Lu. longipalpis salivary proteins reacted to human sera of individuals who converted from S~ — > S to Leishmania (lanes 1-6) or from DTH" →DTH+ to Leishmania (lanes 7—14). Symbols: — , time 0; +, 6 months. FIG. 2C is a bar graph of the frequency of salivary proteins recognized by sera of 13 individuals who converted from DTBT→ DTH+ to Leishmania. The x-axis shows the different Lu. longipalpis salivary proteins (labeled by the approximate molecular weight) recognized by Western blot analysis, while the y-axis indicates the number of human sera recognizing a particular salivary protein.
SEQUENCE LISTING
The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. In the accompanying sequence listing:
SEQ ID NO 1 is the amino acid sequence of LJL34. SEQ ID NO: 2 is the nucleic acid sequence of LJL34. SEQ ID NO 3 is the amino acid sequence of LJL18. SEQ ID NO 4 is the nucleic acid sequence of LJL18. SEQ ID NO 5 is the amino acid sequence of LJS193. SEQ ID NO 6 is the nucleic acid sequence of LJS193. SEQ ID NO 7 is the amino acid sequence of LJS201. SEQ ID NO 8 is the nucleic acid sequence of LJS201. SEQ ID NO 9 is the amino acid sequence of LJL13. SEQ ID NO 10 is the nucleic acid sequence of LJL13. SEQ ID NO 11 is the amino acid sequence of LJL23.
SEQ ΓD NO 12 is the nucleic acid sequence of LJL23.
SEQ ID NO 13 is the amino acid sequence of LJM10. SEQ ID NO 14 is the nucleic acid sequence of LJM10. SEQ ID NO 15 is the amino acid sequence of LJL143. SEQ ID NO 16 is the nucleic acid sequence of LJL143. SEQ ID NO 17 is the amino acid sequence of LJS142. SEQ ID NO 18 is the nucleic acid sequence of LJS142. SEQ ID NO: 19 is the amino acid sequence of LJL17. SEQ ID NO: 20 is the nucleic acid sequence of LJL17. SEQ ID NO: 21 is the atriino acid sequence of LJM06. SEQ ID NO: 22 is the nucleic acid sequence of LJM06. SEQ ID NO: 23 is the amino acid sequence of LJMl 7. SEQ ID NO: 24 is the nucleic acid sequence of LJM17. SEQ ID NO: 25 is the amino acid sequence of LJL04. SEQ ID NO: 26 is the nucleic acid sequence of LJL04. SEQ ID NO: 27 is the amino acid sequence of LJMl 14. SEQ ID NO: 28 is the nucleic acid sequence of LJMl 14. SEQ ID NO: 29 is the amino acid sequence of LJMl 11. SEQ ID NO: 30 is the nucleic acid sequence of LJMl 11. SEQ ID NO: 31 is the amino acid sequence of LJM78. SEQ ID NO: 32 is the nucleic acid sequence of LJM78. SEQ ID NO: 33 is the amino acid sequence of LJS238. SEQ ID NO: 34 is the nucleic acid sequence of LJS238. SEQ ID NO: 35 is the amino acid sequence of LJS169. SEQ ID NO: 36 is the nucleic acid sequence of LJS169. SEQ ID NO: 37 is the amino acid sequence of LJL11. SEQ ID NO: 38 is the nucleic acid sequence of LJL11. SEQ ID NO: 39 is the amino acid sequence of LJL08. SEQ ID NO: 40 is the nucleic acid sequence of LJL08. SEQ ID NO: 41 is the amino acid sequence of LJS105. SEQ ID NO: 42 is the nucleic acid sequence of LJS105. SEQ ID NO: 43 is the amino acid sequence of LJL09. SEQ ID NO: 44 is the nucleic acid sequence of LJL09. SEQ ID NO: 45 is the arnino acid sequence of LJL38. SEQ ID NO: 46 is the nucleic acid sequence of LJL38. SEQ ID NO: 47 is the arnino acid sequence of LJM04. SEQ ID NO: 48 is the nucleic acid sequence of LJM04. SEQ ID NO: 49 is the amino acid sequence of LJM26. SEQ ID NO: 50 is the nucleic acid sequence of LJM26. SEQ ID NO: 51 is the arnino acid sequence of LJS03. SEQ ID NO: 52 is the nucleic acid sequence of LJS03. SEQ ID NO: 53 is the amino acid sequence of LJS192. SEQ ID NO: 54 is the nucleic acid sequence of LJS192. SEQ ID NO: 55 is the amino acid sequence of LJMl 9. SEQ ID NO: 56 is the nucleic acid sequence of LJM19. SEQ ID NO: 57 is the amino acid sequence of LJL138. SEQ ID NO: 58 is the nucleic acid sequence of LJL138. SEQ ID NO: 59 is the amino acid sequence of LJL15. SEQ ID NO: 60 is the nucleic acid sequence of LJL15. SEQ ID NO: 61 is the ainino acid sequence of LJL91. SEQ ID NO: 62 is the nucleic acid sequence of LJL91. SEQ ID NO: 63 is the amino acid sequence of LJMl 1. SEQ ID NO: 64 is the nucleic acid sequence of LJMl 1. SEQ ID NO: 65 is the amino acid sequence of LJS138. SEQ ID NO: 66 is the nucleic acid sequence of LJS138. SEQ ID NO: 67 is the amino acid sequence of LJL124. SEQ JD NO: 68 is the nucleic acid sequence of LJL124. SEQ ID NO: 69 is the amino acid sequence of LJL35. SEQ ID NO: 70 is the nucleic acid sequence of LJL35. SEQ ED NO: 71 is an oligonucleotide primer. SEQ ID NO: 72 is an oligonucleotide primer. SEQ ID NO: 73 is an oligonucleotide primer.
DETAILED DESCRIPTION
Abbreviations
AAV adeno-associated virus
AcNPV Autographa California Nuclear Polyhedrosis Virus alum aluminum phosphate or aluminum hydroxide
BCG Bacillus Calmette Guerin
BLAST Basic Local Alignment Search Tool
BSA bovine serum albumin
CAV canine adenovirus
CDR complementarity determining region
CHV canine herpes virus
CMV cytomegalovirus
CTL cytotoxic T lymphocyte
DMRIE N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-l- propanammonium
DOPE dioleoyl-phosphatidyl-ethanolamine DTH delayed type hypersensitivity fMLP N-formyl-methionyl-leucyl-phenylalanine
GM-CSF granulocyte-macrophage colony stimulating factor
H heavy chains HLB hydrophile-lipophile balance ID intradermal
ΓM intramuscular ISS immunostimulating sequence
KLH keyhole limpet hemocyanin
L light chains
LB Luria broth
Lu. longipalpis Lutzomyia logipalpis
MVA Modified Vaccinia virus Ankara
OFR open reading frame
P. ariasi Phlebotomus ariasi
PCR polymerase chain reaction polyA polyadenylation signal
P. papatasi Phlebotomus papatasi
PVDF polyvinylidene difluoride
SC subcutaneous
SCA Single chain antibody sFv single-chain antigen binding proteins
SGH salivary gland homogenate
SPGA sucrose phosphate glutamate albumin tPA tissue plasminogen activator
VH variable region of the heavy chain
VL variable region of the light chain
VL visceral leishmaniasis
II. Terms
Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes V, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182- 9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).
In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:
Amplification of a nucleic acid molecule (for example, a DNA or RNA molecule): A technique that increases the number of copies of a nucleic acid molecule in a specimen. An example of amplification is the polymerase chain reaction, in which a biological sample collected from a subject is contacted with a pair of oligonucleotide primers, under conditions that allow for the hybridization of the primers to a nucleic acid template in the sample. The primers are extended under suitable conditions, dissociated from the template, and then re-annealed, extended, and dissociated to amplify the number of copies of the nucleic acid. The product of amplification may be characterized by electrophoresis, restriction endonuclease cleavage patterns, oligonucleotide hybridization or ligation, and/or nucleic acid sequencing using standard techniques. Other examples of amplification include strand displacement amplification, as disclosed in U.S. Patent No. 5,744,311; transcription- free isothermal amplification, as disclosed in U.S. Patent No. 6,033,881 ; repair chain reaction amplification, as disclosed in WO 90/01069; ligase chain reaction amplification, as disclosed in EP 0320308; gap filling ligase chain reaction amplification, as disclosed in U.S. Patent No. 5,427,930; and NASBA™ RNA transcription-free amplification, as disclosed in U.S. Patent No. 6,025,134.
Antibody: immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, for instance, molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. A naturally occurring antibody (for example, IgG, IgM, IgD) includes four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. However, it has been shown that the antigen-binding function of an antibody can be performed by fragments of a naturally occurring antibody. Thus, these antigen-binding fragments are also intended to be designated by the term "antibody." Specific, non-limiting examples of binding fragments encompassed within the term antibody include (i) an Fab fragment consisting of the VL, VH; CL, and CHI domains; (ii) an Fd fragment consisting of the VH and CHI domains; (iii) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (iv) a dAb fragment (Ward et al, Nature 341:544-546, 1989) which consists of a VH domain; (v) an isolated complimentarity determining region (CDR); and (vi) an F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region.
Immunoglobulins and certain variants thereof are known and many have been prepared in recombinant cell culture (for example, see U.S. Patent No. 4,745,055; U.S. Patent No. 4,444,487; WO 88/03565; EP 0256654; EP 0120694; EP 0125023; Faoulkner et al, Nature 298:286, 1982; Morrison, /. Immunol. 123:793, 1979; Morrison et al, Ann Rev. Immunol 2:239, 1984). Animal: Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds. The term mammal includes both human and non-human mammals. Similarly, the term "subject" includes both human and veterinary subjects, such as dogs.
Conservative variants: Conservative amino acid substitutions are those substitutions that do not substantially affect or decrease an activity or antigenicity of the Lu. longipalpis polypeptide. Specific, non-limiting examples of a conservative substitution include the following examples: Original Residue Conservative Substitutions
Ala Ser
Arg Lys
Asn Gin, His
Asp Glu
Cys Ser
Gin Asn
Glu Asp
His Asn; Gin lie Leu, Val
Leu He; Val
Lys Arg; Gin; Glu
Met Leu; He
Phe Met; Leu; Tyr
Ser Thr
Thr Ser
Trp Tyr
Tyr Trp; Phe
Val He; Leu
The term conservative variation also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid, provided that antibodies raised to the unsubstituted polypeptide also essentially immunoreact with the substituted polypeptide, or that an immune response can be generated against the substituted polypeptide that is similar to the immune response against the unsubstituted polypeptide. Thus, in one embodiment, non-conservative substitutions are those that reduce an activity or antigenicity. cDNA (complementary DNA): A piece of DNA lacking internal, non-coding segments (introns) and expression control sequences. cDNA is synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells.
Degenerate variant: A polynucleotide encoding a Lu. longipalpis polypeptide that includes a sequence that is degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the disclosure as long as the arnino acid sequence of the Lu. longipalpis polypeptide encoded by the nucleotide sequence is unchanged.
Delayed-type hypersensitivity (DTH): An immune reaction in which T cell-dependent macrophage activation and inflammation cause tissue injury. A DTH reaction to the subcutaneous injection of antigen is often used as an assay for cell-mediated immunity. Epitope: An antigenic determinant. These are particular chemical groups or peptide sequences on a molecule that are antigenic, for instance, that elicit a specific immune response. An antibody specifically binds a particular antigenic epitope on a polypeptide. Specific, non-limiting examples of an epitope include a terra- to penta-peptide sequence in a polypeptide, a tri- to penta- glycoside sequence in a polysaccharide. In the animal most antigens will present several or even many antigenic determinants simultaneously. Such a polypeptide may also be qualified as an immunogenic polypeptide and the epitope may be identified as described further. Expression Control Sequences: Nucleic acid sequences that control and regulate the expression of a nucleic acid sequence, such as a heterologous nucleic acid sequence, to which it is operably linked. Expression control sequences are operably linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus expression control sequences can include appropriate promoters, enhancers, transcription terrninators, polyA signals, a start codon (for instance, ATG) in front of a protein-encoding polynucleotide sequence, splicing signal for introns, maintenance of the correct reading frame of that gene to permit proper translation of mRNA, and stop codons. The term "control sequences" is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Expression control sequences can include a promoter.
A promoter is a minimal sequence sufficient to direct transcription of a nucleic acid. Promoters maybe cell-type specific or tissue specific. A promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase H type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements which can be located as much as several thousand base pairs from the start site of transcription. Both constitutive and inducible promoters are included (see for example, Bitter et al, Methods in Enzymology 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage lambda, plac, ptrp, ptac (ptrp-lac-hybrid promoter) and the like may be used. In one embodiment, when cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (for example, metallothionein promoter) or from mammalian viruses (for example, the retrovirus long teπriinal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter) can be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences. A polynucleotide can be inserted into an expression vector that contains a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host. The expression vector typically contains an origin of replication, a promoter, as well as specific nucleic acid sequences that allow phenotypic selection of the transformed cells. In one embodiment, the promoter is a cytomegaloviras promoter.
Host cells: Cells in which a vector can be propagated and its DNA expressed. The cell may be prokaryoric or eukaryotic. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "host cell" is used. Also includes the cells of the subject.
Immune response: A response of a cell of the immune system, such as a B cell, T cell, or monocyte, to a stimulus. In one embodiment, the response is specific for a particular antigen (an "antigen-specific response"). The response can also be a non-specific response (not targeted specifically to salivary polypeptides) such as production of lymphokines. In one embodiment, an immune response is a T cell response, such as a CD4+ response or a CD8+ response. In another embodiment, the response is a Thl (a subset of helper T cells) response. In yet another embodiment, the response is a B cell response, and results in the production of specific antibodies.
Immunogenic polypeptide: A polypeptide which comprises an allele-specific motif, an epitope or other sequence such that the polypeptide will bind an MHC molecule and induce a cytotoxic T lymphocyte ("CTL") response, and/or a B cell response (for example, antibody production), and/or T-helper lymphocyte response, and/or a delayed type hypersensitivity (DTH) response against the antigen from which the immunogenic polypeptide is derived.
In one embodiment, immunogenic polypeptides are identified using sequence motifs or other methods known in the art. Typically, algorithms are used to determine the "binding threshold" of polypeptides to select those with scores that give them a high probability of binding at a certain affinity and will be immunogenic. The algorithms are based either on the effects on MHC binding of a particular amino acid at a particular position, the effects on antibody binding of a particular amino acid at a particular position, or the effects on binding of a particular substitution in a motif- containing polypeptide. Within the context of an immunogenic polypeptide, a "conserved residue" is one which appears in a significantly higher frequency than would be expected by random distribution at a particular position in a polypeptide. In one embodiment, a conserved residue is one where the MHC structure may provide a contact point with the immunogenic polypeptide.
Immunogenic composition: A composition that, when aάniinistered to a subject induces an immune response to a Lu. longipalpis salivary polypeptide. In one embodiment, in particular a positive DTH response.
Isolated: An "isolated" biological component (such as a nucleic acid or protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, for instance, other chromosomal and extra-chromosomal DNA and RNA, proteins, and organelles. Nucleic acids and proteins that have been "isolated" include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant technology as well as chemical synthesis.
Label: A detectable compound or composition that is conjugated directly or indirectly to another molecule to facilitate detection of that molecule. Specific, non-limiting examples of labels include fluorescent tags, enzymatic linkages, and radioactive isotopes.
Leishmaniasis: A parasitic disease spread by the bite of infected sand flies. The trypanosomatid parasite of the genus Leishmania is the etiological agent of a variety of disease manifestations, which are collectively known as leishmaniasis. Leishmaniasis is prevalent through out the tropical and sub-tropical regions of Africa, Asia, the Mediterranean, Southern Europe (old world), and South and Central America (new world). The old world species are transmitted by the sand fly vector Phlebotomus sp. Humans, wild animals and domestic animals (such as dogs) are known to be targets of these sand flies and to act as reservoir hosts or to develop leishmaniasis. Cutaneous leishmaniasis starts as single or multiple nodules that develop into ulcers in the skin at the site of the bite. The chiclero ulcer typically appears as a notch-like loss of tissue on the ear lobe. The incubation period ranges from days to months, even a year in some cases. The sores usually last months to a few years, with most cases healing on their own. The mucocutaneous type can develop into erosive lesions in the nose, mouth, or throat and can lead to severe disfigurement. Visceral leishmaniasis often has fever occurring in a typical daily pattern, abdominal enlargement with pain, weakness, widespread swelling of lymph nodes, and weight loss, as well as superimposed infections because of a weakened immune system. Visceral leishmaniasis (VL) can result in high death rates. The onset of symptoms can be sudden, but more often tends to be insidious. Lutzomyia longipalpis (Lu. longipalpis): A species of sand fly endogenous to the New
World (South and Central America). This sand fly is the principal vector of American visceral leishmaniasis, a potentially fatal disease that primarily affects children in several countries of South and Central America.
Lymphocytes: A type of white blood cell that is involved in the immune defenses of the body. There are two main types of lymphocytes: B cells and T cells.
Mammal: This term includes both human and non-human mammals. Similarly, the term "subject" includes both human and veterinary subjects.
Oligonucleotide: A linear polynucleotide sequence of up to about 100 nucleotide bases in length. Open reading frame (ORF): A nucleic acid sequence having a series of nucleotide triplets
(codons), starting with a start codon and ending with a stop codon, coding for amino acids without any internal termination codons. These sequences are usually translatable into a polypeptide.
Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.
Polypeptide Modifications: Lu. longipalpis polypeptides include synthetic embodiments of polypeptides described herein. In addition, analogues (non-peptide organic molecules), derivatives (chemically functionalized peptide molecules obtained starting with the disclosed polypeptide sequences) and variants (homologs) of these proteins can be utilized in the methods described herein. Each polypeptide of the disclosure is comprised of a sequence of amino acids, which may be either L- and/or D- amino acids, naturally occurring and otherwise. Polypeptides may be modified by a variety of chemical techniques to produce derivatives having essentially the same activity as the unmodified polypeptides, and optionally having other desirable properties. For example, carboxylic acid groups of the protein, whether carboxyl-terminal or side chain, may be provided in the form of a salt of a pharmaceutically-acceptable cation or esterified to form a C C16 ester, or converted to an amide of formula NRιR2 wherein Ri and R2 are each independently H or CrCι6 alkyl, or combined to form a heterocychc ring, such as a 5- or 6- membered ring. Amino groups of the peptide, whether amino-teraiinal or side chain, may be in the form of a pharmaceutically-acceptable acid addition salt, such as the HC1, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric, and other organic salts, or may be modified to CrCι6 alkyl or dialkyl arnino or further converted to an amide.
Hydroxyl groups of the peptide side chains may be converted to CrCι6 alkoxy or to a CrCι6 ester using well-recognized techniques. Phenyl and phenolic rings of the peptide side chains may be substituted with one or more halogen atoms, such as fluorine, chlorine, bromine, or iodine, or with Cι-C16 alkyl, Cι-C)6 alkoxy, carboxylic acids and esters thereof, or amides of such carboxylic acids. Methylene groups of the peptide side chains can be extended to homologous -C4 alkylenes. Thiols can be protected with any one of a number of well-recognized protecting groups, such as acetamide groups. Those skilled in the art will also recognize methods for introducing cyclic structures into the peptides of this disclosure to select and provide conformational constraints to the structure that result in enhanced stability. Peptidomimetic and organomimetic embodiments are envisioned, whereby the three- dimensional arrangement of the chemical constituents of such peptido- and organomimetics mimic the three-dimensional arrangement of the peptide backbone and component amino acid side chains, resulting in such peptido- and organomimetics of a L. longipalpis polypeptide having measurable or enhanced ability to generate an immune response. For computer modeling applications, a pharmacophore is an idealized, three-dimensional definition of the structural requirements for biological activity. Peptido- and organomimetics can be designed to fit each pharmacophore with current computer modeling software (using computer assisted drug design or CADD). See Walters, "Computer-Assisted Modeling of Drugs," Klegerman & Groves (eds.), 1993, Pharmaceutical Biotechnology, Interpharm Press: Buffalo Grove, IL, pp. 165-174 and Principles of Pharmacology Munson (ed.) 1995, Ch. 102, for descriptions of techniques used in CADD. Also included are mimetics prepared using such techniques.
Pharmaceutically acceptable vehicles or excipients: The pharmaceutically acceptable vehicles or excipients of use are conventional. Remington 's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the polypeptides, plasmids, viral vectors herein disclosed.
In general, the nature of the vehicle or excipient will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (for example, freeze-dried pastille, powder, pill, tablet, or capsule forms), conventional non-toxic solid vehicles or excipients can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically neutral vehicles or excipients, immunogenic compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
Phlebotomus ariasi (P. ariasi): A species of Phlebotomus (sand flies) genus endogenous to the Old World, in particular to southern Europe and Mediterranean countries, more particularly to Spain and France. This sand fly is a proven vector of visceral leishmaniasis. P. ariasi is a member of the subgenera of Phlebotomus Larroussius.
Phlebotomus pe niciosus (P. perniciosus): A species of Phlebotomus (sand flies) genus endogenous to the Old World, in particular to southern Europe, and Mediterranean countries, more particularly to France, Italy, Greece, Morocco, and Spain. This sand fly is a proven vector of the visceral leishmaniasis. P. perniciosus is a member of the subgenera of Phlebotomus Larroussius. Polynucleotide: The term polynucleotide or nucleic acid sequence refers to a polymeric form of nucleotide at least 10 bases in length, thus including oligonucleotides and genes. A recombinant polynucleotide includes a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (for example, a cDNA) independent of other sequences. The polynucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. The term includes single -and double -stranded forms of DNA.
Polypeptide: Any chain of amino acids, regardless of length (thus encompassing oligopeptides, peptides, and proteins) or post-translational modification (for example, glycosylation, phosphorylation, or acylation). A polypeptide encompasses also the precursor, as well as the mature protein. In one embodiment, the polypeptide is a polypeptide isolated fcomLu. longipalpis, or encoded by a nucleic acid isolated from Lu. longipalpis, such as the Lu. longipalpis polypeptides disclosed herein.
Probes and primers: A probe comprises an isolated polynucleotide attached to a detectable label or reporter molecule. Primers are short polynucleotides. In one embodiment, polynucleotides are 15 nucleotides or more in length. Primers may be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, for example, by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods known in the art. One of skill in the art will appreciate that the specificity of a particular probe or primer increases with its length. Thus, for example, a primer comprising 20 consecutive nucleotides will anneal to a target with a higher specificity than a corresponding primer of only 15 nucleotides. Thus, in order to obtain greater specificity, probes and primers may be selected that comprise at least 15, 20, 25, 30, 35, 40, 50 or more consecutive nucleotides. Protein Purification: The Lu. longipalpis polypeptides disclosed herein can be purified by any of the means known in the art. See, for example, Guide to Protein Purification, Deutscher (ed.), Meth. Enzymol 185, Academic Press, San Diego, 1990; and Scopes, Protein Purification: Principles and Practice, Springer Verlag, New York, 1982. Substantial purification denotes purification from other proteins or cellular components. A substantially purified protein is at least 60%, 70%, 80%, 90%, 95%, or 98% pure. Thus, in one specific, non-limiting example, a substantially purified protein is 90% free of other proteins or cellular components.
Purified: The term purified does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified polypeptide preparation is one in which the polypeptide is more enriched than the polypeptide is in its natural environment. A polypeptide preparation is substantially purified such that the polypeptide represents several embodiments at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98%, of the total polypeptide content of the preparation. The same applies for polynucleotides. The polypeptides disclosed herein can be purified by any of the means known in the art (see, for example, Guide to Protein Purification, Deutscher (ed.), Meth. Enzymol. 185, Academic Press, San Diego, 1990; and Scopes, Protein Purification: Principles and Practice, Springer Verlag, New York, 1982).
Recombinant: A recombinant polynucleotide is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, for example, by genetic engineering techniques. In one embodiment, a recombinant polynucleotide encodes a fusion protein.
Selectively hybridize: Hybridization under moderately or highly stringent conditions that excludes non-related nucleotide sequences. In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (for example, GC v. AT content), and nucleic acid type (for example, RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.
A specific, non-limiting example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2 x SSC/0.1% SDS at about 42°C (moderate stringency conditions); and 0.1 x SSC at about 68°C (high stringency conditions). One of skill in the art can readily determine variations on these conditions (for example, Molecular Cloning: A
Laboratory Manual, 2nd ed., vol. 1-3, ed. Sambrook et al, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). The hydridization conditions can be carried out over 2 to 16 hours. Washing can be carried out using only one of the above conditions, for example, high stringency conditions, or each of the conditions can be used, for example, for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be deteπnined empirically. Sequence identity: The similarity between amino acid sequences is expressed in terms of the percentage identity between the sequences. The higher the percentage, the more similar the two sequences are. Homologs or variants of a Lu. longipalpis polypeptide will possess a relatively significant high degree of sequence identity when aligned using standard methods.
Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl Math. 2:482,
1981; Needleman and Wunsch, J. Mol Biol. 48:443, 1970; Pearson and Lipman, Proc. Natl Acad. Sci. USA 85:2444, 1988; Higgins and Sharp, Gene 73:237, 1988; Higgins and Sharp, CABIOS 5:151, 1989; Corpet et al, Nucleic Acids Research 16:10881, 1988; and Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988. Altschul et al, Nature Genet. 6:119, 1994 presents a detailed consideration of sequence alignment methods and identity calculations.
The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al, J. Mol. Biol. 215:403, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn, and tblastx. A description of how to determine sequence identity using this program is available on the NCBI website on the internet.
Homologs and variants of a Lu. longipalpis polypeptide are typically characterized by possession of at least 75%, for example at least 80%, sequence identity counted over the full length alignment with the amino acid sequence of the Lu. longipalpis polypeptide using the NCBI Blast 2.0, gapped blastp set to default parameters. The comparison between the sequences is made over the full length alignment with the amino acid sequence given in this present disclosure, employing the Blast 2 sequences function using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1).
When aligning short peptides (fewer than around 30 amino acids), the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity. When less than the entire sequence is being compared for sequence identity, homologues and, variants will typically possess at least 80% sequence identity over short windows of 10-20 amino acids, and may possess sequence identities of at least 85% or at least 90% or 95% depending on their similarity to the reference sequence. Methods for deteπmning sequence identity over such short windows are available at the NCBI website on the internet. One of skill in the art will appreciate that these sequence identity ranges are provided for guidance only; it is entirely possible that strongly significant homologues could be obtained that fall outside of the ranges provided. Specific binding agent: An agent that binds substantially only to a defined target. Thus a Lu. longipalpis specific binding agent is an agent that binds substantially to a Lu. longipalpis polypeptide.
In one embodiment, the specific binding agent is a monoclonal or polyclonal antibody that specifically binds the Lu. longipalpis polypeptide. Subject: Living multi-cellular vertebrate organisms, a category that includes both human veterinary subjects, including human and non-human mammals. In one embodiment, the subject is a member of the canine family, such as a dog. In another embodiment, the subject is a human.
T Cell: A white blood cell critical to the immune response. T cells include, but are not limited to, CD4+ T cells and CD8+ T cells. A CD4+ T lymphocyte is an immune cell that carries a marker on its surface known as "cluster of differentiation 4" (CD4). These cells, also known as helper T cells, help orchestrate the immune response, including antibody responses as well as killer T cell responses. CD8+ T cells carry the "cluster of differentiation 8" (CD8) marker. In one embodiment, a CD8 T cells is a cytotoxic T lymphocytes. In another embodiment, a CD8 cell is a suppressor T cell.
Therapeutically active polypeptide: An agent, such as a Lu. longipalpis polypeptide, that causes induction of an immune response, as measured by clinical response (for example, increase in a population of immune cells, production of antibody that specifically binds the Lu. longipalpis polypeptide, a measurable reduction in symptoms resulting from exposure to Leishmania, or protection from infection with Leishmania). Therapeutically active molecules can also be made from nucleic acids. Examples of a nucleic acid based therapeutically active molecule is a nucleic acid sequence that encodes a Lu. longipalpis polypeptide, wherein the nucleic acid sequence is operably linked to a control element such as a promoter. Therapeutically active agents can also include organic or other chemical compounds that mimic the effects ofthe - w. longipalpis polypeptide.
The terms "therapeutically effective fragment of a Lu. longipalpis polypeptide" includes any fragment of the Lu. longipalpis polypeptide, or variant of the Lu. longipalpis polypeptide, or fusion protein including a Lu. longipalpis polypeptide, that retains a function of the Lu. longipalpis polypeptide (such as immunogenicity), or retains the ability to reduce the symptoms from exposure to Leishmania, or to protect from infection with Leishmania.
Thus, in one embodiment, a therapeutically effective amount of a fragment of Lu. longipalpis polypeptide is an amount used to generate an immune response to the polypeptide. In another embodiment, a therapeutically effective amount of a fragment of a Lu. longipalpis polypeptide is an amount of use to prevent or treat a Leishmania infection in a subject. Treatment refers to a therapeutic intervention that confers resistance to infection with Leishamania, or a reduction in the symptoms associated with exposure to Leishamania. Specific, non-limiting examples of a polypeptide fragment are the N-terminal half or the C-terminal half of one of the P. Lu. longipalpis polypeptide disclosed herein. It should be noted that fusion proteins are included, such as a fusion with six histidine residues, a c-myc tag, or any other polypeptide tag. Such fusions are known to one of skill in the art, and are often used in protein purification.
Transduced: A transduced cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques. As used herein, the term transduction encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.
Vector: A nucleic acid molecule as introduced into a host cell, thereby producing a transduced host cell. A vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector may also include one or more selectable marker genes and other genetic elements known in the art.
Vaccine: Composition that when administered to a subject, induces a decrease of the severity of the symptoms of a disorder or disease. In one embodiment, a vaccine decreases the severity of the symptoms of leishmaniasis and/or decreases the parasitic load.
Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. "Comprise" means "include," and a composition that comprises a polypeptide includes that polypeptide. It is further to be understood that all base sizes or arnino acid sizes, and all molecular weight or molecular mass values, given for polynucleotides or polypeptides are approximate, and are provided for description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Lu. longipalpis Polynucleotides and Polypeptides
Salivary polypeptides from sand fly species Lu. longipalpis, are disclosed herein.
LJL34 (SEQ ID NO: 1)
MLQIKHLLffVGLLVVVNAQSNYCKQESCSSGGVERPHIGCK-NSGDFSETCSGDAEIVKMDK
O QNLLVmHNRLRDRFARGAWGFAPAAKM^^
RAroVCPYAGQNLAQMMSWTHRDLNYVLKNLTREWFWEYRWAKQSQLDNYVGGPGKD f^QIGHFTAFVHEKTDKVGCAlARFTNEIINF SKKCGPVYKNLCDPSEKVDPTPDVLKQWKHGK
LJL18 (SEQ ID NO:3)
MLLRSLFVLFLIFLTFCNAEEELIER-^TGKTIYISTIXLPWFQALNHCVI^-NGYTMVSIKTFEE Nl- LLI^LKIIVIIITEDTQVWIGGLKHΗQFANFRWVSDGSHVATASGYTNWAPGEPAD YDQFCMAMLFRKDGAPWDDLNCWVKNLFVCEKRDD LJS193 (SEQ ID NO:5)
MKLLQIIFSLFLVFFPTSNGALTGNESAANAAPLPVVLWHGMGDSCCFPFSLGSIKXLIEQQIP GfflVVSLiαGKSLIEDYESGFFVHPDKQIQEVCESLQISrDLTLANGFNAIGFSQGSQFLRGLVQR CSSIQVRNLISIGGQHQGVFGLPYCPSLSRKTCEYFRKLLNYAAYEKWVQKLLVQATYWHD PLNEDAYRTGSTFLAD-NNERQDvrNDYINNIRKLNRFVMVK-FLND DTEVLPLKQSIOYLEDRLGLQS roYLECGGDHLQFTKEWFIKFIIPYLKQ
LJS201 (SEQ ID NO: 7) MRNFAWSLAVAVLLFCAWPTNAEDNEEVGl ^yiEKRGL
LPSLPGFGKKPESGSSEDSGDKTEDTSGSKDDQSKDNTVEES
LJL13 (SEQ ID NO: 9)
MNFLLi ϊSLLCLCGLGYSWQDVl^ADQTLWAYRSCQK]SfPEDI^HWQWRKFELPDDEKT HCYVKCVWTRLGAYNENENVFKID VITKQFNERGLEVPAGLDQELGGSTDGTCKAVYDKS MKFFKSHFMDFRNAYYATYDGSDEWFS!O^DViα>KGTKVSEYCKNEX DGDCKHSCSMYY YRLIDEDNLVIPFSNLPDYPEDl^EECRNEAKSANECKSSVIYQCLENADKSALDASLNIL DEFSGRY
LJL23 (SEQ ID NO: 11)
MFLKWVVCAFATVFLVGVSQAAPPGVEWYIJFGLTADMDKKSIASDKTTFNSVLi )ELRHN TKTDQYlYVRSRVlΩα'VSTRYGFKGRGAELSEIVVFNNiα.YTVDDKSGITFRITl^GKLFPW VILADADGQRPDGFKGEWATIE DTIYVGSTGMLKFTSSLWVK- TKDGVVTSHDWTDKY RMLK-ALNMPNGFVWHEAVTWSPFRKQWVFMPRKCSi PFSQELEERTGCNiαVT DIQVmiQDQPYNLASGFSSFRFIPGTK-NERLLALRTVEQEDQVKTWAVVMDMKGTVLMYE KΕLYDEOΕGLAFFGGIKKN
LJM10 (SEQ ID NO: 13)
MALlOfLPVLLLSCFAMSTALQVTEKELSDGKK-fflSKVELNWFEALDFCIX GLTLLSlKSAK ENVTJVTKAIRAELNFDSKLI^AHWTC
GYWlODEFCLEIYYKTEEGKWNDDKCHVi HFVCQEKK
UL143 (SEQ ID NO: 15)
MNSINFLSIVGLISFGFIVAVKCDGDEYFIGKYl^IΦETLFFASYGLHRDPCQIVLGYKCSNN QTHFVLNFKTNKKSCISAIKLTSYPKINQNSDLTl-^^
IEIYGI AKKCSFKXJRYIGADPLHVDSYGLPYQFDQEHGWNVERYNIFK-DTRFSTE YHI^ GLFNTQITYLAEEDSFSEArølTAKlJTKI^
YNGECSNENKTCELVFDTDELMTYALVKVFTNPESDGSRLKEEDLGRG LJS142 (SEQ ID NO: 17)
MAFSNTLFVLFVSFLTFCGADQTLIEKELTGRTWISK-^^ EENTELSEKXKTVIRTEEFQVWIGGIEFfflQDSSFRW QNNEYCLEILFRKEDGKWNDFPCSARHHFVCEKRTK
LJL17 (SEQ ID NO: 19)
MQNFLLVSLALAALMLCAEAl^YDFPLYQDLIQGVIQRESQAEREi SPNEDYEKQFGDIVD
QlI^ISFNVMK-MPFfFGSSDDNRDDGEYVDFfflYGDEDDRDYDHY
LJMQ6.(SEQ 1D N0: 21)
MICTYIFGVFLVSFLALCNAEDYDKVKXTGRTλ^YISRSK-APWFTALDNCWR
11FTFAMKSQKΕNEELTNALLSV1KSDEENVWIGGLRHDLDDYFRWISFGTALSKTSYTNWA
PKEPTGRPHRTQNDEFCMQMSFIΩDGGKWSDNTCWRKRLYVCEKRD
LJM17 (SEQ JO NO: 23)
MRFFFWLAIVLFQGfflGAYVEIGYSLl^ITFDGLDTDDYNPKFNIPTGLAVDPEGYllLFIAIPR lrøKWYTVAELNMVMNPGFPVERAPSFECTK^^
GKVEYTGGDADQYPKGI 'TLIAYDLK-ΩDHTPEIHRFEIPDDLYSSQVEFGGFAVDVVNTKG
DCTESFVYLTNF10)NSLlVYDETQK-l^WiaϊTDKTFEADKESTFSYSGEEQMKYKVGLFGLAL GDRDEMGHRPACY1AGSSTKVYSVNTKELKTENGQLNPQLHGDRGKYTDAIALAYDPEHK
VLYFAESDSRQVSCWNVNMELl^DNTDVIFSSARFTFGTDILVDSKGMLWIMANGHPPVED
QEi VK-MRFV KIRl-MKVDTER^
EIEV
LJL04 (SEQ ID NO: 25)
MLI Ε SLALLVALAQCANEIP] QGKOYPW
DNRGKSRGGGAAGAREGRLGTNGAKPGQGGTRPGQGGTRPGQGGTRPGQGGTRPGQGGT RPGQGRTL^AQGTTRPAQGTRNPGSVGTL^AQDASKQGQGKELRPGQVGGKRPGQANAPNA GTRKQQKGSRGVGRPDLSRYKDAPAIΠ?WKSPDFSGEGKTPTV]NR^^ DEFVLEILDGDPTGLGLKSETIGIΠDTI^VLENPNGNSIVARVKΓYKNGYSG
LJMl 14 (SEQ ID NO: 27)
MNSVNTLILTLLFAIFLLVK-RSQA FLPSDPSICVK-NLVLDTGRTCEESEYFPDILWVKNGIAIVY IVCTDSDAVDYIO?YICFDMN]H.SGPPYPEEEILRESTVTY^ SKTDDPPAΓRPGFSFRNSISV
LJMl 11 (SEQ ID NO: 29)
Mi FFFLYTFGLVQTIFGVΕIKQGFKWNKILYEGDTSENF 'DNMLTAEAYDPESQKLFLTV
Pl^YPETMYTLAEVDTEia^SFESGDTSPLLGl^SGHETGKELTSVYQPVroECHP WVVDVG SVERNSDGTEGQPEIINPTLVAYDLK-EANYPEVIRYTFPDNSIEK TFLGGFAVDVVKPDECSE TFWITNFLTNALIVYDHK-NIΦSWTVQDS
EGR QAYYLVASSTIΠ.HSRNTKELKQKGSKVNANYLGDRGESTDAIGLVYDPKTKTIFFVES S-^VSCWNTQETLNKDIODVIYIWADFSFGTDISIDSQDNLWFLANGLPPLENSDKFVFTKP RYQIFKVMQEAIAGTKCEKNL
LJM78 (SEQ ID NO: 31)
MTFLIILGAFLLVQIITASALGLPEQFKGLEDLPKIΠ>LAETYYHEGLNDGKTDEMVDΓFKSLSD EFK-FSDENLDVGEEKNYI<-K]^ITQNSVARNFLSNVKG1PSMPSLPSMPSMPS1PSLWSSQTQA APNTALALPESDYSLLDMPMVIΑ FFLL^TRDLYNDVGAFLKAITEALTNRSSSSQLLSSPMVS TISTKTKLEFEEINDEIQKVI^^ EIOFNDGK]YILQLYNNLLKGLI >NDLMVELKKCDTNQNNTLGMICYFLTPLQLEKEQILLPV
EFIKi LELTITYFSTMKEDLrNCGITTIASIT
LJS238 (SEQ ED NO:33)
MLIOVLFLSVLAVLVICVAAMPGSNWWHISREELEKLREARKNIHII^LEI^ΓDELIDKYL
LJS169 (SEQ ED NO:35)
MI^SCPVFVAIFLLCGFYRVEGSSQCEEDLKΕEAEAFF]Α CNEA]^NPGEYENLTKEEMFEE L-^YGVADTDMETVYTO-VEECWNELTTTDCL^
ULll (SEQ lDNO: 37)
MLFFLNFFVLWSIELALLTASAAAEDGSYEΠILHTNDMHARFDQTNAGSNKCQEKDKIASK
CYGGFARVSTMVΕ-L^REENGSSVLFLNAGDTYTGTPWFTLYKETIATEMMNILRPDAASLG NHEFDKGVEGLVPFLNGVTFPILTANLDTSQEPTMTNAKNLKRSMIFTVSGHRVGVIGYLTP
DTIH'LSDVGKλTSIFπ'EVEAINTEAQRLKXEENAEπi tVGHSGLlK^
HTFLYTGSQPDl^WVDVYPVVVTQSSGKXWIVQAYCFTKYLGYFKVTINGKGNVVGWTG QPILLNNNIPQDQEVLTALEKYRERVENYGNRVIGVSRVILNGGHTECRFHECNMGNLITDA FVYANV1STPMSTNAWTDASVVLYQSGGIRAPIDPRTAAGSITRLELDNVLPFGNALYVVKV PGNVLRKALEHSVHRYSNTSGWGEFPQVSGLiαPJ'NVNEEIGKRVKSVKVLCSNCSQPEYQP LRNIO TYNVIMDSFMKDGGDGYSMFl^Li iKTLPLGDIETVEAYIEKMGPlEPAVEGRITV LGGLQKSDEDWH
LJL08 (SEQ ID NO: 39) MKQILLISLVVILAVLAI^VAEGCDATCQFRK- EDCia.KADNSDVLQTSVQTTATFTSMDT SQLPGNNWKACMKΕKAKEFRAGK LJS105 (SEQ ED NO: 41)
MNVLFVSFTLTILLLCVK-Al^EDFVALQDQANFQKCLEQYPEPNQSGEVLACLK-KIlEGAiaD
FREKRSLDDIEGTFQESGN
LWGA
LJL09 (SEQ ID NO: 43)
MJ VILFTGFTIALVSSAVLKi ^ETIEEEEVRAEQ
TEVNLl^MNDVSVETAKYY LASELKGFNAKΕY^
LLEAITWMESNYAKVKVCSYl^PKKCDLALEPEITEILKSI^PEELKYYWKQWYD -AGTP TRESFNKYVQLNREAAKLDGFYSGAES WLDEYEDETFEKQLEDIFAQIRPLYEQLHAYVRFK
LREKYGNDVVSEKGPlPIVfflLLGNMWGQTWSEVAPILWYPEKKLLDVTDEMVKQGYTPIS
MFEKGDEFFQSLNMTI^PKTFWEYSILEKPQDGRELICHASAWDFYTKDDVRKQCTRVTMD
QFFTAHHELGHIQYYLQYQHLPSVYREGANPGFHEAVGDVLSLSVSSPi LEKVGLLKDFKF
DEESQINQLLNLALDK-MAFLPFAYTroKYRWGVERGEISPSEYNC -FWEMRSYYGGIEPPEAR SESDFDPPAKYHISSD VEYLRYLVSFIIQFQFHQAVCQKTGQFVPNDPEKTLLNCDIYQSAEA
GNAF-^MLKLGSSIO'WPDAMEILTGQRK-MDASALIEYFRPLSEWLQKKNKELGAYVGWDK
STKCVKNVS
LJL38 (SEQ ID NO: 45) MKTFALEFLALAVFVLCEDGAPTFVNLLDDVQEEVEVNTYEP
LJM04 (SEQ ED NO:47)
MNIΪLCFIIIALFFLVQQSLAEFJ-PEEKCI- ELARTDEN^ l^αLVTFGAWKKEKK IO.LEHIEACADSANADQPQTIΠ)EKCTIΠNKYYRCVVDGIΠLPWNSYADAIIKFDKTLNV
LJM26 (SEQ ID NO: 49)
M-ΠMLAAFLLADGIWAAEEPSVEIVTPQSVRRILATPKAQDARVGSESATTAPRPSESMDYW
ENDDFWFEGPFO)IGEFDWNLSKTVFEENKGNAILSPLSVKLLMSLLFEASASGTLTQHQLR QATPTIVTHYQSREFYL^IFDGLIΑ XSNDYTVHFGTMYVDQFVTPRQRYAAILEKHYLTDL KVEDFSKAKΕTTQAINSWVSMTNEHIKDLVKΕE^
PLPFHVSADESKTTDFMLTDGLYYFYEAKELDAKILRIPYKGKQYAMTVILPNSKSGIDSFVR QINTVLLHMKWLMDEVECRVILPIA?HFDMTNELKΕSLVKLGISQIFTSEASLPSLARGQGVQ NRLQVSNVIQL^GIIVDEKGSTAYAASEVSLVNL^GDDEFVMFNANHPFLFTIEDETTGAILF TGKWDPTQ LJS03 (SEQ ID NO: 51)
Ml^LLLAFSVALVLSPTFAKPGLWDIVTGINDMVK-NTANALK-NP TTSVTLFTNTITEAD^ NSSVSELLQQVNETLTDIINGVGQVQSAFVNSAGNVVVQIVDAAGNVLEVVVDEAGNIVEV AGTALETIffLPGVVIQKHDALQGNAGTTSDSASSTVPQQS
LJS192 (SEQ ID NO: 53)
MVKYSCLVLVAEFLLAGPYGWGSCENDLTEAAKYLQDECNAGEIADEFLPFSEEEVGEALS
DKPENVQEVTNIVRGCFEAEQAKEHGKCERFSALSQCYIEKNLCQFF
LJM19 (SEQ ED NO: 55)
MI^FYLIFSAIFFLADPALVKCSEDCENEFHDNAYLLKLDCEAGRVDPVEYDDISDEEIYEITV DVGVSSEDQEKVAKIIRECIAQVSTQDCTKI?SEr-πDCT^
LJL138 (SEQ ID NO: 57) MHLQLNLCAILLSVLNGIQGAPKSINSKSCAISFPENVTAKKEPVYLKPSNDGSLSTPLQPSGP
FVSLKIGESLAIFCPGDGKDVETITCNTNFDLASYSCNKSTSTDT ETEEVCGGSGKVYKVGFP
LPSGNFHS1YQTCFDKKNLTPLYS1HILNGQA
VGYHLIOITRGSFRTNGIYGKVNIDKLYKTQIEKTNKLFGPKQTFFRRPLNFLSRGHLSPEV^
TFRREQHATEMYINTAPQYQSINQGNWLRVENHVRDLAKVLQIODITVVTGILGILRLKSKKI EKΕIYLGDDV1A.WAMFWKAWDPQKQEA1VFVSS1^
EYFSNYSIGLTICCKLEEFV-OUSπ ILPKEVN^
A
LJL15 (SEQ ID NO: 59) MNLHLAIILFVSYFTLITATDLIEl^LSDCK-KIFISKAELTWFQALDFCTEQNLTLLSIKSAR-EN DEVTl V] EVHLPDTΩ SHIWLGGIRYDQD]αDFRWISDGTTVTKTVYlNWYQGEPNGGR YQI^FCMELYFKTPAGQWIWDICTAKHHFICQEKK
LJL91 (SEQ ID NO: 61) MNLPLAIILFVSYFTLITAADLTEKELSDGKIOFISKAELSWFDALDACTEKDLTLLTIKSAREN EEVTK-AVRAEVHLPDT1^SHIWLGGIRYDQD1^FRWISDGTTVTKT\^INWYQGEPNGGRY QKEFCMELYFKTPAGQWNDDICTAKHHFICQEKK
LJMll (SEQ ID NO: 63) MKVFFSIFTLVLFQGTLGADTQGYKWKQLLYNNVTPGSYNPDNMISTAFAYDAEGEKLFLA VPRl^PRVPYTLAEVDTKNSLGVKGKHSPLLNl^SGHKTGKΕLTSIYQPVIDDCRRLWVVDI GSVEYRSRGAIODYPSHRPAIVAYDLKQPNYPEVVRYYFPTRLVEKPTYFGGFAVDVANPKG DCSETFVYITNFLRGALFIYDHI^QDSWNVTHPTFKAEl^^ l^SEGNRPAYYLAGSAIKVYSVNTK-ELKQKGGKLNPELLGNRGKYNDAIALAYDPKTKVIF FAEANTKQVSCWNTQ1D PLRMK-NTDVVYTSS1^VFGTDISVDSKGGLWFMSNGFPPIRKSE KFKYDFPRYRLMRIMDTQEAIAGTACDMNA
LJS138 (SEQ ID NO: 65) MQSKILSFVLFTLSLGYVLGETCSNAKVKGATSYSTTDATFVSQIAFVTEFSLECSNPGSEKISL FAEVDGOTPVAMIGDTTYQVSWNEEVNKARSGDYSVKLYDEEGYGAVRKAQRSGEENKV -α LATVVVRHPGTYTGPWFNSEILAAGLIAVVAYFAFSTRSKILS
LJL124 (SEQ ID NO: 67) MVSILLISLILNLLVFYAl^RPLEDISSDLSPDYYITEGYDGVKΕKREIELWVTFGIFNIHTTPA PRITFEW
LJL35 (SEQ ID NO: 69)
MIO.FCLEFVVFVALEVCIETVΕAMEATEEISVKLQDDANEPDDSLDLDEGLPDAFDEDYNNQ AEYKPNPRGDYRRR
In one embodiment, a polypeptide including SEQ ID NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ ID NO: 9, SEQ ID NO: 15, SEQ ED NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ED NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ED NO: 61, SEQ ED NO: 63, SEQ ED NO: 65, or SEQ ED NO: 67 is disclosed herein. Homologous polypeptides having an amino acid sequence at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence as set forth as SEQ ID NO: 3, SEQ ED NO: 5, SEQ ID NO: 7, SEQ ED NO: 9, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ED NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ED NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67 are disclosed herein. Fusion proteins including SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ED NO: 9, SEQ ED NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ID NO: 21, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ED NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67 are also disclosed herein. Fragments and variants of the Lu. longipalpis polypeptides identified above are disclosed herein and can readily be prepared by one of skill in the art using molecular techniques. In one embodiment, a fragment of a Lu. longipalpis polypeptide includes at least 8, 10, 15, or 20 consecutive amino acids of a Lu. longipalpis polypeptide. In another embodiment, a fragment of a Lu. longipalpis polypeptide includes a specific antigenic epitope found on a full-length Lu. longipalpis polypeptide.
In one embodiment, a fragment is at least 19 amino acids, at least 23 amino acids, at least 25 amino acids, or at least 30 amino acids in length from any polypeptide (including polypeptides as given in SEQ ED NO: 3, SEQ ED NO: 5, SEQ ID NO: 7, SEQ ED NO: 9, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ D NO: 31, SEQ ED NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ED NO: 61, SEQ ED NO: 63, SEQ ED NO: 65, or SEQ ED NO: 67 conservative variants thereof, and homologues thereof), or any fragment that retains at least an epitope.
Fusion proteins including a Lu. longipalpis polypeptide can also be produced using methods known to one of skill in the art. In one embodiment, a fusjon protein includes an amino acid sequence set forth as SEQ ED NO: 3, SEQ ED NO: 5, SEQ ED NO: 1, SEQ ED NO: 9, SEQ ID NO: 15, SEQ JD NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ED NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ID NO: 61, SEQ ED NO: 63, SEQ ID NO: 65, or SEQ ED NO: 67, or a conservative variants thereof, and a marker polypeptide. Marker polypeptides include, but are not limited to, polypeptide tags, such as a polypeptide to aid in protein purification (for example, six histidine residues or c-myc polypeptide), or an enzymatic marker (for example, alkaline phosphatase), or a fluorescent maker (for example, green fluorescent protein).
One skilled in the art, given the disclosure herein, can purify a Lu. longipalpis polypeptide using standard techniques for protein purification. The substantially pure polypeptide will yield a single major band on a non-reducing polyacrylamide gel. The purity of the Lu. longipalpis polypeptide can also be determined by amino-terminal amino acid sequence analysis.
Minor modifications of the Lu. longipalpis polypeptide primary amino acid sequences may result in peptides which have substantially equivalent activity as compared to the unmodified counterpart polypeptide described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein.
Polynucleotides encoding salivary polypeptides from Lu. longipalpis sand fly are disclosed herein, such as polynucleotides encoding SEQ ID NO: 3, SEQ ID NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ED NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ED NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67.
Specific, non-limiting examples of Lu. longipalpis nucleic acid sequences include SEQ TD NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ JD NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:26, SEQ ED NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ED NO:42, SEQ ID NO:44, SEQ ID NO:46, or SEQ ID NO:48, SEQ ED NO:50, SEQ ED NO:52, SEQ JD NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ JD NO:68, and degenerate variants thereof. These polynucleotides include DNA, cDNA, and RNA sequences that encode a Lu. longipalpis polypeptide. It is understood that all polynucleotides encoding a Lu. longipalpis polypeptide are also included herein, as long as they encode a polypeptide with the recognized activity, such as the binding to an antibody that recognizes the polypeptide, the induction of an immune response to the polypeptide, or an effect on survival of Leishmania when administered to a subject having leishmaniasis or who undergoes a decrease in a sign or a symptom of Leishmania infection.
The polynucleotides of the disclosure include sequences that are degenerate as a result of the genetic code. There are 20 natural arnino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the disclosure as long as the amino acid sequence of the Lu. longipalpis polypeptide encoded by the nucleotide sequence is functionally unchanged.
Specific, non-limiting examples of a polynucleotide encoding a P. ariasi polypeptide are set forth below:
LJL34 (SEQ ID NO:2) AGTTGTGGAGCTTTTGGTCATTTΓACGTGATGTTGCAAATTAAACATCTTCTGATTTTTGT GGGATTGCTCGTGGTTGTTAATGCACAGAGCAATTACTGCAAACAGGAATCGTGCTCAT
CGGGAGGTGTTGAGAGACCCCATATTGGGTGCAAAAACTCTGGAGATTTTTCCGAAACT
TGCTCCGGAGATGCAGAAATTGTTAAGATGGACAAGAAGAAGCAGAACCTCCTTGTGAA
AATGCACAATCGCCTGAGAGATAGATTTGCTCGTGGTGCAGTGCCAGGTTTTGCACCAG CTGCGAAAATGCCAATGCTTAAATGGAACGATGAACTGGCCAAATTGGCAGAGTACAAC GTGAGAACGTGCAAATTTGCCCACGATAAATGCCGCGCAATTGATGTCTGCCCCTATGCT GGACAGAATCTAGCTCAAATGATGTCCTATCCTACCCATCGAGATCTAAACTATGTTCTT AAGAATCTCACAAGGGAATGGTTCTGGGAGTACAGATGGGCTAAGCAATCTCAGCTTGA TAATTACGTGGGTGGTCCTGGGAAAGACAACAAACAAATTGGACATTTCACAGCTTTTG TGCATGAGAAAACAGACAAAGTTGGATGCGCTATAGCTCGATTTACAAATGAGCACAAT TTTAAGGAGACCCTCCTAGCTTGCAACTACTGCTACACGAATATGATGAAGGAGAGGAT CTACACGCAGGGAAAACCTTGTTCACAGTGTCAGAGCAAAAAGTGTGGGCCAGTCTACA AGAACCTGTGTGATCCTTCGGAGAAGGTTGATCCAACTCCTGATGTCCTTAAGCAATGG AAGCATGGAAAATGATTATTAAGCTCACTTCAAATGTTTCCAATCCAAAAAAAAAAAAA AAAAAAAAAAAAAAAA
LJL18 (SEQ ID NO:4)
TTTTGAGAAAAACATTTCCTTGTGAGTTAAATAGTTGGTAAATTAAATCAAGAGAATGTT
GCTTCGTTCCTTGTTTGTTCTTTTTCTAATTTTCTTAACATTCTGCAACGCTGAGGAAGAA CTTATTGAGAGAAAGTTAACAGGAAAAACGATCTATATCTCAACAATAAAGCTTCCGTG GTTCCAAGCTCTTAATCATTGTGTTAAAAATGGCTACACAATGGTGTCAATTAAGACATT TGAAGAGAATAAAGAACTCCTTAAAGAACTCAAAAGGGTGATTAGGACAGAAGATACA CAAGTTTGGATTGGAGGCCTCAAACATCATCAATTTGCAAACTTTCGTTGGGTAAGCGAT GGAAGCCACGTAGCAACAGCTTCAGGGTACACCAATTGGGCCCCAGGGGAGCCAGCTG ATTCCTTCTATTACGATCAATTTTGCATGGCGATGTTGTTCAGAAAAGACGGCGCTCCGT GGGATGATTTGAATTGTTGGGTTAAGAATCTTTTTGTTTGTGAGAAACGAGATGATTGAG AGGCTATTTTTGTTATCTCACCGTTTTGTTGAATAAAAAAGAAGAAGAAAGACAAAAAA AAAAAAAAAAAAAAAAAAAAAA
LJS193 (SEQ JD NO:6)
TACTTCGTACTCTCAGAATTTCI ACAAGTTCCTTTTTCTCTTAACTTTTAAAGTTTTAT^ AACAAAATTGCTCCATTTTTTCGTTTTCTGAATATTCTGTTGAAATTTTGATTAATCTATT TTATGTGCAGTTTTTACTAAAAATCCCTTATCAGCAACCCGGTGTCTACAGTTTTGTCAC GCTCAGTAGCATCTTCAAGGTGGTAAGAAAAAATGAAACTCCTGCAAATCATCTTCTCTC TCTTCCTGGTCTTTTTCCCGACCTCAAATGGGGCCCTGACCGGAAATGAAAGTGCAGCAA ATGCAGCTCCCTTGCCTGTCGTCCTGTGGCACGGGATGGGCGATTCTTGCTGCTTTCCCTT CAGTTTGGGAAGCATAAAAAAATTAATTGAACAACAAATTCCTGGGATTCATGTTGTTA GCCTGAAAATTGGAAAGTCTCTCATTGAGGACTATGAAAGTGGATTTTTTGTTCATCCAG ACAAGCAAATTCAGGAAGTTTGTGAGTCACTTCAGAACGATCTAACACTCGCAAATGGA TTCAATGCAATTGGATTTTCTCAGGGTAGTCAGTTCCTGCGAGGTCTTGTGCAACGATGT TCTTCTATACAAGTAAGGAATCTCATTTCCATTGGAGGACAGCATCAAGGGGTTTTTGGT CTGCCCTATTGTCCTTCGTTGAGCAGAAAGACTTGCGAATACTTTAGAAAGCTCCTGAAT TATGCAGCTTATGAAAAATGGGTACAGAAACTCCTAGTTCAAGCCACCTACTGGCATGA TCCTCTAAATGAGGATGCATATCGGACTGGAAGCACTTTCCTTGCTGATATAAATAATGA GAGACAAATCAATAATGACTATATTAATAATATTCGGAAGCTAAATCGTTTTGTGATGGT AAAGTTCCTCAACGACAGCATGGTTCAGCCAATTGAATCTAGTTTCTTTGGATTCTACGC TCCAGGAACTGATACAGAAGTTCTCCCATTAAAACAAAGCAAGATTTATTTGGAAGATC GTTTGGGACTTCAATCAGTACCGATAGATTATCTAGAATGCGGAGGAGATCATTTGCAA TTTACAAAAGAATGGTTCATAAAGTTTATCATACCCTATCTGAAGCAATAAGAGCTGCA ATGTAATTGATTAAAAAATGTTAACCATTTCAGGATGATTGGGTGACCCCTTAAAAATAT AAATGAAAAAATATACAAAAGAAATAAATTTTTATATTGATCCCACAAAAAAAAAAAA AAAAAAAAAAAAAAAAA
LJS201 (SEQ ED NO: 8)
GGATCGGCCATTATGGCCGGGGCAGTTAATCGCCACAATTTAATAAAATGAGGAACTTT GCTGTAGTCAGTTTAGCCGTTGCTGTCCTGCTCTTCTGTGCATGGCCTATAAATGCGGAA GATAATGAAGAAGTTGGAAAGGCGAGAGAAAAAAGAGGCTTAAAAGACGCAATGGAA CACTTCAAAAATGGATTTAAGGAGCTGACAAAGGACTTTAAACTTCCAAGCCTTCCAAG TCTTCCTGGATTTGGTAAAAAGCCTGAATCTGGAAGTTCTGAAGATTCTGGAGATAAAA CTGAGGATACCAGTGGATCTAAGGACGACCAATCAAAGGATAATACGGTCGAAGAATCT TAAGAAAGGCGCAAATAGCTATTTTCAAAGTGGCGAATGTTTCTTTCTTTATCTGAAATA AATATTTTTAAACCTTTCGAAACCAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
LJL13 (SEO JD NO:10)
ACTTAAAGATTTTTGTTTAAGCAAAATGAACTTCTTGTTGAAAATTTTCTCTTTGCTCTGT CTCTGTGGACTGGGGTATTCATGGCAGGATGTGAGAAATGCCGATCAAACCCTCTGGGC GTATAGATCGTGCCAAAAGAATCCTGAAGATAAGGATCACGTACCTCAATGGAGGAAGT TCGAATTACCCGACGATGAAAAGACTCATTGCTACGTCAAGTGCGTATGGACGCGTTTG GGAGCTTACAATGAAAATGAAAATGTTTTCAAAATTGATGTCATTACTAAGCAATTTAAT GAACGTGGCCTAGAAGTTCCGGCTGGACTTGATCAAGAATTGGGTGGTTCTACAGATGG AACTTGCAAAGCAGTTTACGATAAATCCATGAAGTTCTTCAAATCTCATTTTATGGACTT TAGGAATGCTTACTACGCAACTTATGACGGTTCTGATGAATGGTTTAGCAAGAACCCTG ATGTAAAACCGAAAGGAACAAAAGTTTCCGAATACTGCAAAAATAAAGATGATGGAGA TTGCAAACATTCCTGCAGTATGTACTACTACCGCTTAATCGATGAAGACAACTTAGTTAT TCCGTTCAGCAACTTACCTGACTATCCCGAAGATAAGCTCGAGGAATGCAGGAATGAAG CCAAGTCCGCAAATGAGTGCAAATCATCTGTTATCTATCAGTGTTTGGAAAATGCGGAT AAGTCAGCTTTAGACGCGTCTTTGAATATACTCGATGAGTTTTCTGGAAGATATTAAAAC AAACTGGATAAAAAACTTAGGCCAACCTATGATTCGAACTTACGATTTTGAACTTGAAA TTCATGTGCTTTAACCTATTGTCCCACTAGGAAGAAAAATCCATATTTGGTGATGTTAAA CTATTTTTGAACCTCTTCAAAATAAACAATTTTCAAAAAAAAAAAAAAAAAAAΛAAA AAAAA
LJL23 (SEQ ID NO:12)
AAAGAGAAGTAGTGAGAATGTTTCTTAAGTGGGTTGTTTGTGCTTTTGCGACTGTCTTCC TTGTTGGGGTGAGTCAGGCAGCCCCACCGGGGGTTGAATGGTATCACTTTGGTCTGATTG CTGATATGGACAAAAAATCCATCGCGAGTGACAAAACCACCTTTAACAGCGTCCTAAAG ATCGATGAATTGCGCCACAACACAAAAACGGATCAATACATTTATGTGCGTAGTCGAGT GAAGAAGCCCGTTTCCACGAGGTATGGGTTCAAAGGACGCGGTGCGGAATTGTCGGAAA TTGTTGTCTTCAACAATAAACTTTACACAGTTGATGATAAATCTGGAATTACGTTCCGCA TAACGAAAGACGGAAAACTCTTCCCGTGGGTTATTCTCGCAGATGCCGATGGACAGCGA CCCGATGGCTTTAAGGGTGAATGGGCTACAATTAAGGATGATACAATCTATGTTGGATC TACGGGGATGCTCAAGTTCACTTCATCCCTTTGGGTGAAGAAGATCACGAAAGATGGCG TTGTTACGAGTCACGATTGGACTGATAAATACCGAAAGATTCTCAAAGCTCTAAACATG CCAAATGGTTTTGTCTGGCATGAGGCTGTTACGTGGTCTCCATTCAGGAAGCAATGGGTC TTCATGCCGAGAAAGTGCTCAAGGCATCCCTTCTCACAGGAACTCGAAGAACGCACAGG GTGCAATAAAATAGTGACGGCAGATGAGAATTTCAACGACATTCAAGTTATTCACATTC AAGATCAGCCATATAATTTAGCTTCTGGTTTCTCTTCCTTCCGCTTTATTCCTGGTACGAA AAATGAAAGACTTCTCGCCTTGAGGACAGTAGAGCAGGAAGATCAGGTTAAAACTTGGG CTGTGGTCATGGATATGAAAGGAACAGTTCTGATGTACGAAAAGGAACTTTATGACGAA AAATTCGAAGGTTTAGCATTCTTTGGTGGTATTAAAAAGAATTAATTTGTTCCAGAAGCT TTTAGATGAAΛTAATAAATTTTATTTCATTTTAAAAAAAAAAAAAAAAAAAAAAAAAAA AA
LJM10 (SEQ ID NO: 14) CGCGGCCGCGTCGACCGACAGAAGGGGTAGTTTGTAGAGAACTTTGAGTTCTAAAGGAA ATTCTCAAGAAGAAAATATTCAAAAGTAAAGAATGGCGTTGAAGTTTCTTCCGGTTCTCC TTCTAAGCTGCTTCGCAATGAGCACGGCACTACAAGTTACTGAGAAGGAACTTTCTGAT GGGAAAAAGATCTTCATCTCCAAAGTTGAGCTAAACTGGTTCGAAGCTCTTGATTTCTGT ATCCATCGTGGTCTTACGTTGCTCTCAATTAAATCCGCCAAGGAAAATGTAGACGTAACA AAAGCAATTCGGGCTGAATTGAATTTTGATTCAAAGAAATTGGCTCATGTGTGGACTGG AGGTATTCGCCATAGTCAAGATAAGTATTTCCGTTGGATAAATGATGGAACTAAAGTTG TTAAACGAGTCTACACCAATTGGTTCACTGGAGAACCAAATAATGGTTACTGGAAGGAT GAATTTTGTCTGGAAATTTACTATAAAACCGAAGAAGGGAAGTGGAATGATGATAAATG TCACGTGAAGCATCATTTTGTATGTCAAGAAAAGAAATAAATTGATTGATTTTGTTTGCT GATTTGCAGTTCAGAATTGAAAAGCCAAAAAAAAAAAAAAAAAAAAAAAAAAAA
LJL143 (SEQ I NO: 16)
CTTCTTTGGATTTATTGAGTGATTAACAGGAAATTAGCTGAAGAAATGAATTCGATTAAT TTCCTATCAATAGTTGGTTTAATCAGTTTTGGATTCATTGTTGCAGTAAAGTGTGATGGT GATGAATATTTCATTGGAAAATACAAAGAAAAΛGATGAGACACTGTTTTTTGCAAGCTA CGGCCTAAAGAGGGATCCTTGCCAAATTGTCTTAGGCTACAAATGCTCAAACAATCAAA CCCACTTTGTGCTTAATTTTAAAACCAATAAGAAATCCTGCATATCAGCAATTAAGCTGA CTTCTTACCCAAAAATCAATCAAAACTCGGATTTAACTAAAAATCTCTACTGCCAAACTG GAGGAATAGGAACAGATAACTGCAAACTTGTCTTCAAGAAACGTAAAAGACAAATAGC AGCTAATATTGAAATCTACGGCATTCCAGCGAAGAAATGTTCCTTCAAGGATCGTTACAT TGGAGCTGATCCACTCCACGTCGATTCCTATGGGCTTCCGTATCAGTTTGATCAGGAACA TGGATGGAATGTGGAACGATATAACATTTTCAAAGACACAAGATTTTCCACAGAAGTTT TCTACCACAAAAATGGTTTATTTAACACCCAAATAACTTATTTGGCTGAAGAAGATTCCT TCTCTGAAGCTCGAGAGATTACTGCGAAGGATATTAAGAAGAAGT1TTCAATTATTTTGC CCAATGAAGAGTATAAGAGGATTAGTTTCTTGGACGTTTATTGGTTCCAGGAGACTATGC GAAAAAAGCCTAAATATCCCTACATTCACTACAATGGAGAATGCAGCAATGAGAATAAA ACTTGTGAACTTGTCTTTGACACCGATGAACTAATGACCTACGCCCTTGTTAAAGTCTTT ACTAATCCTGAGAGTGATGGATCTAGGCTCAAAGAAGAGGATTTGGGAAGAGGATAAA TCTTCTΓAATAAAAAAAAGTTCTGTAAGAAAATATTGTTCAATAAATTAAAAAAAAAAA AAAAAAAAAA LJS142 (SEQ 1D N0: 18)
AATAGATCTTCAAAACGTCTAAGAATGGCTTTCAGCAACACTTTATTTGTTCTTTTTGTG AGTTTTTTAACGTTTTGTGGCGCTGATCAGACACTTATTGAGAAGGAATTAACCGGAAGA ACTGTTTATATCTCCAAAATTAAGCTAAATTGGAACGATGCCTTCGATTACTGCATCCGC AATGGCCTCACCTTTGCTAAGATTAAATCAGCTGAAGAAAACACCGAACTGAGTGAGAA ACTCAAGACAGTCATTCGTACGGAGGAGTTTCAAGTTTGGATTGGAGGCATTGAACATC ATCAAGACAGTTCCTTCCGCTGGGTAAGCGACTCCCAACCAATAACCAACAAATTGGGC TACAAATACACAAACTGGAATACCGGAGAGCCCACAAATTACCAAAACAACGAATATT GCTTGGAAATATTATTCCGGAAGGAAGATGGAAAATGGAATGATTTTCCCTGCAGTGCA AGACATCATTTTGTTTGTGAAAAAAGAACAAAATAAAATGAAGAAAATGTGATTTTCCT TTGGTTGAAGAATAAAATTCTGTTGAAAAAAAAAAAAAAAAAAAAAAAAAAAA
LJL17 (SEQ ED NO: 20) ATTTAGTTTGTGTTTAACAAAACAAGAATGCAGAACTTCCTTTTAGTTTCCTTGGCTTTAG CTGCCTTAATGCTATGTGCCGAAGCAAAGCCGTACGATTTTCCGCTTTATCAGGACTTAA TTCAGGGCGTTATTCAGCGCGAAAGTCAAGCTGAGAGGGAGAAGAGAAGCCCCAATGA GGACTATGAGAAGCAATTTGGGGATATTGTTGATCAAATTAAGGAAATTAGTTTCAATG TCATGAAAATGCCCCATTTTGGAAGCTCTGATGATAATCGTGATGATGGCGAGTACGTTG ATCATCATTATGGTGACGAAGATGATCGTGATTATGATCATTACTAAATACTACTTGCTC CTGCTGAATGACTTGAAGGAATCATTTTTTTGCAAAAATATCCATCAAATTATTGAATTA ATAAAGTTGCAAAAAAAΛAAAAAAAAAAAAAAAAAAAAA
LJM06 (SEQ ID NO: 22) GTTTAAGGAATTTCTTTCATCTCAGTCTTCGATTTTCTTTAAACAAATAATGAAGTTTTAT ATTTTTGGAGTTTTCCTGGTGAGCTTTCTTGCATTATGCAATGCTGAGGATTATGATAAA GTAAAACTTACTGGAAGAACTGTTTACATCTCCAGATCAAAGGCTCCGTGGTTCACAGCT TTAGACAATTGTAATCGTTTACGCTTCACCTTCGCCATGATCAAGTCTCAGAAGGAGAAT GAAGAGCTAACAAATGCGCTTTTAAGTGTAATTAAATCTGACGAAGAAAATGTTTGGAT TGGAGGTCTTAGGCACGATCTGGATGACTACTTCCGTTGGATTAGTTTTGGAACTGCATT GTCAAAGACTTCGTACACCAATTGGGCCCCAAAGGAACCC '
ACAGGAAGGCCCCATAGAACTCAAAATGATGAATTCTGCATGCAAATGTCTTTCAAAGA TGGTGGCAAATGGAGTGATAACACCTGTTGGCGTAAACGTTTGTACGTTTGTGAAAAGC GTGATTAAATAAAGGAACACTGCCAATGAATATTGGGCAATTTGAGAGAAATTAAATTA AAAAAAAAAAAAAAAAAAA
LJM17 (SEQ ED NO: 24)
AGTCAGTGTTAATGAAGAAATTGCAATTATGAGGTTCTTCTTTGTTTTCCTTGCCATCGTC
CTTTTTCAAGGGATCCACGGAGCTTATGTGGAAATAGGATATTCTCTGAGAAATATTACA TTCGATGGATTGGATACAGATGACTACAATCCAAAGTTCAACATTCCAACGGGTTTGGC AGTTGATCCCGAAGGATATAGGCTCTTCATAGCCATCCCAAGGAGAAAGCCAAAGGTTC CCTACACTGTGGCTGAACTGAATATGGTCATGAATCCCGGATTTCCCGTCGAGAGAGCTC CGAGCTTTGAGAAATTCAAAAAATTCAATGGCGAGGGCAAAAAGGATCTTGTTAATGTG TATCAGCCAGTCATTGATGATTGTCGTCGTCTTTGGGTGCTTGACATTGGGAAGGTGGAA TACACCGGTGGTGATGCTGATCAATATCCCAAAGGAAAGCCTACCCTAATTGCCTACGA CCTCAAGAAGGATCATACTCCGGAAATTCATCGATTTGAAATTCCAGACGATCTCTATAG CTCACAAGTTGAATTTGGTGGATTTGCCGTTGATGTTGTTAACACGAAAGGAGACTGTAC GGAGTCATTTGTCTACCTGACCAATTTCAAGGATAACTCTCTAATTGTCTACGATGAGAC ACAAAAGAAAGCTTGGAAATTCACAGATAAAACATTTGAAGCTGATAAGGAATCCACGT TCTCCTACTCGGGAGAGGAACAAATGAAGTACAAAGTCGGTCTTTTTGGGATAGCTCTG GGTGATAGGGATGAAATGGGGCATCGTCCTGCCTGCTACATCGCTGGGAGTAGCACCAA AGTCTACAGTGTTAACACTAAAGAACTCAAAACAGAGAATGGTCAGTTAAATCCTCAGC TTCACGGTGATCGTGGAAAGTACACAGATGCAATTGCCCTAGCCTACGATCCTGAGCAT AAAGTCCTCTACTTTGCTGAATCCGACAGCAGGCAGGTGTCCTGTTGGAATGTAAATATG GAGCTAAAACCAGACAATACGGATGTGATCTTCTCTAGTGCCCGTTTTACTTTTGGAACG GATATTTTGGTTGATAGCAAGGGAATGCTGTGGATAATGGCTAATGGACATCCACCAGT AGAGGATCAAGAGAAGATTTGGAAGATGAGATTCGTAAACCGGAAGATCCGTATTATG AAAGTGGATACGGAACGTGTTTTCAAATATTCACGCTGCAATCCAAATTATAAGCCCCC AAAGGAAATTGAAGTTTGAGACACAGGAAAAAGCTCAATTTTCAACAAGAATTTGATCT TAATCTGAATACCCTAAAGTCTGTCAAAGAATTTCATATTATTTGAAAACCAATAAATTG ATTAATTTTCCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
LJL04 (SEQ ED NO: 26) ACTAAAGCGTCTCACCGAAATCAGGGAAAATGATTAAGGAAGTTTTCTCTCTGGCTCTA CTTGTGGCCTTGGCACAGTGTGCTAATGAAATCCCTATTAATCGTCAGGGGAAAGATTAT CCAGTTCCGATCATTGATCCAΛATAAATCATCTTCGGATGATTATTTCGATGATCGCTTC TACCCTGATATTGATGATGAGGGCATAGCTGAGGCTCCTAAGGATAATAGGGGAAAATC CCGTGGTGGTGGTGCGGCTGGCGCAAGAGAAGGTAGGTTAGGTACGAATGGGGCTAAA CCGGGTCAGGGTGGAACTAGACCAGGACAGGGTGGAACTAGGCCAGGACAGGGTGGAA CTAGGCCAGGTCAGGGTGGAACTAGGCCAGGTCAGGGTGGAACTAGACCTGGGCAAGG TAGAACTAAGCCTGCTCAGGGAACTACTAGGCCAGCTCAGGGAACTAGAAATCCAGGAT CGGTTGGTACGAAAGAAGCCCAGGATGCGTCAAAACAAGGTCAAGGTAAAAGAAGGCC AGGGCAAGTTGGTGGTAAAAGACCAGGACAAGCAAATGCTCCTAATGCAGGCACTAGA AAGCAACAGAAAGGCAGTAGAGGCGTTGGAAGGCCTGATCTATCGCGCTACAAAGATG CCCCTGCTAAATTCGTTTTCAAATCTCCCGATTTCAGTGGAGAAGGCAAAACTCCAACTG TAAATTACTTTAGAACGAAGAAGAAGGAGCACATTGTGACCCGTGGTAGTCCTAATGAT GAATTTGTTCTGGAGATTCTCGATGGGGATCCAACTGGGCTTGGACTAAAGAGTGAAAC CATAGGCAAAGATACGCGTTTAGTGCTGGAGAATCCTAATGGAAATTCCATCGTGGCTC GTGTTAAGATCTACAAGAACGGTTATTCAGGATGAAGAAGAAATCCTTTGATTTCCCCCC CCCCCTCTTCCTTTAAAATTCAACATAATAAAAAAAAAAAAAAAAAA
LJMl 14 (SEQ ID NO: 28) GTCTTTTCCTGAGTGTTTCATTAACAAAATGAATTCAGTAAACACTTTAATTTTAACTCTT CTATTTGCAATTTTTTTATTAGTGAAAAGGTCTCAGGCTTTTCTTCCATCTGACCCAAGTA TCTGTGTTAAAAATTTAGTATTGGATACAGGAAGGACTTGTGAGGAAAGTGAATATTTTC CGGATATCAAGAACGTTAAAAATGGAAAAAGAGTTTACATTGTCTGCACTGATTCAGAT GCAGTTGATTATAAATTTTATATTTGTTTCGATATGAATCGTCTTTCTGGACCACCGTATC CTGAGGAAGAAATCCTTCGTGAATCAACGGTAACTTATGCCCAAATTTATGAGCTGATG ACTACGGAAACCACTGAAACCAAAAAGCCAAAAAAGAAACCAAAGAATTCAAAAACGG ACCCAGACCCTCCAGCAATTCGTCCAGGATTTTCATTTAGAAATTCAATTTCTGTTTAATT TTACAATTTATTTTGAAAGAAAAATGATATTTCGAAATATTCTATACAAAAAAACAACA GTTATAAAACGAAAATTCAATCATTTCAATGAGAAAACTTAGTCTTGAGTAAGGTTTATT CACCACCCGACGCCACGCTATGGTGAATAATTTTCTTTATTCACCACATCAAAATGACGG CTTATAAACTTCAACAAATAGTTTGGAAAATACATTTCTAACTAATGCAATGTTTACTTA AAATCACTTTACAAATTCACGCATTTGAGATGCAACAAATATATACAATTCAACGATAT AAACTTTCCACAAGGAAAACTTTCAACCAAAAAAAAAAAAAAAAAAAA
LJMl 11 (SEQ ID NO: 30)
ATCATTCAAAAGGCAGCAGCACAATGAAGTTATTTTTCTTTCTTTACACTTTTGGTCTAGT CCAAACGATTTTTGGAGTAGAAATTAAACAAGGATTTAAATGGAATAAAATCCTTTATG AGGGCGATACATCAGAAAACTTCAATCCAGATAACAACATCCTTACGGCTTTTGCGTAC GATCCTGAGAGTCAGAAACTCTTCCTAACTGTCCCGAGGAAATATCCCGAAACTATGTA CACTTTGGCAGAAGTTGATACTGAGAAAAATTCTTTTGAATCGGGAGATACTTCCCCGCT CCTTGGAAAATTCAGTGGTCATGAAACTGGGAAAGAACTTACATCAGTTTATCAGCCAG TTATCGATGAATGTCATCGTCTTTGGGTTGTTGATGTTGGATCAGTAGAACGTAACTCAG ACGGCACAGAAGGTCAGCCAGAACATAATCCTACCCTTGTGGCGTACGATCTCAAAGAA GCCAACTATCCTGAAGTTATTCGTTACACGTTTCCCGATAATTCCATTGAGAAGCCCACA TTTCTGGGTGGATTTGCCGTTGATGTTGTAAAGCCGGATGAATGCAGTGAAACTTTTGTC TACATCACAAACTTCCTCACCAACGCCCTCATAGTATACGATCATAAGAATAAGGACTC CTGGACGGTACAAGATTCAACTTTTGGACCAGATAAAAAGTCAAAGTTTGACCACGATG GACAACAGTATGAATACGAAGCAGGAATCTTCGGGATTACCCTTGGAGAGAGAGATAA CGAAGGAAATCGTCAAGCGTACTATTTAGTAGCAAGTAGTACCAAACTTCACAGCATCA ACACCAAAGAACTGAAGCAAAAAGGAAGCAAAGTTAATGCAAATTATTTGGGAGATCG TGGTGAATCCACCGATGCCATAGGCTTAGTTTACGATCCAAAAACCAAAACTATCTTCTT CGTTGAGTCAAATAGCAAAAGAGTATCATGCTGGAATACCCAGGAAACACTAAACAAG GATAAAATTGATGTAATCTATCACAATGCAGACTTTTCCTTTGGAACAGATATATCGATT GATAGTCAGGATAATTTGTGGTTCCTAGCAAATGGACTTCCACCTCTGGAAAATTCTGAT AAATTTGTCTTTACAAAGCCACGTTATCAAATATTCAAAGTCAACATTCAAGAAGCAATT GCTGGAACTAAATGTGAAAAGAATCTTTAACAAATGAAACTTTGTAGAAAAATACATAA TATCTGAATAAAAAGTCATAAATGTACCATAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAA
LJM78 (SEQ ED NO: 32)
CTTTAAAGCAAAAATTTTGTGGGAAAGGAAGTTACCCGGAGATGACGTTTCTAATTATA CTTGGTGCATTTCTCCTTGTTCAAATTATTACAGCTTCAGCTTTAGGATTGCCTGAACAGT TTAAAGGTTTAGAGGATTTACCTAAAAAACCTTTGGCAGAGACTTATTATCACGAAGGA TTGAATGATGGAAAAACGGATGAAATGGTGGATATTTTTAAAAGTCTTAGCGATGAATT TAAATTCAGTGATGAAAATTTAGATGTTGGTGAGGAGAAAAATTACAAGAAACGTGATA TAACCCAAAATTCAGTGGCAAGGAACTTCCTATCAAACGTAAAGGGAATTCCTTCAATG CCATCACTCCCTTCAATGCCTTCAATGCCATCAATTCCTTCACTTTGGTCAAGTCAGACA CAGGCGGCACCAAATACCGCACTTGCCCTTCCTGAATCTGATTATTCCCTTCTAGATATG CCGAATATTGTGAAAAATTTCCTAAAGGAAACAAGAGACCTCTATAACGATGTTGGAGC TTTTCTTAAGGCAATTACAGAAGCTTTAACAAATAGATCTTCATCATCTCAACTTCTTTCC TCCCCAATGGTGAGCACGAATAAAACCAAAGAATTTATTCGGAATGAAATACAAAAAGT CCGAAAAGTGAGAAATTTCGTCCAGGAAACTCTTCAGAAAATCCGAGACATTTCTGCTG CTATTGCCAAAAAGGTAAAATCATCAGAATGTCTGTCCAATCTTACGGACATCAAAGGA CTTGTATCAGACGGAATTAATTGTTTAAAGGAAAAATTCAATGATGGAAAACGAATTAT CCTGCAATTGTACAATAATTTACTAAAAGGACTCAAAATTCCAAATGACCTAATGGTTG AATTGAAGAAATGTGATACAAATCAAAACAATACTTTGGGAAGAATAATCTGTTATTTT TTGACACCATTGCAACTGGAAAAAGAACAAATTCTTCTACCTGTAGAATTTATAAAGCG CATTCTTGAATTAACCCACTACTTTTCCACAATGAAAGAAGATCTTATCAACTGTGGCAT CACAACGATTGCATCCATTACGTAAAAAATGGAAAAATGTGCCGGTGAAATGCTTGAAA TCACCAAAGAAATTTCATCGCAAATAACAGTTCCAGAATAACCAAATTTTAATGATTACT
AAGAAAAAAAAAAAAAAAAAAAAAAAAA
LJS238 (SEQ ED NO: 34)
AGTTAATCTTCTGTCAAGCTACAAAAATGCTTAAAATCGTTTTATTTCTATCAGTTTTGGC TGTATTAGTGATTTGTGTAGCAGCAATGCCAGGATCCAATGTTCCTTGGCACATTTCACG AGAAGAGCTTGAGAAGCTTCGTGAAGCTCGAAAGAATCACAAGGCACTCGAGAAGGCA ATTGATGAATTAATTGACAAATATCTCTGATTTTGAAGAGCAAGGAAGAGGAAATAAAC GGCCGAGGAAGGATTTTCTTTAGAGATTCTTCTTTTTATTACTTCAAACCTAACTTCAAA ATCAGTCTGATATTTTTTTAATTTGAAAAAAATATTGAAAATTTTAACTATTTG TAAATAAATAAAGAATGTCAGAAGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAA LJS169 (SEQ ED NO: 36)
AATTTTCACCATGAAGTTTFCTTGCCCAGTTTTCGTTGCAATTTTCCTTTTGTGCGGATT^ ATCGTGTTGAGGGGTCATCACAATGTGAAGAAGATTTAAAAGAAGAAGCTGAAGCTTTC TTTAAGGATTGCAATGAAGCAAAAGCCAATCCTGGTGAATACGAGAATCTCACCAAAGA AGAAATGTTTGAAGAATTGAAAGAATATGGAGTTGCTGACACAGACATGGAGACAGTTT ACAAACTTGTGGAAGAATGTTGGAATGAATTAACAACAACGGATTGTAAGAGATTTCTC GAAGAGGCTGAATGCTTCAAGAAGAAGAATATTTGTAAATATTTCCCAGATGAAGTGAA ATTGAAGAAGAAATAAATTTTTAGCTTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAA
LJL11 (SEQ ID N0: 38)
GTTCAGCATAGAACTGGCGTTGTTAACAGCATCAGCAGCAGCAGAAGACGGCAGCTATG AGATCATAATTCTTCACACCAATGATATGCACGCGCGTTTTGATCAAACCAATGCTGGAA GCAACAAATGCCAAGAAAAAGACAAGATTGCTTCCAAATGCTACGGAGGATTTGCAAG AGTTTCAACAATGGTGAAAAAATTCCGAGAAGAAAATGGCAGCAGTGTCTTGTTCTTGA ATGCTGGTGACACGTATACAGGTACCCCATGGTTTACCCTCTACAAGGAGACCATTGCA ACGGAGATGATGAACATCCTTCGTCCAGATGCAGCCTCACTGGGAAATCATGAATTCGA CAAAGGAGTAGAAGGACTCGTGCCATTCCTCAATGGTGTCACCTTCCCTATTTTAACAGC GAATTTGGACACTTCTCAAGAGCCAACAATGACCAATGCTAAAAATCTCAAACGCTCAA TGATTTTTACGGTTTCCGGGCACAGAGTTGGTGTAATTGGCTACCTAACGCCTGATACAA AATTCCTCTCGGACGTTGGTAAAGTTAATTTTATTCCGGAAGTTGAAGCCATCAATACGG AAGCACAGCGTCTGAAGAAAGAGGAAAATGCCGAAATAATCATCGTTGTTGGACATTCA GGGTTGATAAAAGATCGAGAAATTGCAGAGAAATGCCCACTGGTTGACATAATTGTTGG AGGACATTCACACACATTCCTCTACACAGGAAGTCAGCCTGATCGTGAGGTTCCTGTAG ACGTTTATCCTGTTGTTGTGACCCAATCCAGTGGGAAGAAAGTTCCAATTGTTCAAGCCT ATTGCTTΓACAAAGTATTTGGGGTACTTTAAAGTGACGATCAACGGAAAAGGAAATGTT GTGGGATGGACTGGGCAGCCAATTCTCCTTAATAACAACATTCCCCAAGATCAGGAAGT
TCTCACTGCTCTTGAAAAGTACAGAGAACGCGTGGAAAACTATGGAAATCGCGTAATTG GAGTTTCCCGTGTAATTCTCAATGGGGGGCATACTGAATGTCGTTTCCATGAATGCAATA TGGGTAATCTCATCACGGACGCTTTTGTGTATGCCAATGTAATCAGTACACCAATGAGTA CGAATGCCTGGACAGATGCAAGTGTTGTTCTGTATCAAAGTGGTGGCATTCGTGCCCCA ATTGATCCTCGTACCGCGGCAGGGAGCATCACACGCCTCGAGTTGGACAATGTTCTACC ATTTGGGAATGCACTGTACGTCGTAAAAGTTCCTGGGAATGTCTTACGCAAAGCTTTGGA ACATTCAGTTCATCGATACTCCAACACTTCGGGATGGGGAGAATTTCCACAAGTTTCGGG GCTAAAGATTCGTTTTAACGTCAATGAAGAAATTGGAAAACGCGTAAAGTCCGTTAAAG TTCTCTGTAGCAATTGCTCTCAACCTGAATACCAACCACTGAGAAATAAAAAAACTTAC AACGTTATCATGGACAGTTTTATGAAGGATGGAGGTGATGGGTATAGCATGTTCAAGCC CTTGAAGATCATCAAGACCCTCCCACTGGGAGATATTGAAACAGTAGAAGCTTATATTG AGAAAATGGGCCCCATTT
TCCCAGCAGTCGAGGGAAGGATCACTGTTCTTGGGGGACTTCAAAAATCAGATGAGGAT TGGCATTAGAAACATCCTGGACGTTATGGAAAGAATAAAAGAAGGATCATAGAAAAAA AAAAAAAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
LJL08 (SEQ 3D NO: 40)
GTCAGTGATCTGATAAGTTATTAAAATGAAGCAAATCCTTCTAATCTCTTTGGTGGTGAT
TCTTGCCGTGCTTGCCTTCAATGTTGCTGAGGGCTGTGATGCAACATGCCAATTTCGCAA AGCCATAGAAGACTGCAAGAAGAAGGCGGATAATAGCGATGTTTTGCAGACTTCTGTAC AAACAACTGCAACATTCACATCAATGGATACATCCCAACTACCTGGAAATAATGTCTTC AAAGCATGCATGAAGGAGAAGGCTAAGGAATTTAGGGCAGGAAAGTAAGAGATTGAGG AAAATTGTAGCCGAAGAGAGAAGGAAGGAAAGTCCCATATTTTGTTTGTTAATTGTAAC GAATTTTGCGAAA-AAAATAAAATATTATGCACTCCAAAAAAAΛAAAAAAAAAAAAAAA AAAAAA
LJS105 (SEQ JD NO: 42)
TATTTTTAATAATTCTGTGTAAAATGAACGTTCTTTTCGTGTCTTTCACGCTCACAATTCT
TCTTCTCTGTGTTAAGGCACGGCCAGAAGATTTCGTAGCTCTTCAGGATCAAGCTAATTT CCAGAAATGCCTCGAACAATATCCAGAACCAAATCAATCTGGAGAAGTTCTTGCGTGCC TCAAGAAGCGCGAAGGTGCCAAAGATTTCCGGGAAAAGAGGAGCCTGGATGACATAGA AGGGACTTTCCAAGAGTCTGGAAATCTCTGGGGTGCATAGGAAGCTCAGAGGACTTCTA ATCAATCTGTGAGAAGAGAACCCAACGGCTAGAGAAAATTTAAGGAAAATAAAGAAAT TAATGAAGCATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAA
LJL09 (SEQ ID NO: 44)
GTATATCAAGTATCATTCAAGTGAATCATTGGCTCCGTAATTTGTACAAAAGAAAAAAA
AAGTTGATAAΛATCATGAAAATCACTGTGATTTTATTCACGGGATTTACAATTGCCCTCG TGAGTAGTGCTGTGCTTAAGAAAAACGGTGAAACTATTGAAGAAGAAGAAGTAAGAGC TGAGCAACGACTTAGAGAGATCAATGAGGAACTTGATCGTAGGAAGAATATCAATACTG TAGCCGCTTGGGCTTATGCATCCAATATTACTGAGGTCAATCTCAAGAACATGAATGATG TGTCGGTTGAAACCGCGAAATACTACAAGGAACTTGCATCTGAATTGAAGGGATTCAAT GCCAAGGAATACAAGAGTGAGGATCTGAAGAGACAAATTAAGAAGCTAAGCAAGTTGG GATATAGTGCTTTACCATCTGAGAAGTATAAGGAGCTTTTGGAAGCTATCACATGGATG GAATCGAATTATGCAAAAGTGAAAGTTTGCTCATACAAGGATCCAAAGAAATGTGATTT AGCACTTGAACCTGAAATTACGGAAATCCTTATTAAAAGTCGAGATCCTGAGGAACTTA AATATTATTGGAAACAATGGTACGACAAAGCTGGCACACCAACTCGAGAGAGTTTTAAT AAGTATGTACAACTAAATCGTGAAGCAGCGAAATTGGATGGATTTTATTCGGGTGCAGA ATCTTGGCTTGATGAATATGAAGATGAGACATTTGAGAAACAACTTGAGGATATCTTCG CCCAAATTCGCCCACTGTACGAGCAACTCCATGCTTATGTTAGATTCAAGCTGAGGGAA AAGTATGGAAATGACGTTGTTTCGGAGAAAGGTCCCATTCCAATGCATCTCTTGGGGAA CATGTGGGGTCAAACGTGGAGTGAAGTTGCCCCAATTTTAGTCCCATACCCCGAAAAGA AGCTCCTCGATGTTACCGATGAGATGGTTAAGCAGGGATACACACCAATTTCTATGTTTG AAAAAGGAGACGAATTTTTCCAAAGCTTGAATATGACGAAACTTCCAAAAACCTTCTGG GAGTACAGTATTTTGGAAAAACCCCAAGATGGTAGGGAATTGATCTGCCATGCAAGTGC ATGGGACTTCTATACAAAGGATGATGTAAGGATTAAACAGTGTACCAGAGTTACAATGG ATCAATTCTTCACGGCTCATCATGAGCTTGGTCACATTCAATATTATTTGCAATATCAAC ATTTGCCGAGTGTTTACAGAGAAGGTGCCAATCCAGGCTTTCACGAGGCTGTTGGGGAT GTTCTCTCTCTTTCGGTATCAAGTCCTAAACATTTGGAAAAAGTTGGTTTGCTTAAAGAC TTCAAATTTGATGAAGAATCCCAGATAAATCAACTTCTAAATTTAGCTCTGGATAAAATG GCATTCCTCCCATTTGCCTATACCATTGATAAATATCGCTGGGGTGTGTTTCGGGGTGAA ATTTCGCCGTCTGAGTACAATTGCAAATTTTGGGAAATGCGTTCCTACTATGGTGGTATA GAACCACCAATTGCACGTTCTGAGAGTGATTTTGATCCACCAGCAAAATATCATATTTCA TCGGATGTTGAGTACCTCAGGTATTTGGTTTCCTTCATTATTCAGTTCCAATTCCATCAAG CTGTGTGCCAAAAGACTGGTCAGTTCGTACCGAATGATCCGGAGAAGACTCTTCTAAAT TGTGACATCTACCAGAGTGCTGAGGCTGGTAATGCCTTCAAAGAAATGCTCAAATTGGG ATCCTCAAAACCATGGCCAGATGCAATGGAAATTCTTACGGGGCAAAGGAAAATGGATG CTTCTGCATTAATTGAGTACTTCCGTCCACTCAGTGAGTGGTTGCAGAAGAAGAATAAG GAACTAGGAGCTTATGTTGGCTGGGACAAATCTACTAAGTGTGTCAAAAACGTCAGTTA ATTTTTTGTGAGCCCTAAAAAATATTCATAACATTTCAATATGACAΛAATATATGATTTT CGTGAAAACTAAGCATGAGTAAGTTTTIT1TGTGAATTTTTAGCAGTTTCATTTCAGAAT AAACGTCAAATTTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
LJL38 (SEQ ID NO: 46)
TCAGTTAGTTGACTAACAAACCACAATAGAGACACTAAAATGAAGACATTCGCCTTAAT CTTCTTGGCTCTTGCTGTTTTTGTGCTCTGCATTGACGGAGCTCCAACTTTTGTGAATTTA CTGGACGACGTACAGGAAGAGGTAGAAGTTAATACGTATGAGCCTTAGGAAGAAAATG TTTGAGGAGTTTCAGGCAGAGGCAGAGCTTTCCCAGAGAGGGAGCTTTTGCCTTGCTGT AGATTTTTAAAAATGAATCAATTTGATTGGAGCAATTACGCTATATTTGTGGGAATATTT TTGAATTAAAAACTAATTATGGAAATTAATATATAATTTTCAGAATTTCAATAAATTCAT CAAAATTGTATTAATTAAAAAATATTGTATGAAATTCCCAATAAAAGCTTTCAAATTAAA AAAAAAAAΛAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
LJM04 (SEQ JD NO: 48)
GGCCATTATGGCCGGGGATAGAACTTAATTGTTGTTAAAATGAATCACTTGTGCTTTATT ATTATTGCTCTATTCTTTTTGGTTCAACAATCTTTGGCTGAACATCCAGAAGAAAAATGT ATTAGAGAATTGGCGAGAACTGATGAAAACTGCATTCTTCATTGTACGTATTCGTACTAC GGATTCGTTGATAAAAATTTCAGGATCGCTAAAAAACATGTTCAAAAATTCAAAAAAAT CCTAGTTACATTCGGCGCTGTTCCTAAGAAAGAAAAAAAGAAACTTTTAGAGCACATTG AGGCTTGTGCGGATTCTGCGAATGCTGATCAACCTCAAACTAAAGATGAAAAATGTACA AAAATAAATAAGTACTATCGTTGTGTTGTGGATGGAAAAATATTACCCTGGAATAGTTA TGCTGATGCAATCATTAAGTTTGATAAAACCCTTAACGTATGAAGCAAAGATATTCGAA AAAAAAACATCAAGATTATGCTGGAAAGAAAAAAATAAAAAAAAATTGTGCTAATCAA ATTGAATTAACGCTTAATGCTATATTAAAAAAAAAAAAAAAAAAAA
LJM26 (SEQ ID NO: 501 GTCGGAGATCGTCTGCCTTGATGATCACATCGTGATTGTGAGTTACAAGAGTGAAACTTT TTAAGTGTGTGTGTCTTAGCAAAGTGATTTCCACAATGAAGATTATTTTTTTAGCCGCTTT TCTACTAGCGGATGGTATTTGGGCTGCTGAAGAACCTTCAGTGGAAATTGTAACACCAC AATCAGTGCGGAGACACGCTACGCCAAAAGCCCAGGACGCGAGGGTAGGAAGTGAATC CGCAACAACAGCACCAAGACCAAGTGAATCAATGGATTACTGGGAGAATGATGATTTCG TCCCATTTGAGGGTCCATTCAAGGATATTGGAGAATTCGACTGGAACCTTTCGAAGATCG TTTTTGAGGAAAACAAAGGTAATGCCATCTTGTCGCCACTCTCTGTGAAGCTACTAATGA GTTTGCTCTTCGAGGCCAGTGCGTCAGGTACCTTGACCCAGCACCAACTCAGACAAGCC ACTCCCACCATCGTCACCCACTATCAGTCTCGAGAATTTTACAAGAATATCTTTGACGGT CTCAAGAAAAAGAGTAACGACTACACGGTTCACTTTGGTACGAGAATCTACGTGGATCA GTTTGTGACGCCTCGCCAGAGATATGCTGCCATTTTGGAGAAGCATTATCTGACTGATCT CAAAGTTGAGGACTTCTCGAAGGCAAAAGAAACAACTCAGGCAATCAATAGTTGGGTGT CAAACATCACAAATGAGCACATAAAGGATCTCGTGAAGGAGGAAGATGTTCAGAATTC AGTTATGCTCATGCTTAATGCAGTCTACTTCCGCGGACTCTGGCGCAAGCCTTTCAATCG TACACTCCCACTGCCCTTCCACGTGAGCGCTGATGAGTCCAAGACGACTGATTTTATGCT AACCGATGGGCTCTACTACTTCTACGAGGCAAAGGAATTGGATGCTAAGATCCTCAGAA TTCCTTACAAAGGTAAACAATACGCAATGACTGTGATCTTACCAAATTCCAAGAGTGGC ATTGATAGCTTTGTGCGTCAGATTAACACGGTCCTCCTGCACAGGATTAAGTGGTTGATG GATGAAGTGGAGTGCAGGGTTATTCTACCCAAGTTCCACTTTGACATGACGAATGAGCT GAAGGAATCGCTCGTAAAGTTGGGCATCAGTCAGATTTTCACATCAGAGGCATCTTTGC CATCATTAGCACGAGGACAGGGCGTACAGAATCGTCTGCAGGTGTCTAATGTGATTCAG AAGGCGGGAATAATTGTGGATGAGAAGGGCAGCACAGCCTATGCTGCGTCAGAAGTGA GCCTAGTCAACAAGTTTGGAGATGATGAGTTCGTCATGTTCAACGCTAATCATCCATTCC TCTTTACAATTGAGGACGAAACCACCGGCGCAATCCTATTTACGGGAAAAGTCGTCGAT
TCCTCATTGAAGGACATTAATAGAGCATCTTCTCAGGAAGGCACTCCTGACTTATTTTTA CTAAATGTGATCCTTGGACACATAAAAAAAACAGCTGTACTTTCTACTTTTTATAATATA CGACCATATTTGTGAGGAAAA-AAAAAAAAAAAAAAAAAAAAAAAAAA LJS03 (SEQ ED NO: 52)
TCAGTTAAGCAGATTTTCAAGCTAAAGAAACTTAACTAAGATGCGATTCCTTCTTTTGGC CTTCTCCGTTGCTTTGGTGCTTTCACCAACATTCGCCAAACCAGGTCTTTGGGACATTGTA ACTGGTATTAATGATATGGTAAAAAATACTGCGAATGCACTCAAAAATCGTCTAACAAC TTCTGTGACATTATTCACAAATACCATCACCGAAGCTATAAAAAATGCAAATTCTTCTGT TTCGGAACTCCTTCAGCAAGTCAATGAAACCCTTACGGATATTATTAATGGTGTAGGACA AGTGCAGAGTGCCTTTGTGAATTCAGCTGGAAATGTTGTTGTGCAAATTGTTGATGCCGC TGGAAATGTTTTGGAAGTTGTTGTTGATGAGGCTGGAAATATCGTGGAGGTAGCTGGAA CAGCATTGGAAACTATCATTCCACTGCCCGGTGTAGTGATTCAGAAGATAATTGATGCTC TCCAAGGAAATGCAGGGACTACATCGGATTCAGCTTCATCAACTGTGCCCCAACAATCT TAACTACAACCGCAATGATGTTGTCTTTAACGGAGAATTTTTAAATTTGAATATCAAAAT CCAAGATGAAATATTCAGATTTTTCAATCAATATGATACGAAΛTTTTGAAATTATTTTTC CGACTAAAGCAATTTGTAAAAGGAAAACCAAATAAATATTTGAAATTGTAAAGAAAAA AAAAAAAAAAAAAAAAAAAAAAA
LJS192 (SEQ ID NO: 54)
ATATCAATTTTATCATCATGGTGAAGTACTCGTGTCTTGTTCTTGTTGCAATTTTTCTTCT GGCCGGACCCTACGGCGTTGTAGGTTCTTGTGAGAATGACCTGACAGAGGCCGCCAAGT ATCTTCAAGATGAATGCAATGCAGGTGAAATTGCAGATGAATTTCTACCCTTCTCTGAAG AAGAAGTGGGTGAAGCATTGAGCGACAAACCAGAAAACGTGCAGGAAGTCACCAACAT CGTGAGAGGATGCTTTGAAGCTGAACAAGCCAAAGAGCATGGA-AAATGTGAAAGATTTT CCGCTTTGAGTCAATGCTACATTGAAAAGAATTTATGTCAATTCTTCTAAAATATTTTGA AGAAAAGTTATGAATGAAAATTTTCTGAAATTTTGTTGCAAAAATATATAAATTGCCCA ATTAAAAAAAAAAAAAAAAAAAAAAAAAAAA
LJMl 9 (SEQ ID NO: 56)
AGTTTAATTTTCATCATGAAGTTCTTCTACTTGATTTTCTCTGCAATTTTCTTTCTGGCTGA TCCTGCTTTGGTCAAGTGTTCAGAGGATTGTGAGAATATTTTTCATGACAATGCGTACCT CCTTAAATTGGATTGTGAAGCAGGAAGGGTTGATCCTGTTGAATACGACGATATTTCGG ATGAAGAAATATATGAAATAACGGTCGATGTTGGAGTTTCATCTGAGGACCAGGAGAAA GTTGCGAAAATAATAAGGGAGTGCATTGCACAAGTTTCAACGCAAGATTGCACGAAATT TTCAGAAATTTATGATTGTTACATGAAGAAGAAAATCTGTAATTATTATCCTGAAAATAT GTAAAAAAAAATTATTTATTTATATAAAAAAATATAAGGATTAAAATCTCTTATTGATTG TAAAAATGGCCTAATATTGAAGCAAAAATTAAAGCATGAAACAAGACCAAAAAAAAAA AAAAAAAAAAAAAAAAAAA
E L138 (SEQ ID NO: 58)
TCAATCTAACAATGCACCTGCAATTGAATTTGTGCGCTATTCTCCTTTCGGTACTAAATG
GAATTCAGGGCGCTCCCAAAAGTATTAATTCAAAATCCTGCGCAATCTCCTTTCCGGAGA ATGTAACGGCTAAGAAGGAGCCAGTGTACTTGAAACCATCAAATGATGGCTCATTGAGT ACCCCCCTACAGCCAAGTGGGCCATTTGTAAGTCTCAAAATTGGAGAATCTCTTGCAATC TTCTGTCCAGGTGATGGAAAGGACGTAGAGACAATTACGTGCAATACAAATTTCGATTT AGCTTCATATTCGTGCAACAAGAGCACATCAACGGATACCATTGAAACGGAAGAAGTTT GCGGAGGAAGTGGAAAAGTGTACAAAGTTGGTTTTCCGCTGCCCTCTGGGAATTTCCAT , TCAATCTACCAAACGTGTTTTGATAAGAAAAATCTCACACCTCTCTACTCAATTCACATT CTCAATGGTCAAGCTGTTGGATATCACCTTAAGCACACAAGAGGAAGCTTTCGTACCAA TGGTATCTACGGGAAAGTCAACATTGATAAACTCTACAAGACGCAAATTGAGAAATTCA ACAAACTTTTCGGCCCTAAACAAACATTTTTCCGTAGACCCCTCAATTTTCTATCACGTG GACACTTAAGCCCCGAAGTGGACTTTACATTCCGTAGGGAACAACATGCAACGGAAATG TACATTAACACAGCACCACAGTACCAATCAATTAATCAAGGAAATTGGCTACGTGTTGA AAATCACGTGAGGGATCTCGCAAAAGTTCTGCAGAAGGACATAACAGTCGTTACGGGAA TTTTGGGGATACTTCGGTTGAAGAGTAAGAAAATAGAGAAAGAAATCTATTTAGGAGAT GACGTAATTGCCGTACCAGCAATGTTCTGGAAGGCTGTTTTTGACCCTCAAAAACAAGA AGCAATTGTCTTTGTTTCCTCAAATAATCCCCACGTGAAGACCTTTAATCCCAACTGCAA GGATGTATGCGCTCAAGCTGGATTTGGGAATGATAATCTTGAATATTTCTCCAATTATTC TATTGGTCTGACTATTTGTTGCAAACTTGAGGAATTTGTTAAAAGAAATAAAATAATTCT ACCCAAAGAAGTAAATAACAAAAACTACACCAAAAAACTCCTTAAGTTTCCTAAAACAA GAAACAAGGAGGGAGATAAGAAGGTGGTACGTAAGCGCGCCAAAGGAGCATAAATATT AAACGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
LJL15 (SEQ JD NO: 60)
GTTCTACGATAAAATTTTCTTTTCAAACTTTTCTTTTAAAGAAAAATCTTCAAAAAGT^
AAATGAATTTGCACCTTGCGATTATCCTCTTTGTGAGTTACTTCACACTGATCACTGCTAC GGATCTAATTGAAAAGGAACTTTCTGATTGCAAAAAGATCTTCATCTCCAAGGCTGAGC TAACTTGGTTCCAAGCTCTCGATTTCTGTACCGAACAAAACCTAACTTTGCTCTCAATTA AATCCGCCCGGGAAAATGATGAGGTGACTAAAGCAGTTCGAGCTGAGGTTCATCTTCCA GACACAAAGAAGTCTCACATTTGGCTCGGAGGTATTCGTTATGATCAAGACAAGGATTT CCGTTGGATAAGCGATGGAACAACTGTTACGAAGACAGTCTACATCAATTGGTACCAAG GAGAACCAAATGGTGGGAGGTACCAAAAGGAATTTTGTATGGAATTGTACTTTAAAACT CCAGCTGGTCAATGGAATGATGATATTTGTACAGCAAAGCATCATTTTATATGTCAGGA GAAAAAATAAATTGAATTGTTCATGTGTCTTTGGCGGTGCGAAGGTATAATTCAGGTTG ACGACATAAATTGATITITCTI CATTAAGAAAATAAAGGCTTGAATTTATAAAA-AAAA AAAAAAAAAAAAAAAAAA
LJL91 (SEQ ED NO: 62)
GTTCTACGATAA-AATTTTCTTTTCAAACTTTTCTTTTAAAGAAAAΛTCTTCAAAAAGπ AAATGAATTTGCCCCTTGCGATTATCCTCTTTGTGAGTTACTTCACACTGATCACTGCTGC GGATCTAACTGAAAAGGAACTTTCTGATGGCAAAAAGATCTTCATCTCCAAGGCTGAGC TAAGTTGGTTCGATGCTCTCGATGCCTGTACCGAAAAAGACCTAACTTTGCTCACAATTA AATCCGCCCGGGAAAATGAGGAAGTGACTAAAGCAGTTCGAGCTGAGGTTCATCTTCCA GACACAAAGAAGTCTCACATTTGGCTCGGAGGTATTCGTTATGATCAAGACAAGGATTT CCGTTGGATAAGCGATGGAACAACTGTTACGAAGACAGTCTACATCAATTGGTACCAAG GAGAACCAAATGGTGGGAGGTACCAAAAGGAATTTTGTATGGAATTGTACTTTAAAACT CCAGCTGGTCAATGGAATGATGATATTTGTACAGCAAAGCATCATTTTATATGTCAGGA GAAAAAATAAATTGAATTGTTCATGTGTCTTTGGCGGTGCGAAGGTATAATTCAGGTTG ACGACATAAATTGATTTTTCTTTCATTAAGAAAATAAAGGCTTGAATTTAGCAAAAAAA AAAAAAAAAAAAAAAAAAA
LJM11 (SEQ JD NO: 64)
TTGAATTGAAGCAGCAGCAATGAAAGTGTTTTTCTCAATTTTTACGCTCGTCCTCTTCCA AGGGACCCTTGGAGCGGATACTCAAGGATATAAATGGAAGCAATTGCTCTACAATAATG TTACACCAGGATCCTACAATCCGGATAATATGATCAGTACGGCTTTTGCCTACGATGCTG AGGGTGAAAAACTCTTCCTAGCTGTCCCAAGGAAGTTACCCAGAGTTCCGTATACATTG GCGGAAGTGGATACAAAGAATAGTCTTGGTGTTAAGGGAAAACATTCACCGTTACTTAA CAAATTCAGTGGGCACAAAACTGGGAAGGAACTAACATCAATCTATCAGCCAGTTATTG ATGATTGTCGTCGCCTTTGGGTGGTTGATATTGGTTCCGTGGAATATCGCTCAAGAGGTG CCAAAGACTACCCGAGTCATCGTCCTGCAATTGTTGCGTACGACCTAAAGCAACCAAAC TACCCCGAAGTTGTTCGATACTATTTCCCCACAAGATTAGTGGAGAAGCCAACATATTTC GGTGGATTTGCCGTTGATGTTGCAAACCCAAAGGGGGATTGTAGTGAAACTTTTGTCTAC ATTACAAACTTCCTCAGGGGAGCTCTCTTTATATACGATCATAAGAAGCAGGATTCGTGG AATGTAACTCATCCCACCTTCAAAGCAGAACGACCCACTAAATTTGATTACGGCGGAAA GGAATATGAATTCAAAGCCGGAATTTTCGGAATTACTCTCGGAGATCGAGACAGTGAAG GCAATCGTCCAGCTTACTACTTAGCCGGAAGTGCCATCAAAGTCTACAGCGTCAACACG AAAGAACTTAAGCAGAAGGGTGGAAAGCTGAATCCGGAGCTTCTTGGAAACCGCGGGA AGTACAACGATGCCATTGCCCTAGCTTACGATCCCAAAACTAAAGTTATCTTCTTTGCTG AGGCCAACACAAAGCAAGTATCCTGCTGGAACACACAGAAAATGCCACTGAGGATGAA GAATACCGACGTAGTCTACACTAGTTCTCGCTTTGTCTTTGGAACGGACATTTCGGTTGA TAGCAAGGGCGGCCTCTGGTTCATGTCTAACGGCTTTCCGCCTATAAGGAAATCAGAAA AATTCAAATATGACTTCCCACGCTACCGTCTAATGAGGATCATGGACACACAGGAAGCA ATTGCCGGAACTGCTTGCGATATGAATGCATAAAAGTTAATTTTCAACCCAAGAAGAAG ACCTAAAGAGGCTTTTCCAGGCTTTGATGCAGGAGAGGTGGTTATCAACGCAAAATCAG CTATTGTTGTATGAGGAGGAGAAATTATTGATTCTGAATTCTATAAAAAAAATTTAATTT GTGAAATATTTGGCAATAATAAATTAATTGAATTACAAAAAAAAAAAAAAAAAAAAAA AAAAAAA LJS138 (SEQ ID NO:66)
TCTCTTTGGTTAACATTGTGAAGTTATCGGACGTGGCCGGTTTCTATTTCTTTTGCAAAAA
TGCAGTCAAAAATTCTTTCTTTCGTCCTTTTCACCTTATCCTTGGGCTATGTTTTGGGTGA
<
AACATGCTCAAATGCTAAGGTTAAGGGAGCTACCTCTTATTCCACAACGGATGCCACAA TTGTAAGCCAAATTGCCTTTGTGACTGAATTCTCCTTGGAATGCTCAAATCCTGGATCCG AGAAAATCTCCCTATTTGCTGAAGTCGATGGCAAAATTACTCCTGTTGCCATGATCGGGG ATACCACCTACCAGGTGAGCTGGAATGAAGAGGTTAATAAGGCTAGAAGTGGTGACTAC AGTGTGAAGCTGTACGATGAAGAAGGATACGGAGCAGTACGCAAAGCTCAGAGATCAG GTGAAGAGAACAAGGTCAAACCACTAGCAACCGTTGTTGTTCGACATCCAGGAACATAC ACTGGACCATGGTTCAATTCCGAAATCCTCGCAGCTGGTCTCATTGCTGTTGTTGCCTAC TTTGCTTTCTCAACGCGAAGCAAAATTCTTTCCTAAAGAGACGCAGCATGAAATTTCACA AAAAAATAAAAACAAATTCAAGTCATCAACCATGTCTCTTTGGCACTCAGACTGTTTCTG TGAAATACAAACTATTATTTAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
LJL124 (SEQ ID NO: 68)
ATTCCCACAAGAAGCTGCTAAAATGGTGTCAATTCTGTTAATCTCCTTGATTCTTAATTT GTTGGTTTTCTATGCTAAAGCTAGACCACTAGAAGACATCTCGTCAGATCTTTCCCCTGA TTATTACATCACTGAAGGCTATGACGGTGTGAAGGAGAAGAGAGAGATCGAACTTGTAC CTGTGACATTTGGAATATTTAATATACATACAACACCTGCTCCCAGAATTACCTTTGAAT GGTAAAAAATCCAAGAAGAATTTATGATTTTATTCTTCCTTCCATTGGGATGGATTGTAA GTCAGCATAAAACGCCGTTAAAAATGAATTTTTAATAAAAAAAAATTATTCCAAAAAAA AAAAAAAAAAAAAAAAAAAAA
LJL35 (SEQ ED NO: 70) CACTATTCATTGGAAGATTTATTAACTTCAAGATGAAATTATTTTGTTTAATTTTTGTTGT GTTTGTTGCTTTAGAAGTCTGTATAGAGACCGTGAAAGCTATGGAAGCAACGGAGGAGA TATCTGTAAAATTGCAAGATGATGCGAATGAACCTGATGACTCTCTGGATTTAGACGAA GGTCTTCCTGATGCATTCGATGAGGACTATAATAATCAGGCTGAGTACAAGCCGAATCC TAGAGGGGACTACAGAAGACGATAATTAATATAAATTCAGGAAAACACTCTAAAAATTT CCAATTGACTCTACTTTAAACGATTTAATACCTACCTACACTAAATACCATATGCAATAA TTATGTTTTAATTATTTAGTGCAAGATCTACTAGTTTCAGTTCATATTTTGGGACTTTCCC GCCTTTCTCTCGATGGAAAAATGATTTTACGGATTCTTAATTTTCATTGTACAGAGTTAAT AAAACAATTGAAAGCAATTAAAAAAAAAAAΛAAAAAAAAAAAAAAAA
Also included are fragments of the above-described nucleic acid sequences that are at least
33 bases, at least 36 bases, at least 42 bases or at least 48 bases in length, which is sufficient to permit the fragment to selectively hybridize to a polynucleotide that encodes a disclosed Lu. longipalpis under specified conditions. The term "selectively hybridize" refers to hybridization under moderately or highly stringent conditions, which excludes non-related nucleotide sequences. Also disclosed herein are open reading frames (ORFs) encoding a Lu. longipalpis polypeptide. These ORFs are delimited by a start codon and by a stop codon. This also includes the degenerate variants and nucleotide sequences encoding conservative variants and homologs.
Specific, non-limiting examples of open reading frames are as follows: The LJL34 unprocessed protein is encoded by nucleic acids 30-842 of SEQ ID NO: 1 , and the mature protein is encoded by the nucleic acid sequence 87-842 of SEQ ID NO:l.
The LJL18 unprocessed protein is encoded by nucleic acids 56-532 of SEQ ID NO:3, and the mature protein is encoded by the nucleic acid sequence 113-532 of SEQ ID NO:3.
The LJS193 unprocessed protein is encoded by nucleic acids 216-502 of SEQ JD NO:5, and the mature protein is encoded by the nucleic acid sequence 276-502 of SEQ ID NO:5.
The LJS201 unprocessed protein is encoded by nucleic acids 48-353 of SEQ ID NO:7, and the mature protein is encoded by the nucleic acid sequence 117-352 of SEQ ED NO:7.
The LJL1 unprocessed protein is encoded by nucleic acids 26-766 of SEQ TD NO:9, and the mature protein is encoded by the nucleic acid sequence 83-766 of SEQ ID NO:9. The LJL23 unprocessed protein is encoded by nucleic acids 18-992 of SEQ TD NO:ll, and the mature protein is encoded by the nucleic acid sequence 81-992 of SEQ TD NO: 11.
The LJM10 unprocessed protein is encoded by nucleic acids 92-571 of SEQ D NO:13, and the mature protein is encoded by the nucleic acid sequence 149-571 of SEQ TD NO:13.
The LJL143 unprocessed protein is encoded by nucleic acids 46-948 of SEQ JD NO:15, and the mature protein is encoded by the nucleic acid sequence 115-948 of SEQ TD NO: 15.
The LJS142 unprocessed protein is encoded by nucleic acids 25-507 of SEQ ED NO:17, and the mature protein is encoded by the nucleic acid sequence 85-507 of SEQ ED NO: 17.
The LJL17 unprocessed protein is encoded by nucleic acids 28-342 of SEQ ID NO: 19, and the mature protein is encoded by the nucleic acid sequence 88-342 of SEQ TD NO:19. The LJM06 unprocessed protein is encoded by nucleic acids 50-523 of SEQ ED NO:21 , and the mature protein is encoded by the nucleic acid sequence 107-523 of SEQ ID NO:21.
The LJM17 unprocessed protein is encoded by nucleic acids 24-1264 of SEQ ID NO:23, and the mature protein is encoded by the nucleic acid sequence 83-1264 of SEQ ID NO:23.
The LJL04 unprocessed protein is encoded by nucleic acids 30-914 of SEQ ID NO:25, and the mature protein is encoded by the nucleic acid sequence 81-914 of SEQ ID NO:25.
The LJMl 14 unprocessed protein is encoded by nucleic acids 29-475 of SEQ ID NO:27, and the mature protein is encoded by the nucleic acid sequence 101-475 of NO:27.
The LJMl 11 unprocessed protein is encoded by nucleic acids 24-1214 of SEQ ID NO:29, and the mature protein is encoded by the nucleic acid sequence 78-1214 of SEQ ID NO:29. The LJM78mature unprocessed protein is encoded by nucleic acids 42-1091 of SEQ ID
NO:31, and the mature protein is encoded by the nucleic acid sequence 102-11091 of SEQ ID NO:31.
The LJS238 unprocessed protein is encoded by nucleic acids 27-206 of SEQ ID NO:33, and the mature protein is encoded by the nucleic acid sequence 87-206 of SEQ ID NO:33. The LJS169 unprocessed protein is encoded by nucleic acids 11-370 of SEQ ED NO:35, and the mature protein is encoded by the nucleic acid sequence 77-370 of SEQ ED NO:35.
The LJL11 unprocessed protein is encoded by nucleic acids 30-1745 of SEQ TD NO:37, and the mature protein is encoded by the nucleic acid sequence 105-1745 of SEQ ID NO:37. The LJL08 unprocessed protein is encoded by nucleic acids 26-238 of SEQ JD NO:39, and the mature protein is encoded by the nucleic acid sequence 95-238 of SEQ ED NO:39.
The LJS105 unprocessed protein is encoded by nucleic acids 24-275 of SEQ ED NO:41, and the mature protein is encoded by the nucleic acid sequence 81-275 of SEQ ID NO:41.
The LJL09 unprocessed protein is encoded by nucleic acids 74-1954 of SEQ ID NO:43, and the mature protein is encoded by the nucleic acid sequence 128-1954 of SEQ ID NO:43.
The LJL38 unprocessed protein is encoded by nucleic acids 40-165 of SEQ ID NO:45, and the mature protein is encoded by the nucleic acid sequence 100-165 of SEQ TD NO:45.
The LJM04 unprocessed protein is encoded by nucleic acids 40-456 of SEQ ED NO:47, and the mature protein is encoded by the nucleic acid sequence 100-456 of SEQ ID NO:47. The LJM26 unprocessed protein is encoded by nucleic acids 96-1616 of SEQ ED NO:49, and the mature protein is encoded by the nucleic acid sequence 147-1616 of SEQ TD NO:49.
The LJS03 unprocessed protein is encoded by nucleic acids 41-553 of SEQ ID NO:51, and the mature protein is encoded by the nucleic acid sequence 98-553 of SEQ ID NO:51.
The LJS192 unprocessed protein is encoded by nucleic acids 18-344 of SEQ ID NO:53, and the mature protein is encoded by the nucleic acid sequence 87-344 of SEQ ID NO:53.
The LJM19 unprocessed protein is encoded by nucleic acids 16-360 of SEQ ED NO:55, and the mature protein is encoded by the nucleic acid sequence 82-360 of SEQ ID NO:55.
The LJL138 unprocessed protein is encoded by nucleic acids 12-1238 of SEQ ED NO:57 and the mature protein is encoded by the nucleic acid sequence 72-1238 of SEQ ID NO:57. The LJL15 unprocessed protein is encoded by nucleic acids 63-542 of SEQ ID NO:59, and the mature protein is encoded by the nucleic acid sequence 120-542 of SEQ ID NO:59.
The LJL91 unprocessed protein is encoded by nucleic acids 63-542 of SEQ ID NO:61, and the mature protein is encoded by the nucleic acid sequence 120-542 of SEQ ID NO:61.
The LJMl lunprocessed protein is encoded by nucleic acids 20-1216 of SEQ ID NO:63, and the mature protein is encoded by the nucleic acid sequence 74-1216 of SEQ ID NO:63.
The LJS138 unprocessed protein is encoded by nucleic acids 12-1238 of SEQ ED NO:65, and the mature protein is encoded by the nucleic acid sequence 72-138 of SEQ ID NO:65.
The LJL124 unprocessed protein is encoded by nucleic acids 23-241 of SEQ ID NO:67, and the mature protein is encoded by the nucleic acid sequence 83-241 of SEQ ID NO:67. The LJL35 unprocessed protein is encoded by nucleic acids 12-1238 of SEQ ED NO:69, and the mature protein is encoded by the nucleic acid sequence 72-1238 of SEQ ID NO:69.
Another specific non-limiting example of a polynucleotide encoding a Lu. longipalpis polypeptide is a polynucleotide having at least 75%, 85%, 90%, 95%, or 99% homology to one of the sequences set forth above that encodes a polypeptide having an antigenic epitope or function of a Lu. longipalpis polypeptide. Yet another specific non-limiting example of a polynucleotide encoding a Lu. longipalpis polypeptide is a polynucleotide that encodes a polypeptide that is specifically bound by an antibody that specifically binds the Lu. longipalpis polypeptide. The Lu. longipalpis polynucleotides include a recombinant DNA which is incoφorated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (for example, a cDNA) independent of other sequences. The nucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. The term includes single and double forms of either nucleotide. The term includes single and double forms of DNA.
Recombinant vectors are also disclosed herein that include a polynucleotide encoding a polypeptide or a fragment thereof according to the disclosure. Recombinant vectors include plasmids and viral vectors and may be used for in vitro or in vivo expression.
A plasmid may include a DNA transcription unit, for instance a nucleic acid sequence that permit it to replicate in a host cell, such as an origin of replication (prokaryotic or eukaryotic). A plasmid may also include one or more selectable marker genes and other genetic elements known in the art. Circular and linear forms of plasmids are encompassed in the present disclosure.
For in vivo expression, the promoter is generally of viral or cellular origin. In one embodiment, the cytomegalovirus (CMV) early promoter (CMV-IE promoter), including the promoter and enhancer, is of use. The CMV-IE promoter can be of human or murine origin, or of other origin such as rat or guinea pig (see EP 0260148; EP 0323597; WO 89/01036; Pasleau et al, Gene 38:227-232, 1985; Boshart M. et al, Cell 41:521-530, 1985). Functional fragments of the CMV-IE promoter may also be used (WO 98/00166). The SV40 virus early or late promoter and the Rous Sarcoma virus LTR promoter are also of use. Other promoters include but are not limited to, a promoter of a cytoskeleton gene, such as (but not limited to} the desmin promoter (Kwissa M. et al, Vaccine 18(22):2337-2344, 2000), or the actin promoter (Miyazaki J. et al, Gene 79(2):269-277, 1989). When several genes are present in the same plasmid, they may be provided in the same transcription unit or in different units.
The plasmids may also comprise other transcription regulating elements such as, for example, stabilizing sequences of the intron type. In several embodiments the plasmids include the first intron of CMV-IE (Published PCT Application No. WO 89/01036), the intron II of the rabbit β- globin gene (van Ooyen et al, Science 206:337-344, 1979), the signal sequence of the protein encoded by the tissue plasminogen activator (tPA; Montgomery et al, Cell. Mol Biol. 43:285-292, 1997), and/or a polyadenylation signal (polyA), in particular the polyA of the bovine growth hormone (bGH) gene (U.S. Patent No. 5,122,458) or the polyA of the rabbit β-globin gene or of SV40 virus. In a specific, non-limiting example, the pVR1020 plasmid (VICAL Inc.; Luke C. et al, Journal of Infectious Diseases 175:91-97, 1997; Hartikka J. et al, Human Gene Therapy 7:1205- 1217, 1996)) can be utilized as a vector for the insertion of such a polynucleotide sequence, generating recombinant plasmids.
The plasmids are evaluated in dogs in order to determine their efficacy against a Leishmania infection (Vidor E. et al, P3.14, XXIV World Veterinary Congress, Rio de Janeiro, Brazil, 18-23 August 1991).
Various viral vectors are also of use with a polynucleotide encoding a Lu. longipalpis polypeptide. A specific, non-limiting example includes recombinant poxvirus, including avipox viruses, such as the canarypox virus. Another specific, non-limiting example includes recombinant poxvirus, including vaccinia viruses (U.S. Patent No. 4,603,112), such as attenuated vaccinia virus such as NYVAC (see U.S. Patent No. 5,494,807) or Modified Vaccinia virus Ankara (MVA, Stickl H. and Hochstein-Mintzel V., Munch. Med. Wschr. 113:1149-1153, 1971; Sutler G. et al, Proc. Natl. Acad. Sci. USA 89:10847-10851, 1992; Carroll M. W. et al, Vaccine 15(4):387-394, 1997; Stittelaar K. J. et al, J. Virol. 74(9) :4236-4243, 2000; Sutler G. et al, Vaccine 12(11): 1032-1040, 1994). When avipox viruses are used, canarypox viruses (U.S. Patent No. 5,756,103.) and fowlpox viruses (U.S. Patent No. 5,766,599) are of use, such as attenuated viruses. For recombinant canarypox virus vectors, the insertion sites may be in particular in the ORFs C3, C5 or C6. When the expression vector is a poxvirus, the heterologous polynucleotide can be inserted under the control of a poxvirus specific promoter, such as the vaccinia virus 7.5kDa promoter (Cochran et al, J. Virology 54:30-35, 1985), the vaccinia virus I3L promoter (Riviere et al, J. Virology 66:3424-3434, 1992), the vaccinia virus HA promoter (Shida, Virology 150:451-457, 1986), the cowpox virus ATI promoter (Funahashi et al, J. Gen. Virol. 69:35-47, 1988), other vaccinia virus H6 promoter (Taylor et al, Vaccine 6:504-508, 1988; Guo et al, J. Virol. 63:4189-4198, 1989; Perkus et al, J. Virol. 63:3829-3836, 1989).
Other viral vectors of use are herpes virus or adenovirus vectors. Specific, non-limiting examples include a canine herpes virus (CHV) or canine adenovirus (CAV) vector (for example, see U.S. Patent No. 5,529,780; U.S. Patent No. 5,688,920; Published PCT Application No. WO 95/14102). For CHV, the insertion sites may be in particular in the thymidine kinase gene, in the ORF3, or in the UL43 ORF (see U.S. Patent No. 6, 159,477). For CAV, the insertion sites may be in particular in the E3 region or in the region located between the E4 region and the right ITR region (see U.S. Patent No. 6,090,393; U.S. Patent No. 6,156,567). In one embodiment in CHV or CAV vectors the insert is in general under the control of a promoter (as described above for the plasmids), such as CMV-IE promoter.
Multiple insertions can be done in the same vector using different insertion sites or using the same insertion site. When the same insertion site is used, each polynucleotide insert is inserted under the control of different promoters. The insertion can be done tail-to-tail, head-to-head, tail-to-head, or head-to-tail. IRES elements (Internal Ribosome Entry Site, see European Patent EP 0803573) can also be used to separate and to express multiple inserts operably linked to the same promoter. Bacterial vectors can also be used for in vivo expression. Any polynucleotide according to the disclosure can be expressed in vitro by DNA transfer or expression vectors into a suitable host cell. The host cell may be prokaryotic or eukaryotic. The term "host cell" also includes any progeny of the subject host cell. Methods of stable transfer, meaning that the foreign polynucleotide is continuously maintained in the host cell, are known in the art. Host cells can include bacteria (for example, Escherichia coli), yeast, insect cells, and vertebrate cells. Methods of expressing DNA sequences in eukaryotic cells are well known in the art.
As a method for in vitro expression, recombinant Baculovirus vectors (for example, Autographa California Nuclear Polyhedrosis Virus (AcNPV)) can be used with the nucleic acids disclosed herein. For example, polyhedrin promoters can be utilized with insect cells (for example, Spodopterafrugiperda cells, like Sf9 cells available at the ATCC under the Accession number CRL- 1711, or Sf21 cells) (see for example, Smith et al, Mol. Cell Biol. 3:2156-2165, 1983; Pennock e? α/., Mol. Cell Biol. 4: 399-406, 1994; Vialard et al, J. Virol. 64:37-50, 1990; Verne A., Virology 167:56- 71, 1988; O'Reilly et al, "Baculovirus expression vectors, A laboratory manual," New York Oxford, Oxford University Press, 1994; Kidd I. M. & Emery V.C., "The use of baculoviruses as expression vectors," Applied Biochemistry and Biotechnology 42:37-159, 1993; European Patent No. EP 0370573; European Patent No. EP 0265785; U.S. Patent No. 4,745,051). For expression the BaculoGold ™ Starter Package (Cat # 21001K) from Phaπriingen (Becton Dickinson) can be used.
As a method for in vitro expression, recombinant E. coli can be used with a vector. For example, when cloning in bacterial systems, inducible promoters such as arabinose promoter, pL of bacteriophage lambda, plac, ptrp, ptac (ptrp-lac hybrid promoter), and the like may be used.
Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as E. coli, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl2 method using procedures well known in the art. Alternatively, MgCl2 or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell if desired, or by electroporation.
When the host is a eukaryote, such methods of transduction of DNA as calcium phosphate coprecipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be cotransformed with Lu. longipalpis polynucleotide sequences, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector (see above), such as a herpes virus or adenovirus (for example, canine adenovirus 2), to transiently transduce eukaryotic cells and express the protein (see for example, Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982). In addition, a transfection agent can be utilized, such as dioleoyl-phosphatidyl-emanolamine (DOPE).
Isolation and purification of recombinantly expressed polypeptide may be carried out by conventional means including preparative chromatography (for example, size exclusion, ion exchange, affinity), selective precipitation and ultra-filtration. Such a recombinantly expressed polypeptide is part of the present disclosure. The methods for production of such a polypeptide are also encompassed, in particular the use of a recombinant expression vector comprising a polynucleotide according to the disclosure and of a host cell.
Antibodies A Lu. longipalpis polypeptide of the disclosure or a fragment thereof according to the disclosure can be used to produce antibodies. Polyclonal antibodies, antibodies which consist essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibodies are included. Such antibodies are of use as markers for exposure, and as immunodiagnostic tools to follow the development of the immune response to Lu. longipalpis salivary proteins.
The preparation of polyclonal antibodies is well-known to those skilled in the art. See, for example, Green et al, "Production of Polyclonal Antisera," Immunochemical Protocols, pp. 1-5, Manson, ed., Humana Press, 1992; Coligan et al, "Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters," Current Protocols in Immunology, section 2.4.1, 1992. The preparation of monoclonal antibodies likewise is conventional. See, for example,
Kohler & Milstein, Nature 256:495, 1975; Coligan et al, sections 2.5.1-2.6.7; and Harlow et al, Antibodies: A Laboratory Manual, p. 726, Cold Spring Harbor Pub., 1988. Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising an antigen, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B lymphocytes, fusing the B lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures. Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion- exchange chromatography. See, for example, Coligan et al, sections 2.7.1-2.7.12 and sections 2.9.1- 2.9.3; Barnes et al, "Purification of Immunoglobulin G (IgG)," Methods in Molecular Biology, Vol. 10, pp. 79-104, Humana Press, 1992.
Methods of in vitro and in vivo multiplication of monoclonal antibodies are well known to those skilled in the art. Multiplication in vitro may be carried out in suitable culture media such as Dulbecco's Modified Eagle Medium or RPMI 1640 medium, optionally supplemented by a mammalian serum such as fetal calf serum or trace elements and growth-sustaining supplements such as normal mouse peritoneal exudate cells, spleen cells, thymocytes, or bone marrow macrophages. Production in vitro provides relatively pure antibody preparations and allows scale-up to yield large amounts of the desired antibodies. Large-scale hybridoma cultivation can be carried out by homogenous suspension culture in an airlift reactor, in a continuous stirrer reactor, or in immobilized or entrapped cell culture. Multiplication in vivo may be carried out by injecting cell clones into mammals histocompatible with the parent cells, for example, syngeneic mice, to cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane) prior to injection. After one to three weeks, the desired monoclonal antibody is recovered from the body fluid of the animal.
Antibodies can also be derived from subhuman primate antibody. General techniques for raising therapeutically useful antibodies in baboons can be found, for example, in WO 91/11465, 1991, and Losman et α/., 7»t. J. Cancer 46:310, 1990.
Alternatively, an antibody that specifically binds a polypeptide can be derived from a humanized monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementarity deteiniining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then substituting human residues in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by Orlandi et al, Proc. Nat'lAcad. Sci. USA 86:3833, 1989. Techniques for producing humanized monoclonal antibodies are described, for example, by Jones et al, Nature 321:522, 1986; ^ec τaa et al, Nature 332:323, 1988; Verhoeyen et al, Science 239:1534, 1988; Carter et al, Proc. Nat'lAcad. Sci. USA 89:4285, 1992; Sandhu, Crit. Rev. BiotechA2:437, 1992; and Singer et al, J. Immunol. 150:2844, 1993.
Antibodies can be derived from human antibody fragments isolated from a combinatorial immunoglobulin library. See, for example, Barbas et al, Methods: a Companion to Methods in Enzymology, Vol. 2, p. 119, 1991; Winter et al, Ann. Rev. Immunol. 12:433, 1994. Cloning and expression vectors that are useful for producing a human immunoglobulin phage library can be obtained, for example, from STRATAGENE Cloning Systems (La Jolla, CA).
In addition, antibodies can be derived from a human monoclonal antibody. Such antibodies are obtained from transgenic mice that have been "engineered" to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain loci are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody- secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described by Green et al, Nature Genet. 7:13, 1994; Lonberg et al, Nature 368:856, 1994; and Taylor et al, Int. Immunol. 6:579, 1994.
Antibodies include intact molecules as well as fragments thereof, such as Fab, F(ab')2, and Fv which are capable of binding the epitopic deteπriinant. These antibody fragments retain some ability to selectively bind with their antigen or receptor and are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain (L) and a portion of one heavy chain(H); (2) Fab', the fragment of an antibody molecule that can be obtained by treating a whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule;
(3) (Fab')2, the fragment of the antibody that can be obtained by treating a whole antibody with the enzyme pepsin without subsequent reduction; F(ab')2 is a dimer of two Fab' fragments held together by two disulfide bonds;
(4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain (VL) and the variable region of the heavy chain (VH) expressed as two chains; and
(5) Single chain antibody (SCA), defined as a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.
Methods of making these fragments are known in the art. (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988). Antibody fragments can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')2. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly (see U.S. Patent No. 4,036,945 and U.S. Patent No. 4,331,647, and references contained therein^isonhoff et αt., rc/z. Biochem. Biophys. 89:230, 1960; Porter, Biochem. J 73:119, 1959; Edelman et al, Methods in Enzymology, Vol. 1, page 422, Academic Press, 1967; and Coligan et al. at sections 2.8.1-2.8.10 and 2.10.1-2.10.4). Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.
For example, Fv fragments comprise an association of VH and VL chains. This association may be noncovalent (Inbar et al, Proc. Nat'lAcad. Sci. USA 69:2659, 1972). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. See, for example, Sandhu, supra. In one embodiment, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are known in the art (see Whitlow et al, Methods: a Companion to Methods in Enzymology, Vol. 2, page 97, 1991; Bird et al, Science 242:423, 1988; U.S. Patent No. 4,946,778; Pack et al, Bio/Technology 11:1271, 1993; and Sandhu, supra).
Another form of an antibody fragment is a peptide coding for a single complementarity- deterrriining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells (Larrick et al, Methods: a Companion to Methods in Enzymology, Vol. 2, page 106, 1991).
Antibodies can be prepared using an intact polypeptide or fragments containing small peptides of interest as the iπimunizing antigen. The polypeptide or a peptide used to immunize an animal can be derived from substantially purified polypeptide produced in host cells, in vitro translated cDNA, or chemical synthesis, which can be conjugated to a carrier protein, if desired. Such commonly used carriers which are chemically coupled to the peptide include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid. The coupled peptide is then used to immunize an animal (for example, a mouse, a rat, or a rabbit).
Polyclonal or monoclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound. Those of skill in the art will know of various techniques common in the immunology arts for purification and or concentration of polyclonal antibodies, as well as monoclonal antibodies (See for example, Coligan et al, Unit 9, Current Protocols in Immunology, Wiley Interscience, 1991).
It is also possible to use the anti-idiotype technology to produce monoclonal antibodies which mimic an epitope. For example, an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region that is the "image" of the epitope bound by the first mono-clonal antibody. In view of the large number of methods that have been reported for attaching a variety of radiodiagnostic compounds, radiotherapeutic compounds, label (for example, enzymes or fluorescent molecules) drugs, toxins, and other agents to antibodies one skilled in the art will be able to determine a suitable method for attaching a given agent to an antibody or other polypeptide.
In one embodiment, an antibody that binds a Lu. Longipalpis polypeptide can be used to assess whether a subject has been bitten by a sand fly. In one specific, non-limiting example, a sample is obtained from a subject of interest, such as a human or a dog. The sample can be a body fluid (for example, blood, serum, urine, saliva, etc.) or a tissue biopsy. The sample or a fraction thereof is contacted with the antibody, and the ability of the antibody to form an antigen-antibody complex is assessed. One of skill in the art can readily detect the formation of an antigen-antibody complex. For example, ELISA, Western blot, or radio-immune assays can be utilized.
Immunogenic Compositions, Vaccines and Methods of Use
Immunogenic compositions and vaccines are disclosed herein. In one embodiment the immunogenic compositions and vaccines include a polypeptide. In another embodiment, the immunogenic compositions and vaccines include a recombinant vector, such as a viral vector or a plasmid. When administered to a subject such an immunogenic composition or vaccine generates an immune response to the sand fly's salivary protein(s), and surprisingly a reduction of the leishmaniasis symptoms and a decrease of the leishmania parasite load results. Thus, without being bound by theory, a cellular response, such as a Thl response, produced against the salivary protein can indirectly kill a Leishmania parasite. For example, a Thl type response can allow macrophages to take up Leishmania antigens and present them to T cells in a Thl context. The induction the Thl response can produce an anti-Leishmania immune response, or can prime the immune system of the mammalian host for anti-Leishmania immunity in response to a later infection. In one embodiment, the immunogenic composition or the vaccine includes an effective amount of at least one Lu. longipalpis polypeptide disclosed herein. The immunogenic composition and the vaccine can include a pharmaceutically acceptable excipient and/or an adjuvant. In one embodiment, the immunogenic composition or vaccine includes a polypeptide having an amino acid sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ TD NO: 7, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ED NO: 33, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ID NO: 51, SEQ ED NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ED NO: 61, SEQ ED NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67, a polypeptide at least 80%, at least 90%, at least 95%, or at least 99%) homologous to one of these polypeptides, a conservative variant, a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides, or a combination of these polypeptides. In one specific, non-limiting example, the immunogenic composition or vaccine includes a polypeptide having an amino acid sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ED NO: 17, SEQ ED NO: 19, SEQ JD NO: 21, SEQ JD NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ TD NO: 31, SEQ TD NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ TD NO: 49, SEQ ID NO: 51, SEQ TD NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ED NO: 67. In specific, non-limiting examples, the immunogenic composition includes a polypeptide having a sequence set forth as one of SEQ TD NO: 3, SEQ ID NO: 11, SEQ ID NO: 19, SEQ ED NO: 29, SEQ ED NO: 55, or SEQ ID NO: 59.
In one embodiment, the immunogenic composition includes more than one Lu. longipalpis polypeptide, such as two, three, four, five, six, ten or more of the polypeptides disclosed herein. Thus, the immunogenic composition includes at least one polypeptide having an amino acid sequence as set forth as SEQ ID NO: 3, SEQ TD NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ TD NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ED NO: 33, SEQ ID NO: 35, SEQ ED NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ TD NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ED NO: 65, or SEQ ED NO: 67, a polypeptide at least 80%, at least 90%, at least 95%, or at least 99% homologous to one of these polypeptides, a conservative variant, a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides, and optionally another polypeptide having an amino acid sequence as set forth as SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ TD NO: 9, SEQ TD NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ED NO: 17, SEQ ID NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ED NO: 31, SEQ TD NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67, or SEQ ED NO: 69, a polypeptide at least 80%, at least 90%, at least 95%, or at least 99% homologous to one of these polypeptides, a conservative variant of one of these polypeptides, or a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides.
In specific non-limiting examples, the immunogenic composition includes an amino acid having a sequence as set forth as SEQ ID NO: 1, SEQ ID NO: 23, SEQ ID NO: 39, a polypeptide at least 80%, at least 90%, at least 95%, or at least 99% homologous to one of these polypeptides, a conservative variant of one of these polypeptides, or a homolog or an immunogenic fragment comprising at least eight or at least ten consecutive amino acids of one of these polypeptides, or a combination of these polypeptides. Thus, the immunogenic composition can include a polypeptide having a sequence as set forth as SEQ ID NO: 1, SEQ ID NO: 23, or SEQ ID NO: 39. These compositions include, but are not limited to, an immunogenic composition including a polypeptide having a sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 11, SEQ ED NO: 19, SEQ ED NO: 29, SEQ ED NO: 55, or SEQ ID NO: 59, and a polypeptide having a sequence as set forth as SEQ ID NO: 1, SEQ LD NO: 23, or SEQ ID NO: 39.
The immunogenic composition or the vaccine can include a pharmaceutically acceptable excipient and/or an adjuvant.
In another embodiment, the immunogenic composition or the vaccine includes an effective amount of at least one Lu. longipalpis polypeptide in conjunction with one or more P. perniciosus polypeptide(s) and/or one or more P. ariasi polyeptide(s). These polypeptide sequences are disclosed in U.S. Patent Application No. 60/412,327, filed September 19, 2002, U.S. Patent Application No. 60/425,852, filed November 12, 2002, and PCT Application No. PCT/US03/29833, filed September 18, 2003, which are incorporated herein by reference.
In one embodiment, the immunogenic composition or the vaccine comprises an effective amount of a recombinant vector expressing at least one Lu. longipalpis polypeptide disclosed herein and a pharmaceutically acceptable vehicle or excipient. In one specific, non-limiting example the recombinant vector encodes at least one polypeptide having an amino acid sequence as set forth as SEQ JD NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ TD NO: 15, SEQ ED NO: 17, SEQ ED NO: 19, SEQ ID NO: 21, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ED NO: 65, or SEQ ED NO: 67, a conservative variant, a homolog, an immunogemc fragment, or a fusion protein thereof. In specific non-limiting examples the vector encodes a polypeptide having a sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 19, SEQ ID NO: 29, SEQ ID NO: 55, or SEQ TD NO: 59, a polypeptide at least 80%), at least 90%, at least 95%, or at least 99% homologous to one of these polypeptides, a conservative variant, a homolog, an immunogenic fragment, or a fusion protein thereof. In several examples the vector encodes one or more polypeptides having a sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 19, SEQ ED NO: 29, SEQ ED NO: 55, or SEQ ED NO: 59. The vector can also optionally encode a polypeptide having a sequence as set forth as SEQ TD NO: 1, SEQ ED NO: 23, or SEQ ID NO: 39.
The immunogenic composition can include a nucleic acid sequence encoding a P. ariasi polypeptide(s) and/or a P. perniciosus polypeptide(s) (see U.S. Provisional Application No. 60/412,327, which is incorporated by reference herein in its entirety). In one embodiment, the Lu. longipalpis polypeptide(s) having an amino acid sequence as set forth as SEQ ID NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ID NO: 13, SEQ ED NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ED NO: 21, SEQ ED NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ED NO: 31, SEQ ID NO: 33, SEQ ED NO: 35, SEQ ED NO: 41, SEQ ED NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ TD NO: 51, SEQ TD NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ID NO: 61, SEQ ED NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67, a conservative variant, a homolog, an immunogenic fragment, or a fusion protein thereof, are encoded by the same recombinant vector as a P. ariasi polypeρtide(s) and or a P. perniciosus polypeptide(s). In another embodiment, the Lu. longipalpis polypeptide(s), a P. ariasi polypeptide(s) and/or a P. perniciosus polypeptide(s), are encoded by different recombinant vectors.
The Lu. longipalpis polypeptide can be administered by any means known to one of skill in the art (See Banga, A., "Parenteral Controlled Delivery of Therapeutic Peptides and Proteins,"
Therapeutic Peptides and Proteins, Technomic Publishing Co., Inc., Lancaster, PA, 1995) such as by intramuscular (IM), intradermal (ID), subcutaneous (SC), or intravenous injection, but even oral, nasal, or anal administration is contemplated. In one embodiment, administration is by subcutaneous, intradermal, or intramuscular injection using a needleless injector (Biojector™, Bioject, Oregon, USA).
To extend the time during which the peptide or protein is available to stimulate a response, the peptide or protein can be provided as an implant, an oily injection, or as a particulate system. The particulate system can be a microparticle, a microcapsule, a microsphere, a nanocapsule, or similar particle, (see, for example, Banja, supra). A particulate carrier based on a synthetic polymer has been shown to act as an adjuvant to enhance the immune response, in addition to providing a controlled release. Aluminum salts may also be used as adjuvants to produce a humoral immune response. Thus, in one embodiment, a Lu. longipalpis polypeptide is aciministered in a manner to induce a humoral response. In another embodiment, a Lu. longipalpis polypeptide is administered in a manner to direct the immune response to a cellular response (that is, a CTL response), rather than a humoral (antibody) response. A number of means for inducing cellular responses, both in vitro and in vivo, are known. Lipids have been identified as agents capable of assisting in priming CTL in vivo against various antigens. For example, as described in U.S. Patent No. 5,662,907, palmitic acid residues can be attached to the alpha and epsilon amino groups of a lysine residue and then linked (for example, via one or more linking residues, such as glycine, glycine-glycine, serine, serine-serine, or the like) to an immunogenic peptide. The lipidated peptide can then be injected directly in a micellar form, incorporated in a liposome, or emulsified in an adjuvant. As another example, E. coli lipoproteins, such as tripalrnitoyl-S-glycerylcysteinylseryl-serine can be used to prime tumor specific CTL when covalently attached to an appropriate peptide (see, Deres et al, Nature 342:561, 1989). Further, as the induction of neutralizing antibodies can also be primed with the same molecule conjugated to a peptide which displays an appropriate epitope, the two compositions can be combined to elicit both humoral and cell-mediated responses where that is deemed desirable. In yet another embodiment, an MHC class El-restricted T-helper epitope is added to the polypeptide of the disclosure to induce T-helper cells to secrete cytokines in the microenvironment to activate CTL precursor cells. The technique further involves adding short lipid molecules to retain the construct at the site of the injection for several days to localize the antigen at the site of the injection and enhance its proximity to dendritic cells or other "professional" antigen presenting cells over a period of time (see Chesnut et al, "Design and Testing of Peptide-Based Cytotoxic T-Cell- Mediated Immunotherapeutics to Treat Infectious Diseases and Cancer," Powell, et al, (eds.), Vaccine Design, the Subunit and Adjuvant Approach, Plenum Press, New York, 1995).
An immunogemc composition or a vaccine according to the disclosure can be prepared in accordance with standard techniques well known to those skilled in the pharmaceutical or veterinary art. Such compositions can be administered in dosages and by techniques well known to those skilled in the medical or veterinary arts, taking into consideration such factors as the age, sex, weight, species, and condition of the particular subject, and the route of administration. The immunogenic composition or the vaccine can be aάniinistered alone, or in combination with adjuvant(s) and or with other antigen(s). The other antigen(s) can be a Leishmania antigen. In one embodiment, the Leishmania antigen is the A2 antigen, such as the A2 antigen from L. infantum (see Published PCT Patent Application No. WO 95/06729 and in particular the sequence given in SEQ ID NO:2). The other antigen(s) can be present in the composition as a protein, or as an immunological fragment thereof (for example, an epitope), or as an insert in an expression vector (for example, recombinant viral vector, recombinant plasmid, in particular the pVR1012 (Vical Inc.; Hartikka J. et al, Human Gene Therapy 7:1205-1217, 1996)).
Any immunogenic composition, vaccine, or therapeutic composition according to the disclosure can be mixed with an adjuvant. Polypeptide-based compositions:
In several embodiments, the polypeptide-based immunogenic compositions and vaccines according to the disclosure are formulated with (1) vitamin E, saponin (for example, Quil A™, QS21™), aluminum hydroxide, aluminum phosphate, aluminum oxide ("Vaccine Design, The subunit and adjuvant approach," Pharmaceutical Biotechnology, vol. 6, Edited by Micheal F. Powell and Mark J. Newman, 1995, Plenum Press New York), (2) an acrylic acid or methacrylic acid polymer, a polymer of maleic anhydride and of alkenyl derivative, (3) an immunostimulating sequence (ISS), in particular an oligodeoxyribonucleotidic sequence bearing one or more non- methylated CpG groups (Klinman D. M. et al, Proc. Natl. Acad. Sci. USA 93:2879-2883, 1996; Published PCT Application No. WO 98/16247), (4) to formulate the immunogenic or vaccine preparation in the form of an oil-in-water emulsion, in particular the SPT emulsion described on page 147 of "Vaccine Design, The Subunit and Adjuvant Approach" edited by M. Powell and M. Newman, Plenum Press, 1995, and the emulsion MF59 described on page 183 of this same book, (5) cytokines, or (6) combinations or mixtures thereof. The cytokines (5) that can be added to the composition, include, but are not limited to, GM-
CSF (granulocyte-macrophage colony stimulating factor) or cytokines inducing Thl (for example, IL-12). All these cytokines can be added to the composition as a protein or as a vector encoding this cytokine protein. In one embodiment, the cytokines are from canine origin, for example, canine GM- CSF, for which a gene sequence has been deposited at the GenBank database (Accession No. S49738). This sequence can be used to create the vector in a manner similar to what was made in the Published PCT Patent Application No. WO 00/77210.
In one specific, non-limiting example the adjuvant contains two or more of an emulsifier, a micelle-forming agent, and an oil. Suitable emulsifiers, micelle-forming agents, and oils are detailed in U.S. Patent Nos. 5, 585,103; 5,709,860; 5,270,202; and 5,695,770, all of which are incorporated by reference. An emulsifier is any molecule that allows the components of the emulsion to remain as a stable emulsion. Such emulsifiers include polysorbate 80 (Sorbitan-mono-9-octadecenoate-poly(oxy- 1,2-ethanediyl); manufactured by ICI Americas, Wilmington, Del), polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 85, dodecyl-N,N-dimethyl-3-ammonio- 1-propanesulfonate, TEEPOL HB7 ™, and SPAN 80 ™ SPAN 85 ™, ethoxylated fatty alcohols, ethoxylated fatty acids, ethoxylated castor oil (hydrogenated or not). In one embodiment, these emulsifiers are provided in an amount of approximately 0.05 to approximately 0.5%. In another embodiment, these emulsifiers are provided in an amount of approximately 0.2%. A micelle forming agent is an agent which is able to stabilize the emulsion formed with the other components such that a micelle-like structure is formed. Examples of such agents include polymer surfactants described by BASF Wyandotte publications, for example, Schmolka, J. Am. Oil. Chem. Soc. 54:110, 1977, and Hunter et al, J. Immunol. 129:1244, 1981, PLURONIC™ L62LF, L101, L121, and L64, PEG1000, and TETRONIC™ 1501, 150R1, 701, 901, 1301, and 130R1. The chemical structures of such agents are well known in the art. In one embodiment, the agent is chosen to have a hydrophile-lipophile balance (HLB) of between about 0 and about 2, as defined by Hunter and Bennett, J. Immun. 133:3167, 1984. In one embodiment, the agent can be provided in an effective amount, for example between about 0.5 and about 10%. In another embodiment, the agent can be provided in an effective amount, for example between about 1.25 and about 5%. In one embodiment, the oil included in the composition is chosen to promote the retention of the antigen in oil-in-water emulsion, for instance, to provide a vehicle for the desired antigen. In another embodiment, the oil has a melting temperature of less than about 65° C such that emulsion is formed either at room temperature (about 20° C to about 25° C), or once the temperature of the emulsion is brought down to room temperature. The oil-in-water emulsion (4) can be based in particular on light liquid paraffin oil
(European Pharmacopea type); isoprenoid oil such as squalane, squalene, EICOSANE ™ or tetratetracontane; oil resulting from the oligomerization of alkenes, in particular of isobutene or decene; esters of acids or of alcohols containing a linear alkyl group, more particularly plant oils, ethyl oleate, propylene glycol di(caprylate/caprate), glyceryl tri(caprylate/caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, in particular isostearic acid esters. The oil is used in combination with emulsifiers to form the emulsion. In several embodiments, the emulsifiers are nonionic surfactants, in particular esters of sorbitan, mannide (for example, arihydrornannitol oleate), glycerol, polyglycerol, propylene glycol, and oleic, isostearic, ricinoleic, or hydroxystearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in particular the Pluronic® products, especially L121. In one specific, non- limiting example, the oil is provided in an amount between about 1 and about 60%. In another specific, non-limiting example, the oil is provided in an amount between about 5 and about 30%. In one embodiment, the adjuvant is a mixture of emulsifiers, nacelle-forming agent, and oil available under the name Provax® (EDEC Pharmaceuticals, San Diego, CA). The acrylic acid or methacrylic acid polymers (2) can be cross-linked in particular with polyalkenyl ethers of sugars or of polyalcohols. These compounds are known under the term "carbomer" (Pharmeuropa, Vol. 8, No. 2, June 1996). A person skilled in the art may also refer to U.S. Patent No. 2,909,462 (incorporated by reference) describing such acrylic polymers cross-linked with a polyhydroxylated compound containing at least 3 hydroxyl groups. In one embodiment, a polyhydroxylated compound contains not more than 8 hydroxyl groups. In another embodiment, the hydrogen atoms of at least 3 hydroxyls are replaced with unsaturated aliphatic radicals containing at least 2 carbon atoms. In other embodiments, radicals contain from about 2 to about 4 carbon atoms, for example, vinyls, allyls, and other ethylenically unsaturated groups. The unsaturated radicals can themselves contain other substituents, such as methyl. The products sold under the name Carbopol® (Noveon Inc., Ohio, USA) are particularly suitable. They are cross-linked with an allyl sucrose or with allylpentaerythritol Among these, mention may be made of the products Carbopol® 974P, 934P, and 971P. The copolymers of maleic anhydride and of an alkenyl derivative, such as the EMA® products (Monsanto) which are copolymers of maleic anhydride and of ethylene, maybe linear or cross-linked, for example cross-linked with divinyl ether. Reference may be made to J. Fields et al, Nature 186:778-780, 1960 (incorporated by reference). In one embodiment, the acrylic acid or methacrylic acid polymers and the EMA® products are formed from units based on the following formula:
R R,
Figure imgf000057_0001
in which:
Ri and R2, which may be identical or different, represent H or CH3 x = 0 or 1, in one embodiment, x = 1 y = 1 or 2, with x + y = 2.
For the EMA® products, x = 0 and y = 2. For the carbomers, x = y = 1. In one embodiment, the dissolution of these polymers in water leads to an acid solution, which is neutralized to physiological pH, in order to give to the subject the adjuvant solution into which the immunogenic composition or the vaccine itself is incorporated. The carboxyl groups of the polymer are then partly in COO" form.
In one embodiment, a solution of adjuvant, especially of carbomer, is prepared in distilled water. In another embodiment, a solution of adjuvant, especially of carbomer, is prepared in the presence of sodium chloride, the solution obtained being at acidic pH. In another embodiment, this stock solution is diluted by adding it to the desired quantity (for obtaining the desired final concentration), or a substantial part thereof, of water charged with NaCl. In yet another embodiment, stock solution is diluted by adding it to the desired quantity of physiological saline (NaCl 9 g/1) all at once in several portions with concomitant or subsequent neutralization (pH 7.3 to 7.4). In one embodiment, the stock solution is neutralized with NaOH. This solution at physiological pH is used as it is for mixing with the immunogenic composition or with the vaccine, which may be especially stored in freeze-dried, liquid or frozen form.
In one embodiment, the polymer concentration in the final vaccine composition is from about 0.01 to about 1.5% W/V. In another embodiment, the final vaccine composition is from about 0.05 to about 1% W/V. In yet another embodiment, the final vaccine composition is from about 0.1 to about 0.4% W/V. Lipids have been identified as agents capable of stimulating the immune response for various antigens. For example, as described in U.S. Patent No. 5,662,907, palmitic acid residues can be attached to the alpha and epsilon amino groups of a lysine residue and then linked (for example, via one or more linking residues, such as glycine, glycine-glycine, serine, serine-serine, or the like) to an immunogenic peptide. The lipidated peptide can then be injected directly in a micellar form, incorporated in a liposome, or emulsified in an adjuvant. As another example, E. coli lipoproteins, such as tripaln±oyl-S-glyceiylcyste ylseiγl-serine, can be used.
To extend the time during which the peptide or protein is available to stimulate a response, the peptide or protein can be provided as an implant, an oily injection, or as a particulate system. The particulate system can be a microparticle, a microcapsule, a microsphere, a nanocapsule, or similar particle, (see, for example, Banja, supra). A particulate excipient based on a synthetic polymer has been shown to act as an adjuvant to enhance the immune response, in addition to providing a controlled release.
Plasmid-based compositions:
In one embodiment, the plasmid-based compositions is formulated with cationic lipids, in particular with cationic lipids containing a quaternary ammonium salt having the following formula:
CH 3
R., - 0 - CH 2 - CH - CH 2 - N 2 - X
OR 1 CH 3 in which Rl is a saturated or unsaturated linear aliphatic radical from 12 to 18 carbon atoms, R2 is another aliphatic radical comprising from 2 to 3 carbon atoms, and X is an hydroxyl or amine group. In one embodiment, DMRIE (N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(terradecyloxy)-l- propanammonium; Published PCT Application No. WO 96/34109) is the cationic lipid. In another embodiment, the cationic lipid is in association with a neutral lipid, for example DOPE (dioleoyl- phosphatidyl-ethanolamine; Behr J. P., Bioconjugate Chemistry 5:382-389, 1994), in order to form the DMRIE-DOPE. In yet another embodiment, the mixture is made extemporaneously about 10 minutes to about 60 minutes before administration. In another embodiment, the mixture is made extemporaneously about 30 minutes before administration. In one embodiment, the molar ratio DMRIE/DOPE is from about 95/5 to about 5/95. In another embodiment, the molar ratio DMRIE/DOPE is about 1/1. In one embodiment, the weight ratio plasmid/DMRIE or DMRIE- DOPE adjuvant is from about 50/1 to about 1/10. In another embodiment, the weight ratio plasmid/DMRIE or DMRIE-DOPE adjuvant is from about 10/1 to about 1/5. In yet another embodiment, the weight ratio plasmid DMRIE or DMRIE-DOPE adjuvant is from about 1/1 to about 1/2. In one embodiment, a cytokine or non-methylated CpG groups is added to the composition, as described above for polypeptide-based compositions. The addition can be done advantageously by a plasmid encoding the cytokine.
Viral vector-based composition:
The recombinant viral vector-based composition can be supplemented with fMLP (N- formyl-methionyl-leucyl-phenylalanine; U.S. Patent No. 6,017,537) and/or acrylic acid or methacrylic acid polymer adjuvant as described above for polypeptide-based compositions. They can also be formulated with emulsions as described above. In one embodiment, cytokines, non-methylated CpG groups, or emulsions are added to the composition as described above for polypeptide-based compositions. The addition can be done advantageously by a viral vector encoding said cytokine.
The immunogenic compositions and vaccines according to the disclosure are conserved and stored either in formulated form at 5°C, or in lyophihzed form. In one embodiment, the immunogenic compositions and vaccines according to the disclosure are conserved and stored either in formulated form at 5°C, or in lyophihzed form with a stabilizer. Freeze-dryrng can be done according to well-known standard freeze-drying procedures. The pharmaceutically acceptable stabilizers may be SPGA (sucrose phosphate glutamate albumin) (Bovarnik et al, J. Bacteriology 59:509, 1950), carbohydrates (for example, sorbitol, mannitol, lactose, sucrose, glucose, dextran, trehalose), sodium glutamate (Tsvetkov T. et al, Cryobiology 20(3) :318-23, 1983 ; Israeli E. et al, Cryobiology 30(5):519-23, 1993), proteins such as peptone, albumin, or casein, protein containing agents such as skimmed milk (Mills CK et al, Cryobiology 25(2): 148-52, 1988; Wolff E. et al, Cryobiology 27(5):569-75, 1990), and buffers (for example, phosphate buffer, alkaline metal phosphate buffer). An adjuvant may be used to make soluble the freeze-dried preparations.
Methods of Immunization The present disclosure provides methods for inducing an immune response to a Lutzomyia sand fly polypeptide in a subject. The present disclosure provides further methods for inhibiting or preventing leishmaniasis in a subject. These methods include the administration of at least one immunogenic composition or vaccine according to the disclosure.
An immunogenic composition or a vaccine according to the disclosure can be prepared in accordance with standard techniques well known to those skilled in the pharmaceutical or veterinary art. Such compositions can be administered in dosages and by techniques well known to those skilled in the medical or veterinary arts, taking into consideration such factors as the age, sex, weight, species, and condition of the particular subject, and the route of administration.
If more than one aάtainistration is required, they can be adiriinistered concurrently (for example, different compositions given during the same period of time via the same or different routes, or a same composition given in the same period of time via different routes), or sequentially (for example, the same or different compositions given at least two times via the same or different routes). In one embodiment, the delay between two sequential administrations is from about 1 week to about 6 months. In another embodiment, the delay is from about 3 weeks to about 6 weeks. In yet another embodiment, the delay is from about 4 weeks. Following vaccination, annual boost administrations may be done. Advantageously, in a prime-boost vaccination schedule, at least one prime-adininistration can be done with a composition containing a plasmid according to the disclosure, following by at least one booster aclminisrration done with a composition containing a recombinant viral vector according to the disclosure, on the condition that a same Lu. longipalpis salivary polypeptide is present twice, coded by the plasmid and by the viral vector. Alternatively, the booster aάnτinistration can be done with a composition containing a polypeptide according to the disclosure, on the condition that a same Lu. longipalpis salivary polypeptide is present twice, coded by the prime-administration plasmid and in the booster polypeptide-based composition.
In such compositions the antigen(s) may be in admixture with a suitable vehicle or excipient such as sterile water, physiological saline, glucose, or the like. The compositions can contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, adjuvants, gelling, or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. Standard texts, such as Remington's Pharmaceutical Science, 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation. The compositions can also be lyophihzed.
Suitable dosages can also be based upon the examples below. For polypeptide-based compositions, the route of administration can be ED, EM, SC, intravenous, oral, nasal, or anal. This a<-ministration can be made with a syringe and a needle or with a needle-less apparatus like, for example, Biojector™ (Bioject, Oregon, USA). In several embodiments, polypeptide dosages can be from about 1 to 250 μg/ml, from about 15 to about 150 μg/dose, or from about 20 to about 100 μg/dose. In another embodiment, using a needle-less apparatus the volume of a dose can be between about 0.1 ml and about 0.5 ml. In yet another embodiment, using a needle-less apparatus the volume of a dose can be about 0.25 ml. Administration with multiple points of injection is preferred. In one embodiment, for conventional injection with a syringe and a needle, the volumes are from about 0.1 to about 2 ml. In another embodiment, for conventional injection with a syringe and a needle, the volumes are from about 0.5 to about 1 ml.
For plasmid-based compositions, the route of administration can be ID, IM, SC, intravenous, oral, nasal, or anal. This administration can be made with a syringe and a needle or with a needle-less apparatus like, for example, Biojector™. The dosage is from about 50 μg to about 500 μg per plasmid. When DMRIE-DOPE is added, about 100 μg per plasmid is preferred. In one embodiment, when canine GM-CSF or other cytokine is used, the plasmid encoding this protein is present at a dosage from about 200 μg to about 500 μg. In another embodiment, the plasmid encoding this protein is present at a dosage of about 200 μg. In one embodiment, using a needle-less apparatus, the volume of a dose can be between about 0.1 ml and about 0.5 ml. In another embodiment, the volume of a dose can be about 0.25 ml. In yet another embodiment, aά^ninistration is performed using multiple points of injection. In one embodiment, for conventional injection with a syringe and a needle, the volumes are from about 0.1 to about 2 ml. In another embodiment, the volumes are from about 0.5 to about 1 ml. The dosage are the same than mentioned above. For recombinant viral vector-based compositions, the route of administration can be ID, EM,
SC, intravenous, oral, nasal, or anal. This aclministration can be made with a syringe and a needle or with a needle-less apparatus like, for example, Biojector™. The dosage is from about 103 pfu to about 109 pfu per recombinant poxvirus vector. In one embodiment, when the vector is a canarypox virus, the dosage is from about 105 pfu to about 109 pfu. In another embodiment, the dosage is from about 106 pfu to about 10s pfii. In one embodiment, the volume of needle-less apparatus doses could be between about 0.1 ml and about 0.5 ml. In another embodiment, the volume of needle-less apparatus dose is 0.25 ml. In yet another embodiment, administration is performed using multiple points of injection. In one embodiment, for conventional injection with a syringe and a needle, the volumes are from about 0.1 to about 2 ml. In another embodiment, the volumes are from about 0.5 to about 1 ml. The dosages are the same as mentioned above. In one embodiment, when a syringe with a needle is used, the injection is IM.
Advantageously for the prime boost adrnirήstration regimen, the prime-administration is made with a plasmid-based composition and the boost administration is made with a recombinant viral vector-based composition. In one embodiment, the boost administration is made with a canarypox vector. Both priming and boosting administrations include vectors encoding at least one identical Lu. longipalpis salivary antigens, and optionally Leishmania A2 antigens. The dosage of plasmids and recombinant viral vectors are the same as above. Optionally, the boost admimstration can be done with a polypeptide-based composition. In this case, the dosage of polypeptide is from about 1 to about 250 μg/ml, from about 15 to about 150 μg/dose, or from about 20 to about 100 μg/dose.
Immunization by nucleic acid constructs is well known in the art and taught, for example, in U.S. Patent No. 5,643,578 (which describes methods of immunizing vertebrates by introducing DNA encoding a desired antigen to elicit a cell-mediated or a humoral response) and U.S. Patent No. 5,593,972 and U.S. Patent No. 5,817,637 (which describe operably linking a nucleic acid sequence encoding an antigen to regulatory sequences enabling expression). U.S. Patent No. 5,880,103 describes several methods of delivery of nucleic acids encoding immunogenic peptides or other antigens to an organism. The methods include liposomal delivery of the nucleic acids (or of the synthetic peptides themselves), and immune-stimulating constructs, or ISCOMS ™, negatively charged cage-like structures of 30-40 nm in size formed spontaneously on mixing cholesterol and Quil A™ (saponin). Protective immunity has been generated in a variety of experimental models of infection, including toxoplasmosis and Epstein-Barr virus-induced tumors, using ISCOMS ™ as the delivery vehicle for antigens (Mowat and Donachie, Immunol Today 12:383, 1991). Doses of antigen as low as 1 μg encapsulated in ISCOMS ™ have been found to produce class I mediated CTL responses (Takahashi et al, Nature 344:873, 1990). In another approach to using nucleic acids for irrimunization, a Lu. longipalpis polypeptide, or an immunogenic fragment thereof, can also be expressed by attenuated viral hosts or vectors or bacterial vectors. Recombinant vaccinia virus, adeno-associated virus (AAV), herpes virus, retrovirus, or other viral vectors can be used to express the peptide or protein, thereby eliciting a CTL response. For example, vaccinia vectors and methods useful in immunization protocols are described in U.S. Patent No. 4,722,848. BCG (Bacillus Calmette Guerin) provides another vector for expression of the peptides (see Stover, Nature 351:456-460, 1991).
In one embodiment, a nucleic acid encoding a Lu. longipalpis polypeptide, or an immunogenic fragment thereof, is introduced directly into cells. For example, the nucleic acid may be loaded onto gold microspheres by standard methods and introduced into the skin by a device such as Bio-Rad's Helios™ Gene Gun. A needless injector can also be utilized, such as a Bioinjector2000™. The nucleic acids can be "naked," consisting of plasmids under control of a strong promoter. Typically, the DNA is injected into muscle, although it can also be injected directly into other sites. Exemplary dosages for injection are around 0.5 μg/kg to about 50 mg/kg, and typically are about 0.005 mg/kg to about 5 mg/kg (see, for example, U.S. Patent No. 5,589,466). In one embodiment, a prime-boost strategy for immunization is utilized. Thus, in one embodiment, a nucleic acid encoding a Lu. longipalpis polypeptide is administered to the subject, followed by immunization with an attenuated or inactivated form of Leishmania.
The immunogenic compositions and the vaccines disclosed herein can be administered for preventative and therapeutic treatments. In therapeutic applications, compositions are administered to a subject suffering from a disease, such as Leishmaniasis, in a therapeutically effective amount, which is an amount sufficient to cure or at least partially arrest the disease or a sign or symptom of the disease. Amounts effective for this use will depend upon the severity of the disease and the general state of the subject's health. An effective amount of the compound is that which provides either subjective relief of a symptom(s) or an objectively identifiable improvement as noted by the clinician or other qualified observer.
Single or multiple administrations of the compositions are administered depending on the dosage and frequency as required and tolerated by the subject. In one embodiment, the dosage is adniinistered once as a bolus, but in another embodiment can be applied periodically until a therapeutic result is achieved. Generally, the dose is sufficient to treat or ameliorate symptoms or signs of disease without producing unacceptable toxicity to the subject.
As noted above, the dosage of the composition varies depending on the weight, age, sex, and method of administration. The dosage can also be adjusted by the individual physician as called for based on the particular circumstances. The compositions can be administered conventionally as vaccines containing the active composition as a predetermined quantity of active material calculated to produce the desired therapeutic or immunologic effect in association with the required pharmaceutically acceptable carrier or diluent (for instance, carrier or vehicle). For example, about 50 μg of a DNA construct vaccine of the present disclosure can be injected intradermally three times at two week intervals to produce the desired therapeutic or immunologic effect. In another embodiment, a about 1 mg/Kg dosage of a protein vaccine of the present disclosure can be injected intradermally three times at two week intervals to produce the desired therapeutic or immunologic effect. A vaccine is provided herein that includes a Lu. longipalpis polypeptide or polynucleotide.
Administration of the vaccine to a subject, such as a human or veterinary subject, results in resistance to infection with Leishamania. In one embodiment, the subject is a human subject. In another embodiment, the subject is a canine subject, such as a dog.
Methods and Kits for the Diagnosis of Leishmania Infection
It is disclosed herein that individuals who experience an anti-Leishmania DTH response conversion also have an increase in antibodies against Lu. Longipalpis polypeptide salivary proteins. Thus, the presence or absence of antibodies to Lu. Longipalpis polypeptide salivary proteins can be used to ascertain if a subject has a Leishmania infection. A method is disclosed herein for diagnosing infection with Leishmana by detecting the presence of antibodies that specifically bind one or more polypeptides having an amino acid sequence as set forth as SEQ ID NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ TD NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ TD NO: 29, SEQ LD NO: 31, SEQ JD NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ED
NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ED NO: 63, SEQ ED NO: 65, or SEQ ID NO: 67, or a polypeptide at least 80%, at least 90%, at least 95%, or at least 99% homologous to one of these polypeptides, a conservative variant, a homolog or an immunogenic fragment of one of these polypeptides. The method can utilize a single Lu. Longipalpis polypeptide or a combination of these polypeptides. In certain examples, the method of diagnosis detects antibodies that specifically bind at least 3, 6, or 10 of these polypeptides, or immunogenic fragments thereof.
In one embodiment, one or more Lu. Longipalpis polypeptide can be bound to a solid substrate. For example, the Lu. Longipalpis polypeptide having an amino acid sequence as set forth as SEQ TD NO: 3, SEQ ED NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ID NO: 21, SEQ TD NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ED NO: 33, SEQ ID NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67 can be bound to the substrate. One of more of these polypeptides can be bound to the substrate, for example at least 3, 6, or 10 of these polypeptides, or an immunogenic fragment thereof. In one example, one or more polypeptides having a sequence set forth as one of SEQ ID NO: 3, SEQ ID NO: 11, SEQ D NO: 19, SEQ ID NO: 29, SEQ ED NO: 55, or SEQ ID NO: 59 can be bound to the substrate. In another example, one or more Lu. Longipalpis a polypeptides having a sequence set forth as one of SEQ ID NO: 1, SEQ ID NO: 23, or SEQ ID NO: 39 can be bound to the substrate. In one specific, non- limiting example, at least six Lu. Longipalpis polypeptides are bound to a solid substrate, wherein each of the polypeptides comprises an amino acid sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 19, SEQ D NO: 29, SEQ ID NO: 55, or SEQ ED NO: 59, or an immunogenic fragment thereof. In another specific, non-limiting example, at least three Lu. Longipalpis polypeptides are bound to a solid substrate, wherein each of the polypeptides comprises an amino acid sequence as set forth as SEQ ED NO: 1, SEQ ID NO: 23, or SEQ ED NO: 39, or an immunogenic fragment thereof.
In one embodiment, two or more (for example at least 3, 6, or 10) Lu. Longipalpis polypeptides (or immunogenic fragments thereof) are applied to a solid substrate, for example as a series of "dots," such as in a "dot blot" assay. In another embodiment, two or more Lu. Longipalpis polypeptides are applied to a substrate such as in a linear array. In a further embodiment, Lu. Longipalpis polypeptides are applied to a membrane in a two-dimensional array. In this manner, the presence of antibodies to more than one Lu. Longipalpis polypeptide is assessed. ΕaάxLu. Longipalpis polypeptide can be applied directly to the surface of a membrane in a single location or in a combination of locations.
The solid substrate can be a polystyrene bead, a membrane, a chip or a plate. A plastic or glass substrate can be utilized. In other embodiments, a membrane is utilized that is composed of porous materials such as nylon, nitrocellulose, cellulose acetate, glass fibers, and other porous polymers. The surface of a solid support may be activated by chemical processes that cause covalent linkage of polypeptide to the support. However, any other suitable method may be used for immobilizing a polypeptide to a solid support including, without limitation, ionic interactions, hydrpphobic interactions, covalent interactions and the like. Once the polypeptide is applied to the substrate, the substrate can be contacted with a substance, such as protem-containing solution, which non-specifically saturates the binding sites thereon. Specific, non-limiting examples of a protein- containing solution include a solution made from powdered milk or serum albumin, such as bovine serum albumin.
A specimen (for example, sera, blood, plasma, urine, semen, saliva, sputum, lacrimal fluid, lymph fluid) is then added to the substrate, and the combined specimen and substrate are incubated for a sufficient time to allow specific binding. Specific binding of antibodies to the Lu. Longipalpis polypeptides disclosed herein, are then detected using any means known to one of skill in the art. In one embodiment, a labeled secondary antibody is used to detect the antibodies that specifically bind the Lu. Longipalpis polypeptides. The label can be a radiolabel (for example, I25I), an enzymatic label (for example, alkaline phosphatase or horseradish peroxidase), or a fluorescent label (for example, fluoroscein isothiocyanate). Detection systems for these labels are known to one of skill in the art. Binding of the specimen, or a component of the specimen, to the Lu. Longipalpis polypeptide, as indicated by the presence of the marker, indicates infection with Leishmania.
In another embodiment, the specimen is adsorbed onto a solid substrate containing binding sites for polypeptides, such as antibody molecules. In one embodiment, the solid substrate is a polystyrene bead, a chip, a membrane or a plate. The substrate is thereafter contacted with a substance, such as a protein-containing solution that non-specifically saturates the binding sites thereon. The substrate is then washed with a buffer. A solution of one or more Lu. Longipalpis polypeptides is then added to the bound specimens. In one embodiment, the Lu. Longipalpis polypeptide is directly labeled. The labeling of the Lu. Longipalpis polypeptide can be brought about by use of any marker, such as by incorporation of a radioactive isotope or group, or by coupling this component to an enzyme, a dyestuff, for example a chromophoric moiety or a fluorescent group. The enzymes of use are those which can be colorimetrically, spectrophotometrically, or fluorimetrically determined. Non-limiting examples of enzymes for use in the present invention include enzymes from the group of oxidoreductases, such as catalase, peroxidase, glucose oxidase, beta-glucuronidase, beta-D-glucosidase, beta-D-galactosidase, urease and galactose oxidase. After the labeled Lu.
Longipalpis polypeptide is incubated with the solid substrate, any unbound labeled Lu. Longipalpis polypeptide is removed by washing. Bound labeled Lu. Longipalpis polypeptide is then detected by an appropriate assay. Binding of the labeled Lu. Longipalpis polypeptide to the specimen, or to a component of the specimen, is indicative of infection with Leishmania. In general, the incubation steps utilized in carrying out the procedures can be performed in a known manner, such as by incubating at temperatures between about 4° C and about 25° C, for about 30 minutes to about 48 hours. Washings can be included with an aqueous solution such as a buffer, wherein the buffer is from about pH 6 to about pH 8, such as by using an isotonic saline solution of a pH of about 7. Competitive binding assays are also of use in detecting infection with Leishmania. One of skill in the art, given the Lu. Longipalpis polypeptides disclosed herein, will readily be able to design additional assays, such as competitive binding assays, of use in detecting Leishmania infection.
In another embodiment, the Lu. Longipalpis polypeptides disclosed herein can be included in a diagnostic test kit. For example, a diagnostic test kit for detecting a Leishmania infection includes a solid substrate having applied thereon one or more Lu. Longipalpis polypeptide disclosed herein. In other embodiments, the kit includes written instructions and/or a container including a specified amount of labeled antibodies to immunoglobulins, such as IgG or IgM, or labeled secondary antibodies that bind antibodies from a species of interest. For example labeled antibodies can be provided that specifically detect dog or human immunoglobulins. The labeled antibodies can be fiuorescently labeled, enzymatically labeled, or radiolabeled. Labeled antibodies used in the above- described test kits can be packaged in either solution form, or in lyophilized forms suitable for reconstitution.
In another embodiment the test kit includes a specified amount of one or more Lu. Longipalpis polypeptide described herein in a container, and written instructions. In one example, the Lu. Longipalpis polypeptide is directly labeled. In another example, the one or more Lu.
Longipalpis polypeptide is unlabeled. If the Lu. Longipalpis polypeptide is unlabeled, a container can also be included with a detection reagent that specifically binds the Lu. Longipalpis polypeptide, such as a labeled monoclonal antibody. The kit can also optionally include a solid substrate for binding the specimen. The above described process and test kit for detection of antibodies to the Lu. Longipalpis polypeptides disclosed herein can be utilized in many applications, including, but not limited to detecting Leishmania infection in a subject using the methods disclosed herein. The tests and kits disclosed herein can be used to detect the efficacy of a therapeutic treatment in a subject. In yet another embodiment, the tests and kits disclosed herein can also be used to assess a primary infection with Leishmania or to predict recovery from Leishmania infection by taking a body fluid from an infected subject, for example at various times following infection, and applying the above described detection procedures.
The disclosure is illustrated by the following non-limiting Examples.
EXAMPLES
Example 1
Library Construction
Sand Flies and Preparation of salivary gland homogenate (SGH). Sand fly Lutzomyia longipalpis salivary glands were obtained from colonized sand flies at Walter Reed Army Institute and at the National Institutes of Health.
Salivary glands dissected under a dissection microscope and collected in microfuge tubes in sterile phosphate buffered saline (PBS), pH 7.0 are stored in dry ice and transferred to -70° C until use.
The salivary gland of Lu. longipalpis is a sac-like structure consisting of a unicellular epithelium layer surrounding a large lumen (Adler and Theodor, Ann. Trop. Med. Parasitol 20: 109, 1926). After a blood meal, the gland total protein content decreases to half or less from its ~lμg value (Ribeiro et al, Insect Biochem. 19:409-412, 1989). Accordingly, most of the protein from the fly SGH must be destined for secretion. Indeed, SDS-PAGE of SGH reveals a low complexity composition consisting of ~12 major bands varying from 10-100 kD (Valenzuela et al, J. Exp. Med. 194:331-42, 2001). For SDS-PAGE, Tris-glycine gels (16%), 1 mm thick, and NUPAGE 12% BIS- tris gels were used (Invitrogen, Carlsbad, CA). Gels were run with either Tris-glycine or MOPS Nupage running buffer according to the manufacturer's instructions. To estimate the molecular weight of the samples, See BlueJ markers from Invitrogen (myosin, BSA, glutamic dehydrogenase, alcohol dehydrogenase, carbonic anhydrase, myoglobin, lysozyme, aprotinin, and insulin, chain B) were used.
SGH were treated with equal parts of 2X SDS sample buffer (8% SDS in Tris-HCl buffer, 0.5M, pH 6.8, 10% glycerol and 1% bromophenol blue dye). Thirty pairs of homogenized salivary glands per lane (approximately 30μg protein) were applied when visualization of the protein bands stained with Coomassie blue was desired. For arnino terminal sequencing of the salivary proteins, 40 homogenized pairs of glands were electrophoresed and transferred to polyvinylidene difluoride (PVDF) membrane using 10 mM CAPS, pH 11, 10% methanol as the transfer buffer on a Blot- Module for the XCell II Mini-Cell (Invitrogen, Carlsbad, CA). The membrane was stained with Coomassie blue in the absence of acetic acid. Stained bands were cut from the PVDF membrane and subjected to Edman degradation using a Procise sequencer (Perkin-Elmer Corp, Foster City, CA). Salivary Gland cDNA Library Construction. Lu. longipalpis salivary gland mRNA was isolated from 80 salivary gland pairs from adult females. The Micro-FastTrack mRNA isolation kit (Invitrogen, Carlsbad, CA) was used, yielding approximately 100 ng poly (A)+ mRNA. The PCR- based cDNA library was made following the instructions for the SMART cDNA library construction kit (Clontech, Palo Alto, CA). One hundred nanograms of Lu. longipalpis salivary gland mRNA was reverse transcribed to cDNA using Superscript II RNase H- reverse transcriptase (Gibco-BRL, Gaithersburg, MD) and the CDS/3 ' primer (Clontech, Palo Alto, CA) for 1 hour at 42° C. Second strand synthesis was performed using a PCR-based protocol by using the SMART III primer (Clontech, Palo Alto, CA) as the sense primer and the CDS/3' primer as anti-sense primer, these two primers additionally, create at the ends of the nascent cDNA Sfil A and B sites respectively. Double strand cDNA synthesis was done on a Perkin Elmer 9700 Thermal cycler (Perkin Elmer Corp., Foster City, CA) and using the Advantage Klen-Taq DNA polymerase (Clontech, Palo Alto, CA). PCR conditions were the following: 94° C for 2 minutes; 19 cycles of 94°C for 10 seconds and 68° C for 6 minutes. Double-stranded cDNA was immediately treated with proteinase K (0.8 μg/μl) for 20 minutes at 45° C and washed three times with water using Amicon filters with a 100 kDa cut off (Millipore Corp., Bedford MA). The double-stranded cDNA was then digested with Sfi I for 2 hours at 50° C (The Sfi I sites were inserted to the cDNA during the second strand synthesis using the
SMART III and the CDS/3' primer). The cDNA was then fractionated using columns provided by the manufacturer (Clontech, Palo Alto, CA). Fractions containing cDNA of more than 400 base pairs (bp) were pooled, concentrated, and washed three times with water using an Amicon filter with a 100 kDa cut-off. The cDNA was concentrated to a volume of 7 μl The concentrated cDNA was then ligated into a lambda triplex2 vector (Clontech, Palo Alto, CA), and the resulting ligation reaction was packed using the Gigapack gold III from Stratagene/Biocrest (Cedar Creek, TE) following manufacturer's specifications. The obtained library was plated by infecting log phase XLl-blue cells (Clontech, Palo Alto, CA) and the amount of recombinants was determined by PCR using vector primers flaiiking the inserted cDNA and visualized on a 1.1 % agarose gel with ethidium bromide (1.5 μg/ml)
Massive Sequencing ofLu. longipalpis Salivary Gland cDNA Library. Lu. longipalpis salivary gland cDNA library was plated to approximately 200 plaques per plate (150 mm Petri dish). The plaques were randomly picked and transferred to a 96 well polypropylene plate containing 100 μl of water per well The plate was covered and placed on a gyrator shaker for 1 hour at room temperature. Four microliters of a phage sample was used as a template for a PCR reaction to amplify random cDNAs. The primers used for this reaction were sequences from the triplex2 vector, the primers were named PT2F1 (5'- AAGTACTCT AGCAAT TGTGAGC- 3') (SEQ ID NO:71) which is positioned upstream of the cDNA of interest (5' end), and PT2R1 (5'- CTCTTCGCTATTACGCCAGCT G- 3') (SEQ ID NO:72) which is positioned downstream of the cDNA of interest (3' end). Platinum Taq polymerase (Gibco-BRL, Gaithersburg, MD) was used for these reactions. Amplification conditions were the following: 1 hold of 75° C for 3 minutes, 1 hold of 94° C for 3 minutes and 34 cycles of 94° C for 30 seconds, 49° C for 30 seconds and 72° C for 1 minute and 20 seconds. Amplified products were visualized on a 1.1% agarose gel with ethidium bromide. Clean PCR was used as a template for a cycle sequencing reaction using the DTCS labeling kit fromBeckman Coulter Inc. (Fullerton, CA). The primer used for sequencing (PT2F3) (5'- TCTCGGGAAGCGCGCCATTGTGTT - 3') (SEQ ED NO:73) is upstream of the inserted cDNA and downstream of the primer PT2F1. Sequencing reaction was performed on a Perkin Elmer 9700 thermacycler. Conditions were 75° C for 2 minutes, 94° C for 4 minutes, and 30 cycles of 96° C for 20 seconds, 50° C for 20 seconds and 60° C for 4 minutes.
After cycle sequencing the samples, a cleaning step was done using the multi-screen 96 well plate cleaning system from Millipore (Bedford, MA). The 96 well multi-screening plate was prepared by adding a fixed amount (according to the manufacturer's specifications) of Sephadex-50 (Amersham Pharmacia Biotech, Piscataway, NJ) and 300 μl of deionized water. After 1 hour of incubation at room temperature, the water was removed from the multi screen plate by centrifugation at 750 g for 5 minutes. After the Sephadex in the multi-screen plate was partially dried, the whole cycle sequencing reaction was added to the center of each well, cenrrifuged at 750 g for 5 minutes and the clean sample was collected on a sequencing microtiter plate (Beckman Coulter, Fullerton, CA). The plate was then dried on Speed- Vac SC 110 model with a microtiter plate holder (Savant Instruments Inc, Holbrook, NY). The dried samples were immediately resuspended with 25 μl of deionized ultrapure formamide (J.T. Baker, Phillipsburg, NJ), and one drop of mineral oil was added to the top of each sample. Samples were sequenced immediately on a CEQ 2000 DNA sequencing instrument (Beckman Coulter Inc., Fullerton, CA) or stored at -30° C. The entire cDNA of selected genes was fully sequenced using custom primers using a CEQ 2000 DNA sequencing instrument (Beckman Coulter Inc., Fullerton, CA) as described above.
DNA Vaccine Construction and Description of the VRl 020 Vector. The genes coding for the predicted secreted proteins were amplified froml-. longipalpis specific cDNA by PCR using Platinum Taq polymerase (GIBCO BRL, Gaithersburg, MD) and specific primers carrying the Predicted N-terminus (Forward primer); and the stop codon (Reverse primer) of the selected cDNA. The PCR product was immediately cloned into the custom made VR-2001 -TOPO (derived fromVR1020 vector) cloning vector following manufacturers specifications (Invitrogen, Carlsbad, CA). The ligation mixture was used to transform TOP 10 cells (Invitrogen, Carlsbad, CA) and the cells were incubated overnight at 37° C. Eight colonies were picked and mixed with 10 μl of sterile water. Five microliters of each sample were transferred to Luria broth (LB) with ampicillin (100 μg/ml) and grown at 37° C. The other 5 μl were used as a template for a PCR reaction using two vector-specific primers from the PCRII vector to coiifirm the presence of the insert and for sequencing analysis. After visualization of the PCR product on a 1.1 % agarose gel, the eight PCR products were completely sequenced as described above using a CEQ2000 DNA sequencing rnstrument (Beckman Coulter). Cells containing the plasmid carrying the selected Lu. longipalpis gene were grown overnight at 37° C on Luria broth with ampicillin (100 μg/ml), and plasmid isolation was performed using the Wizard Miniprep kit (Promega, Madison, Wl). The VR-2001-TOPO (a variant of the VRl 020 plasmid from Vical) plasmid contains a kanamycin resistance gene, the human cytomegalovirus promoter, and the tissue plasminogen activator signal peptide upstream of the TOPO TA cloning site. The sample that contained the sequence from the start codon to the stop codon in the right orientation and in the correct open-reading-frame following the nucleotide sequence encoding the tissue plasminogen activator signal peptide was chosen.
Plasmids were transformed into the TOP-10 strain of is. coli (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The transformed bacteria were grown in LB medium and the plasmid was subsequently purified using the commercial plasmid purification kit Megaprep (Qiagen, Valencia, CA). Each plasmid was named according to the name of the polypeptide. Thus pLJL34 is a plasmid encoding LJL34, and pLJMl 1 is a plasmid encoding LJMl 1 polypeptide, etc. Study population. Sera used in the study using human subjects were obtained from an epidemiologic survey of visceral leishmaniasis (VL) in children less than 7 years of age in an endemic region of Sao Luiz, Maranhao State, in northeastern Brazil. During this prospective study, anti-Leishmania DTH and serology were performed twice a year during 1997 and 1998. Only children who had neither VL, a positive serology, nor DTH on the first survey were included in the study. None of the individuals in the data set had the disease, and all had negative responses to leishmanial antigen during the preceding 6-month period. Positivity in the anti-leishmanial tests reported here indicates a recent conversion determined by a sensitive and specific ELISA (Barral et al, Am J Trop MedHyg 62:740-5, 200) and/or DTH test (Barral et al, ibid). To determine the cutoff value for IgG anti-iw. longipalpis in ELISA assays, sera were obtained from children in the same age range from a nonendemic area. Assuming that recent seroconversion represents infection and that a positive DTH response is a marker of protection against leishmaniasis in subclinical cases, we classified children in two groups according to their anti-Leishmania responses: Group I, positive serology (S~ → S"*") (n =15) and Group II, positive DTH (DTET → DTH+) (n = 15).
Anti-sand fly saliva serology. Anti-sand fly saliva serology ELISA was performed as previously described (Barral et al, ibid). Sera IgG subclasses were determined using anti-human IgGl, IgG3, or IgG4 alkaline-phosphatase conjugates (Sigma-Aldrich, St. Louis, MO). To determine IgE levels, sera were previously absorbed using Rheumatoid Factor. Anti-human IgE (Sigma-Aldrich, St. Louis, MO) was used in the ELISA.
Western blots. Western blots of salivary gland antigens were performed as previously described (Barral et al, ibid). Statistical analysis Qiuman studies). The non-parametric paired Wilcoxon test was used to compare levels of anti-Zκ. longipalpis saliva antibodies in the same children at time 0 (beginning of survey) and after 6 months. P value < 0.05 was established as the significance level. Graph Pad Prism software (San Diego, CA) was used to perform the statistical tests. Example 2 DNA and Predicted Protein Sequence Analysis.
DNA data derived from the mass sequencing project were analyzed by an in-house program written in VisualBASIC (Microsoft). This program removed vector and primer sequences from the raw sequence. Stripped sequences were compared to the NCBI non-redundant protein database using the program BlastX using the BLOSUM-62 matrix (Altschul et al, Nucleic Acids Research 25:3389, 1997). DNA sequences were clustered by blasting the database against itself with a preselected threshold cutoff, usually le"10 (BlasfN program) (Altschul et al, Nucleic Acids Research 25:3389, 1997). Sequences from the same cluster were aligned using ClustalX (Jeanmougin et al, Trends
Biochem. Sci. 23:403, 1998). To find the cDNA sequences corresponding to the amino acid sequence obtained by Edman degradation of the proteins transferred to PVDF membranes from SDS-PAGE gels, a search program was written that checked these amino acid sequences against the three possible protein translations of each cDNA sequence obtained in the mass sequencing project. This was written using the same approach used in the BLOCKS (Henikoff et al, Bioinformatics 15:471, 1999) or Prosite (Bairoch, Nucleic Acids Res. 19 (Suppl):2241,1991) programs. Protein translations of the full-length clones were further processed to identify the predicted signal peptides using the Signal P program (Nielsen et al, Protein Eng. 10:1, 1997), available online. Predicted signal peptide cleaved sites were compared to the N-terminus sequence obtained from Edman degradation of Phlebotomus salivary proteins. Estimation of isoelectric point and molecular weight of translated protein was performed using the DNA STAR program (DNASTAR). Full-length translated protein sequence information was compared with the non-redundant protein database of NCBI using the BLAST-P program (Altschul et al, Nucleic Acids Research 25:3389, 1997) and searched for motifs by submitting each sequence to the electronic database. To characterize the primary structure of the main proteins of Lu. longipalpis SGH, SDS-
PAGE gels were transferred to PVDF membranes, and the amino terminal sequence of each cut band by Edman degradation were estimated.
In addition, the following values were ascertained:
Table 1 Protein Characteristics
Figure imgf000071_0001
Example 3 Antibodies against Lu. longipalpis saliva
It has previously been shown that sera from children living in an area endemic for VL have anti-SGS IgG antibodies that differentially recognize salivary gland antigens. Individuals with a positive anti-Leishmania DTH response exhibited anti-Lu. longipalpis saliva antibodies. A positive correlation was observed between anti-J-u. longipalpis saliva antibodies and anti-Leishmania DTH, but no correlation was observed between anti-saliva antibodies and anti-Leishmania serology (Barral et al, ibid). The change in humoral and cell-mediated anti-Leishmania responses in a 6-month follow up of individuals in an area endemic for VL as well as the change in anti-Lu. longipalpis saliva antibody responses in the same individuals was studied. Individuals (n = 15) who converted to positive anti- Leishmania DTH significantly increased their anti-ZM. longipalpis IgG (FIG. 1A; P = 0.02) and IgE antibody levels (FIG. IB, P = 0.002). IgGl was the principal antibody subclass involved in the increase of anti-saliva antibodies in the group converting anti-Leishmania DTH (n = 15) (FIG. 1C); no significant changes were observed in other IgG subclasses. The cut-off value for anti-Lu. longipalpis IgG in ELISAs was 0.045. A significant decrease in anti-saliva IgG antibody levels (P = 0.035) was observed in sera from children who converted their anύ-Leishmania serology (Group I) (FIG. 1.4). No significant changes were observed in anti-saliva IgE in Group I (FIG. 15). Although IgG anti-saliva levels in Group II children decreased in the 6-month period, a significant increase in IgG4 anti-saliva was observed in this group (P = 0.0245; FIG. ID).
The number and pattern of Lu. longipalpis salivary proteins recognized by the sera of individuals who converted either from S~ -> S+ or from DTH" -> DTH + was evaluated by Western blot. From seven randomly selected sera of individuals who converted their anti-Leishmania serology, two poorly recognized two different salivary proteins of 33 kDa and 200 kDa, respectively (FIG. 2A, lane 4); the remaining sera did not recognize any salivary protein at any time point. Conversely, from 13 randomly selected sera of DTH" — > DTH individuals, 12 recognized a variety of salivary proteins with various intensities. FIGS. 2A and 2B show the diversity of salivary antigens recognized by these sera (lanes 7-14). Additionally, sera from six DTH" -» DTH+ individuals showed an increase in the number and/or intensity of salivary proteins recognition when comparing time 0 (-) and 6 months (+) time points (FIG. 2A, lanes 7(-) and 8(+), ll(-) and 12(+), 13(-) and 14(+); FIG. 2B, lanes 11(-) and 12(+), 13(-) and 14(+), and data not shown). Some individuals in the DTH" → DTH + group did not show any change from time 0 to 6 months (FIG. 2A, lanes 9(-) and 10(+); FIG. 2B, lanes !(-) and 8(+)) or did not recognize any salivary protein (FIG. 2B, lanes 9(-) and - 10(+)).
The sera of the DTH" -> DTH+ individuals recognized a total of 16 different salivary proteins; however, the frequency of recognition varies among these individuals (FIG. 2C). A salivary protein of 45 kDa was recognized by 12 sera, followed by proteins of 44 and 43 and 35 kDa recognized by 8 sera (each), a protein of 17 kDa by 6 sera, and a protein of 16 kDa by 5 sera. Other salivary proteins were recognized as well but with less frequency (3 sera or less, FIG. 2C).
Thus, Group II children, who convert their anύ-Leishmania DTH, also present an increase in anti-sand fly saliva antibodies as evidenced by ELISA and Western blot. A correlation between anti- saliva antibody titers and anti-Leishmania DTH has been shown (Barral et al, ibid); the results presented herein show that development of anti-parasite DTH temporally coincides with development of anti-Lu. longipalpis saliva antibodies. Without being bound by theory, neutralization of sand fly salivary component(s) by antibodies or cellular response to salivary proteins allows for a more efficient mounting of an anύ-Leishrnania cell-mediated immune response, probably by developing a Thl response against the parasite. Sand fly saliva components, such as maxadilan, are able to impair macrophage function (Charlab et al, Proc Natl Acad Sci USA 96:15155-60, 1999), which interferes with Leishmania survival and antigen presentation (Soares et al, J. Immunol. 160: 1811-6, 1998). The higher antibody levels observed in DTH" -> DTH + individuals suggest that mounting an immune response against anti-saliva components is linked to developing cell-mediated immunity against Leishmania.
The results presently reported by Western blot analysis showed that individuals who converted their anti-Leishmania serology practically did not recognize any salivary protein whereas individuals who converted their an -Leishmania DTH recognized a number of different salivary proteins. Frequency of salivary antigens recognized by these sera reveals a cluster of only a few proteins, including antigens with an approximate molecular mass of 45, 44, 43, 35, 27 and 16 kDa (FIG. 2C).
Among these antigens, the recognition of at least two salivary proteins (45 kDa and 35 kDa), represent two of the highest frequencies of recognition by human sera. Surprisingly, only two sera recognized a protein in the range of 6 kDa, the molecular weight of maxadilan (Titus and Ribeiro, Parasitol Today 6: 157-159, 1990) suggesting that, in humans, maxadilan may not induce a strong antibody response, although it could be a strong inducer of cellular immunity.
Individuals who converted their anti-Leishmania cell-mediated immunity exhibited increased IgGl and IgE levels. IgGl has been related to a human Thl response. Elevation of IgE antibodies suggests the development of an immediate hypersensitivity, since IgE is considered a marker of Th2-type responses. Without being bound by theory, it is likely that a mixed Tlι2-type (related to immediate hypersensitivity) and Thl-like response (related to DTH) against saliva components coexist in individuals who recently converted their anti-Leishmania DTH. In fact, this type of mixed response was reported in individuals exposed to insect bites, where the host immune response against insect saliva starts with DTH response and evolves to a predominant immediate-type hypersensitivity and finally desensitization (Melanby, Nature. 158, 554-555.13, 1946).
As disclosed herein, in mice, iLmmunization using Lu. longipalpis salivary genes resulted in a typical DTH and/or antibody response to Lu. longipalpis salivary proteins (see below), suggesting that Lu. longipalpis bites could induce Thl and Th2 responses in humans. Of interest, the P. papatasii (SP15) salivary protein responsible for the DTH response in mice is highly homologous to the SL1 protein present in Lu. longipalpis saliva (Charlab et al, Proc Natl Acad Sci USA 96:15155— 60, 1999). Without being bound by theory, the results presented herein suggest that a mixed anti- saliva response with both Thl and Th2 components can help in establishing an anti-immune Leishmania response.
Example 4 DNA Vaccination in Mice
For genetic immunization, Swiss Webster mice were purchased from Taconic Farms. Mice were maintained in the NIAED Animal Care Facility under pathogen-free conditions. Mice were inoculated in the right ear with 30 μg of the plasmid encoding the selected cDNA from Lu. longipalpis suspended in 5 μl of PBS. Each group is boosted 2 weeks later using the same regimen. Mice were challenged on the opposite ear with salivary gland homogenate of Lu. longipalpis and delayed type hypersensitivity (DTH) response is measured 24 hours after the injection by measuring thickness and redness of ear (++: at least 2 mice with a good DTH response, +++ : at least three mice had a good DTH response).
Table 2 DTH Response in Mice
Figure imgf000074_0001
*Delayed type hypersensitivity (DTH) response induced by injection of salivary gland homogenate on the ear of mice (group of three) previously immunized with salivary DNA vaccine. Mice were previously sensitized with specific DNA plasmids two times at two weeks interval then injected with salivary gland homogenate of the sand fly Lutzomyia longipalpis. DTH response was measured at 24 hours (tickness and redness of ear) after salivary gland homogenate injection. (++= at least 2 mice had good DTH response, +++ at least three mice had a good DTH response).
Example 5
Production of an Immune Response in Dogs
In a first experiment DTH (delayed type hypersensitivity) reaction is performed in dogs with natural immunity against the leishmaniasis in order to determine which Lu. longipalpis salivary proteins are recognized by a protective immune response. These dogs with natural immunity survived without symptoms after two years of exposure in an endemic area. In a second experiment naive dogs are immunized with the Lu. longipalpis salivary gland protein expressed by a plasmid in order to evaluate the capability to induce a cellular immune response measured by DTH. Twelve dogs approximately three years old with natural immunity against Leishmaniasis are injected via an intradermal route (ID) in the back after shaving, with 100 μg of each individual plasmid suspended in 100 μl of PBS. Each plasmid is injected at a different point. The points are separated by at least 3 cm to avoid interference between DTH responses. The negative control (100 μl of buffer) is also inoculated by ID route.
The DTH response is assessed 72 hours after injection by measuring the larger diameter of the skin tumefaction area. The results are expressed as the mean value of the tumefaction area for all the dogs and as a percentage of dogs having a positive DTH response. A positive DTH is a tumefaction area diameter greater than or equal to 4 mm at 72 hours after injection. In a second study, 10 na'ive dogs 4 to 6 months old are immunized by ID injection in 10 points (100 μl per point) in the right ear with a pool of the plasmids encoding a Lu. longipalpis polypeptide, 100 μg for each one suspended in 1000 μl of PBS. On day 21, dogs are injected in 10 points (100 μl per point) in the left ear and in 10 points (100 μl per point) in the belly with a pool of the plasmids, 100 μg for each one suspended in 2000 μl of PBS. All dogs are challenged on day 35 by inoculation by ED route in the back (after shaving), with 100 μg of each individual plasmid suspended in 100 μl of PBS. Each plasmid is injected at a different point. The points are separated by at least 3 cm to avoid interference. As a negative control, 100 μl of buffer is inoculated intradermally. The DTH response is assessed 72 hours after challenge, by measuring the larger diameter of the skin tumefaction area. The results are expressed as the mean value of the tumefaction area for all the dogs and as a percentage of dogs having a positive DTH response. A positive DTH is a tumefaction area diameter higher or equal of 4 mm at 72 hours after injection.
The results of this study show that plasmids can induce a cellular immunity in dogs after injection, a cellular immunity reveled by a DTH response. The variation of the DTH response level can be by the variation of the expression of the insert.
It will be apparent that the precise details of the methods described may be varied or modified without departing from the spirit of the described disclosure. We claim all such modifications and variations that fall within the scope and spirit of the claims below.

Claims

CLAIMSWe claim:
1. A substantially purified salivary Lu. longipalpis polypeptide.
2. The polypeptide of claim 1, wherein the polypeptide comprises a) an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ TD NO: 3, SEQ TD NO: 5, SEQ ID NO: 7, SEQ TD NO: 9, SEQ TD NO: 13, SEQ TD NO: 15, SEQ TD NO: 17, SEQ ED NO: 19, SEQ TD NO: 21, SEQ ED NO: 25, SEQ ID NO: 27, SEQ TD NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ED NO: 51, SEQ ED NO: 53, SEQ ED NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ED NO: 63, SEQ ED NO: 65, or SEQ ED NO: 67; b) a conservative variant of the amino acid sequence set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ TD NO: 7, SEQ TD NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ID NO: 17, SEQ ID
NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ED NO: 29, SEQ TD NO: 31, SEQ ED NO: 33, SEQ ED NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ TD NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ TD NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ TD NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ED NO: 65, or SEQ ID NO: 67; c) an immunogenic fragment comprising at least eight consecutive amino acids of the amino acid sequence set forth as SEQ ED NO: 3, SEQ ID NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ED NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ED NO: 31, SEQ ID NO: 33, SEQ TD NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ED NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67, that specifically binds to an antibody that specifically binds the amino acid sequence set forth as SEQ TD NO: 3, SEQ ID NO: 5, SEQ ED NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ED NO: 21, SEQ ED NO: 25, SEQ ID NO: 27, SEQ TD NO: 29, SEQ ED NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ED NO: 43, SEQ ED NO: 45, SEQ ID NO: 47, SEQ ED NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67, respectively; or d) the amino acid sequence set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ TD NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ TD NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ED NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ED NO: 65, or SEQ ID NO: 67, and wherein administration of the polypeptide to a subject produces an immune response to Lu. longipalpis.
3. The Lu. longipalpis polypeptide of claim 2, wherein the polypeptide comprises an amino acid sequence as set forth as SEQ TD NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ LD NO: 17, SEQ D NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ TD NO: 35, SEQ ED NO: 41, SEQ ED NO: 43, SEQ ED NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ED NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ TD NO: 65, or SEQ ID NO: 67, or a conservative variant thereof.
4. The Lu. longipalpis polypeptide of claim 3, wherein the polypeptide comprises an amino acid sequence set forth as SEQ TD NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ID NO: 13, SEQ ED NO: 15, SEQ LD NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ED NO: 25, SEQ ID NO: 27, SEQ TD NO: 29, SEQ ID NO: 31, SEQ TD NO: 33, SEQ ED NO: 35, SEQ ED NO: 41, SEQ ED NO: 43, SEQ ED NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ED NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ED NO: 67.
5. An antigenic fragment of the polypeptide of claim 4.
6. The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth as SEQ TD NO: 3, SEQ ID NO: 5, SEQ TD NO: 7, SEQ TD NO: 9, SEQ TD NO: 13, SEQ TD NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ED NO: 21, SEQ ED NO: 25, SEQ ID NO: 27, SEQ ED NO: 29, SEQ ED NO: 31, SEQ ED NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ED NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ TD NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67.
7. An isolated nucleic acid encoding the polypeptide of claim 1.
8. The nucleic acid of claim 7, wherein the nucleic acid comprises a sequence as set forth as
SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ED NO: 10, SEQ ID NO: 14, SEQ ED NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ED NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ED NO: 34, SEQ ID NO: 36, SEQ ED NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ED NO: 54, SEQ TD NO: 56, SEQ TD NO: 58, SEQ ID NO: 62, SEQ TD NO: 64, SEQ TD NO: 66, or SEQ ID NO: 68, or a degenerate variant thereof.
9. The nucleic acid of claim 7, wherein the nucleic acid comprises a sequence as set forth as SEQ ID NO: 4, SEQ ID NO: 6, SEQ ED NO: 8, SEQ ED NO: 10, SEQ ID NO: 14, SEQ ED NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ED NO: 26, SEQ ID NO: 28, SEQ ED NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ED NO: 44, SEQ ID NO: 46, SEQ ED NO: 48, SEQ ED NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 62, SEQ ED NO: 64, SEQ ED NO: 66, or SEQ ED NO: 68.
10. The nucleic acid of claim 7, wherein the nucleic acid encodes an amino acid sequence at least 80% identical to the amino acid sequence set forth as SEQ TD NO: 4, SEQ TD NO: 6, SEQ ED NO: 8, SEQ ED NO: 10, SEQ ED NO: 14, SEQ TD NO: 16, SEQ TD NO: 18, SEQ TD NO: 20, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ED NO: 28, SEQ ED NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ED NO: 36, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ED NO: 54, SEQ ID NO: 56, SEQ ED NO: 58, SEQ TD NO: 62, SEQ ID NO: 64, SEQ ED NO: 66, or SEQ ED NO: 68.
11. The nucleic acid of claim 7, operably linked to an expression control sequence.
12. The nucleic acid of claim 11, wherein the expression control sequence is a promoter.
13. The nucleic acid of claim 12, wherein the promoter is an inducible or constitutive promoter.
14. The nucleic acid of claim 13, wherein the promoter is a cytomegalovirus promoter.
15. A vector comprising the nucleic acid of claim 7.
16. The vector of claim 15, wherein the vector is a plasmid.
17. The vector of claim 15, wherein the vector is a viral vector.
18. A host cell transformed with the vector of claim 15.
19. An antibody that specifically binds the polypeptide of claim 1.
20. The antibody of claim 19, wherein the antibody is a monoclonal antibody.
21. The antibody of claim 20, comprising a detectable label.
22. The antibody of claim 21, wherein the label is a fluorescent, enzymatic or radioactive label
23. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
24. A pharmaceutical composition comprising the nucleic acid of claim 7 and a pharmaceutically acceptable carrier.
25. A method for inducing an immune response to a Lu. longipalpis polypeptide in a subject, comprising: aciministering to the subject a therapeutically effective amount of : a) an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ TD NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ED NO: 31, SEQ ED NO: 33, SEQ ED NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ED NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ED NO: 67; b) a conservative variant of the amino acid sequence set forth as SEQ ID NO: 3, SEQ TD NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ED NO: 17, SEQ ID NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ TD NO: 27, SEQ TD NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ TD NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ TD NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ED NO: 51, SEQ ED NO: 53, SEQ ED NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ TD NO: 63, SEQ TD NO: 65, or SEQ ED NO: 67; c) an immunogenic fragment comprising at least eight consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 3, SEQ ED NO: 5, SEQ ID NO: 7, SEQ ED NO: 9, SEQ ID NO: 13, SEQ ED NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ TD NO: 29, SEQ TD NO: 31, SEQ ED NO: 33, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ TD NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ED NO: 65, or SEQ ID NO: 67, that specifically binds to an antibody that specifically binds the amino acid sequence set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ TD NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ED NO: 31, SEQ ID NO: 33, SEQ ED NO: 35, SEQ ID NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ED NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67, respectively; or d) the amino acid sequence set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ED NO: 17, SEQ ED NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ED NO: 27, SEQ JD NO: 29, SEQ ID NO: 31, SEQ JD NO: 33, SEQ ID NO: 35, SEQ JD NO: 41, SEQ JD NO: 43, SEQ JD NO: 45, SEQ JD NO: 47, SEQ JD NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ TD NO: 63, SEQ ED NO: 65, or SEQ ED NO: 67; or
(e) a polynucleotide encoding the polypeptide set forth in (a), (b), (c), or (d), thereby inducing the immune response to the Lu. longipalpis polypeptide in a subject.
26. The method of claim 25, wherein the immune response is a T cell response.
27. The method of claim 25, wherein the immune response is a B cell response.
28. The method of claim 25, wherein the subject is a non-human veterinary subject.
29. The method of claim 25, wherein the subject is a dog.
30. The method of claim 25, wherein the subject is a human.
31. A method for inhibiting a symptom of a Leishmania infection or preventing a Leishmania infection in a subject, comprising administering to the subject a therapeutically effective amount of: a) an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ ED NO: 3, SEQ ED NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ED NO: 17,. SEQ ID NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ED NO: 31, SEQ TD NO: 33, SEQ TD NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ED NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ED NO: 61, SEQ ID NO: 63, SEQ ED NO: 65, or SEQ ID NO: 67; b) a conservative variant of the amino acid sequence set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ED NO: 9, SEQ ED NO: 13, SEQ ID NO: 15, SEQ TD NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ED NO: 27, SEQ ED NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 41, SEQ TD NO: 43, SEQ TD NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ID NO: 51, SEQ ED NO: 53, SEQ ED NO: 55, SEQ ID NO: 59, SEQ ED NO: 61, SEQ ED NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67; c) an immunogenic fragment comprising at least eight consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ ED NO: 7, SEQ ED NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ED NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ED NO: 33, SEQ ED NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ TD NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 59, SEQ TD NO: 61, SEQ ED NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67, that specifically binds to an antibody that specifically binds the amino acid sequence set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ ED NO: 7, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ TD NO: 19, SEQ ID NO: 21, SEQ ED NO: 25, SEQ ED NO: 27, SEQ ED NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ED NO: 35, SEQ ED NO: 41, SEQ ED NO: 43, SEQ ID NO: 45, SEQ ED NO: 47, SEQ ED NO: 49, SEQ ED NO: 51, SEQ ED NO: 53, SEQ ED NO: 55, SEQ ED NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ED NO: 65, or SEQ ED NO: 67, respectively; or d) the amino acid sequence set forth as SEQ ID NO: 3, SEQ ED NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ED NO: 17, SEQ ED NO: 19, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ED NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ED NO: 35, SEQ ED NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ TD NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67; or
(e) a polynucleotide encoding the polypeptide set forth in (a), (b), (c), or (d); thereby inhibiting the symptom of the Leishmania infection or preventing the Leishmania infection.
32. Use of a composition comprising the polypeptide of claim 1 or a nucleic acid encoding the polypeptide of claim 1 for the manufacture of a medicament.
33. Use of the composition of claim 32, in conjunction with a composition comprising a P. ariasi or a P. perniciosus polypeptide for the manufacture of a medicament.
34. A method of diagnosing Leishmania infection in a subject, comprising: contacting a solid substrate comprising at least three, six, or ten polypeptides, wherein each of the polypeptides comprises one amino acid sequence as set forth as SEQ ID NO: 3, SEQ ID NO: 5, SEQ TD NO: 7, SEQ ID NO: 9, SEQ ED NO: 13, SEQ ED NO: 15, SEQ ED NO: 17, SEQ ED NO: 19, SEQ ED NO: 21, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ED NO: 33, SEQ ID NO: 35, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ED NO: 45, SEQ TD NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ TD NO: 53, SEQ TD NO: 55, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, or SEQ ID NO: 67, or an immunogemc fragment thereof; contacting the solid substrate with a sample obtained from the subject; and detecting binding of a component of the sample to at least one polypeptide on the solid substrate, wherein detection of binding of the component to the substrate indicates that the subject is infected with Leishmania, thereby diagnosing Leishmania infection in the subject.
35. The method of claim 34, wherein one of the at least three polypeptides comprises an amino acid sequence as set forth as SEQ ID NO: 1, wherein another of the at least three polypeptides comprises an amino acid sequence as set forth as SEQ ID NO: 23, and wherein a further of the at least three polypeptides comprises an amino acid sequence as set forth as SEQ ID NO: 39.
36. The method of claim 34, wherein the solid substrate comprises at least six polypeptides, wherein a first polypeptide comprises an amino acid sequence as set forth as SEQ ID NO: 3, wherein a second polypeptide comprises an amino acid sequence as set forth as SEQ TD NO: 11, wherein a third polypeptide comprises an amino acid sequence as set forth as SEQ TD NO: 19, wherein a fourth polypeptide comprises an amino acid sequence as set forth as SEQ ID NO: 29, wherein a fifth polypeptide comprises an amino acid sequence as set forth as SEQ ID NO: 55, and wherein a sixth polypeptide comprises an amino acid sequence as set forth as SEQ TD NO: 59.
37. The method of claim 34, wherein the solid substrate comprises a polystyrene bead, a chip, a membrane, or a plate.
38. The method of claim 34, wherein detecting comprises contacting the component bound to the solid substrate with a labeled secondary antibody.
PCT/US2003/034453 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use WO2004039958A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AT03781500T ATE429487T1 (en) 2002-10-29 2003-10-29 LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHOD OF USE
BRPI0315872-1A BR0315872A (en) 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and processes of use and method of use
EP03781500A EP1572968B1 (en) 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use
JP2004548595A JP2006516187A (en) 2002-10-29 2003-10-29 Lutzomia longipalpis polypeptide and methods of use
DE60327366T DE60327366D1 (en) 2002-10-29 2003-10-29 LUTZOMYIA LONGIPALPIC POLYPEPTIDES AND METHOD OF USE
US10/533,811 US7485306B2 (en) 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use
AU2003287267A AU2003287267A1 (en) 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use
MXPA05004714A MXPA05004714A (en) 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use.
US12/350,179 US8628780B2 (en) 2002-10-29 2009-01-07 Lutzomyia longipalpis polypeptides and methods of use
US14/097,991 US9120867B2 (en) 2002-10-29 2013-12-05 Lutzomyia longipalpis polypeptides and methods of use
US14/802,168 US9382302B2 (en) 2002-10-29 2015-07-17 Lutzomyia longipalpis polypeptides and methods of use
US15/175,329 US9884100B2 (en) 2002-10-29 2016-06-07 Lutzomyia longipalpis polypeptides and methods of use
US15/866,050 US10314900B2 (en) 2002-10-29 2018-01-09 Lutzomyia longipalpis polypeptides and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42230302P 2002-10-29 2002-10-29
US60/422,303 2002-10-29

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10533811 A-371-Of-International 2003-10-29
US10/533,811 A-371-Of-International US7485306B2 (en) 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use
US12/350,179 Division US8628780B2 (en) 2002-10-29 2009-01-07 Lutzomyia longipalpis polypeptides and methods of use

Publications (2)

Publication Number Publication Date
WO2004039958A2 true WO2004039958A2 (en) 2004-05-13
WO2004039958A3 WO2004039958A3 (en) 2005-12-08

Family

ID=32230337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034453 WO2004039958A2 (en) 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use

Country Status (10)

Country Link
US (6) US7485306B2 (en)
EP (2) EP1572968B1 (en)
JP (2) JP2006516187A (en)
AT (1) ATE429487T1 (en)
AU (1) AU2003287267A1 (en)
BR (1) BR0315872A (en)
DE (1) DE60327366D1 (en)
ES (1) ES2447843T3 (en)
MX (1) MXPA05004714A (en)
WO (1) WO2004039958A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034041A2 (en) * 2007-09-13 2009-03-19 Peptcell Limited Peptide sequences and compositions
EP2085467A2 (en) 2002-10-29 2009-08-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia Longipalpis polypeptides and methods of use
WO2009137577A2 (en) 2008-05-08 2009-11-12 Merial Limited Leishmania vaccine using sand fly salivary immunogen
WO2010021940A1 (en) * 2008-08-18 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insect proteins as adjuvants to accelerate the immune response
US7741437B2 (en) 2002-09-19 2010-06-22 The United States Of America As Represented By The Department Of Health And Human Services P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
US11643440B2 (en) 2017-06-02 2023-05-09 Amgen Inc. Peptide PAC1 antagonists

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
BRPI0603490B1 (en) * 2006-07-21 2018-04-24 Universidade Federal De Minas Gerais RECOMBINING VACCINE AGAINST CANCER VISCERAL LEISHMANIASIS
JP5590986B2 (en) 2010-06-23 2014-09-17 株式会社シマノ Fishing reel one-way clutch

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3584341D1 (en) 1984-08-24 1991-11-14 Upjohn Co RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
ATE143052T1 (en) 1986-07-07 1996-10-15 Centocor Inc CHIMERIC MUINE-HUMAN IMMUNOGLOBULIN SPECIFIC FOR TUMOR-ASSOCIATED 17-1A ANTIGEN
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DK175363B1 (en) 1986-09-12 2004-09-13 Genentech Inc Process for Continuous Production of a Desired Heterologous Protein in a Eukaryotic Host Cell, Vector Adding That Ability, and Cells Transformed with the Vector
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
DE3743138A1 (en) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg SLIP RINGLESS, ELECTROMAGNETIC OVERLOAD CLUTCH
EP0425563B1 (en) 1988-07-20 1996-05-15 David Segev Process for amplifying and detecting nucleic acid sequences
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5397772A (en) * 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
KR100242671B1 (en) 1991-03-07 2000-03-02 고돈 에릭 Genetically engineered vaccine strain
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
DK0596032T4 (en) 1991-07-25 2004-07-26 Idec Pharma Corp Induction of cytotoxic T lymphocyte responses
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
EP0671926B1 (en) 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DE69432417T2 (en) 1993-09-03 2004-02-12 Mcgill University, Montreal DIFFERENTIALLY EXPRESSED LEISHMANIA GENES AND PROTEINS
FR2712603B1 (en) 1993-11-18 1996-02-09 Centre Nat Rech Scient Recombinant viruses, preparation and use in gene therapy.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
KR100392551B1 (en) 1994-07-15 2003-10-30 아크조 노벨 엔브이 Use of RNA Polymerase to Improve Nucleic Acid Amplification Methods
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
AT402203B (en) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr METHOD FOR TRANSCRIPTION-FREE AMPLIFICATION OF NUCLEIC ACIDS
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
FR2750865B1 (en) 1996-06-27 1998-12-04 Rhone Merieux RECOMBINANT LIVING VACCINE BASED ON CANINE HERPESVIRUS, IN PARTICULAR FOR SQUARE DISEASE, RABIES OR TYPE 2 PARAINFLUENZA VIRUS
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
WO1998000166A1 (en) 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
ES2241042T3 (en) 1996-10-11 2005-10-16 The Regents Of The University Of California IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA.
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
BR0210539A (en) 2001-06-19 2005-04-26 Us Gov Health & Human Serv Selection and use processes for antiarthropod vector vaccines
EP1545575A4 (en) 2002-09-19 2006-04-05 Us Gov Health & Human Serv P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
EP1572968B1 (en) * 2002-10-29 2009-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARRAL A. ET AL: 'Human immune response to sand fly salivary glans antigens: a useful epidemiological marker.' AM J TROP MED HYG. vol. 62, no. 6, June 2000, pages 740 - 745, XP002991565 *
CHARLAB R. ET AL: 'Toward an understanding of the biochemical and pharmacological complexity of the saliva of a hematophagous sand fly Lutzomya longipalpis.' PROC NATL ACAD SCI USA. vol. 96, no. 26, 21 December 1999, pages 15155 - 15160, XP002329856 *
See also references of EP1572968A2 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741437B2 (en) 2002-09-19 2010-06-22 The United States Of America As Represented By The Department Of Health And Human Services P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
EP2085467A2 (en) 2002-10-29 2009-08-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia Longipalpis polypeptides and methods of use
EP2783694A3 (en) * 2007-09-13 2015-01-07 Peptcell Limited Peptide sequences and compositions from Anopheles gambiase
EP2783694A2 (en) * 2007-09-13 2014-10-01 Peptcell Limited Peptide sequences and compositions from Anopheles gambiase
USRE47222E1 (en) 2007-09-13 2019-02-05 Pep Tcell, Ltd. Peptide sequences and compositions
US8986703B2 (en) 2007-09-13 2015-03-24 PepTCell, Ltd. Peptide sequences and compositions
WO2009034041A3 (en) * 2007-09-13 2009-06-25 Peptcell Ltd Peptide sequences and compositions
WO2009034041A2 (en) * 2007-09-13 2009-03-19 Peptcell Limited Peptide sequences and compositions
EP2407172A1 (en) * 2007-09-13 2012-01-18 Peptcell Limited Peptide sequences and compositions
EP2567706A3 (en) * 2007-09-13 2013-06-12 Peptcell Limited Peptide sequences and compositions
US20140294875A1 (en) * 2008-05-08 2014-10-02 The Government of the United States of America as represented by the Secretary of the Department Leishmania Vaccine Using Sand Fly Salivary Immunogen
WO2009137577A2 (en) 2008-05-08 2009-11-12 Merial Limited Leishmania vaccine using sand fly salivary immunogen
CN102066411A (en) * 2008-05-08 2011-05-18 梅里亚有限公司 Leishmania vaccine using sand fly salivary immunogen
WO2009137577A3 (en) * 2008-05-08 2010-03-25 Merial Limited Leishmania vaccine using sand fly salivary immunogen
EP2899203A2 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
EP2899203A3 (en) * 2008-05-08 2015-08-05 Merial Limited Leishmania vaccine using sand fly salivary immunogen
US9228002B2 (en) * 2008-05-08 2016-01-05 Merial, Inc. Leishmania vaccine using sand fly salivary immunogen
WO2010021940A1 (en) * 2008-08-18 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insect proteins as adjuvants to accelerate the immune response
US11643440B2 (en) 2017-06-02 2023-05-09 Amgen Inc. Peptide PAC1 antagonists

Also Published As

Publication number Publication date
ATE429487T1 (en) 2009-05-15
EP1572968B1 (en) 2009-04-22
EP2085467A3 (en) 2009-10-14
DE60327366D1 (en) 2009-06-04
US7485306B2 (en) 2009-02-03
US20060051364A1 (en) 2006-03-09
US20160279211A1 (en) 2016-09-29
WO2004039958A3 (en) 2005-12-08
EP2085467B1 (en) 2013-12-11
EP1572968A4 (en) 2006-07-19
US20180147269A1 (en) 2018-05-31
US20140093531A1 (en) 2014-04-03
JP2010142226A (en) 2010-07-01
US9884100B2 (en) 2018-02-06
US9120867B2 (en) 2015-09-01
JP2006516187A (en) 2006-06-29
US8628780B2 (en) 2014-01-14
US9382302B2 (en) 2016-07-05
US20090117139A1 (en) 2009-05-07
US20150315254A1 (en) 2015-11-05
ES2447843T3 (en) 2014-03-13
EP2085467A2 (en) 2009-08-05
US10314900B2 (en) 2019-06-11
AU2003287267A1 (en) 2004-05-25
EP1572968A2 (en) 2005-09-14
AU2003287267A8 (en) 2004-05-25
MXPA05004714A (en) 2006-03-17
BR0315872A (en) 2006-07-18

Similar Documents

Publication Publication Date Title
US10314900B2 (en) Lutzomyia longipalpis polypeptides and methods of use
US8343499B2 (en) Anti-arthropod vector vaccines, methods of selecting and uses thereof
US9228002B2 (en) Leishmania vaccine using sand fly salivary immunogen
US20100196381A1 (en) P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
CZ20012360A3 (en) Pharmaceutical preparation, vaccine, protein and prevention or therapy method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 168249

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2006051364

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10533811

Country of ref document: US

Ref document number: PA/A/2005/004714

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004548595

Country of ref document: JP

Ref document number: 2003781500

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1918/DELNP/2005

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2003781500

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 10533811

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0315872

Country of ref document: BR